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Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are ubiquitous environmental 
toxicants used in consumer products and industry, such as non-stick cookware, food packaging 
materials, personal care products, and aqueous fire-fighting foams. PFAS have received 
unprecedented attention recently due to nationwide drinking water contamination that impacts up 
to 110 million residents in the United States. Due to the widespread use and chemical stability of 
these compounds, more than 98% of the general population in the United States likely has at 
least one PFAS detectable in their blood. Growing evidence suggests that ovaries may be a 
potential target for PFAS toxicity. The ovary is a primary regulator of reproductive and 
endocrine function in females. Menopause marks the cessation of ovarian function, and its 
timing has physiologic impacts beyond the reproductive system. As age at the final menstrual 
period reflects a woman’s overall health, investigation of the role of potential endocrine-
disrupting chemicals in ovarian aging is warranted.  
The overall goal of my dissertation was to explore the impact of PFAS on ovarian aging 
and timing of natural menopause. The following specific aims were tested using a community-
based, longitudinal cohort of midlife women, the Study of Women’s Health Across the Nation 
(SWAN). 
Aim 1 examined temporal variations in serum concentrations of PFAS and determined 
assessed whether the time trends differed by race/ethnicity, menstruation status and parity to 
better understand longitudinal changes in PFAS across the menopausal transition. We observed
xviii 
 
longitudinal declines in serum concentrations of legacy PFAS including perfluorooctanoic acid 
(PFOA), perfluorooctane sulfonic acid (PFOS) and their precursors but increases in other PFAS 
compounds such as perfluorononanoic acid (PFNA) from 1999 to 2011. Menstruating women 
had consistently lower concentrations than non-menstruating women. Temporal trends in PFAS 
concentrations were not uniform across race/ethnicity and parity groups. 
Previous epidemiologic studies of PFAS and menopausal timing conducted in cross-
sectional settings were limited by reverse causation bias because PFAS serum concentrations 
increase after cessation of menstrual bleeding. Aim 2 examined the associations between PFAS 
exposure and incident natural menopause among 1120 midlife women aged 45-56 years at 
baseline from 1999 to 2017. Higher serum concentrations of PFOA and PFOS were associated 
with earlier onset of natural menopause, a risk factor for adverse health outcomes in later life. 
Women were classified into four clusters based on their overall PFAS concentrations as 
mixtures: low, low-medium, medium-high, and high. Compared to the low cluster, the high 
cluster had a HR of 1.66 (95% CI: 1.17-2.36), which is interpreted as 1.8 years earlier experience 
of natural menopause which is equivalent to the impact of smoking tobacco.  
Aim 3 explored the mediating role of follicle-stimulating hormone (FSH) in the 
associations between PFAS exposure and incident natural menopause to understand potential 
underlying mechanisms. The proportion of the effect mediated through FSH was 26.9% (95% 
CI: 15.6%, 38.4%) for linear PFOA and 13.2% (95% CI: 0.0%, 24.5%) for branched PFOS. The 
effect of PFAS on natural menopause may be partially explained by their association with 
variations in FSH concentrations. 
Overall this dissertation provides evidence that PFAS exposure may accelerate ovarian 
xix 
 
aging, possibly through endocrinologic mechanisms associated with changing serum 
concentrations of FSH. Future studies that can confirm these findings and steps to limit exposure 
to these chemicals appear warranted. 
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Background: Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are found widespread in 
drinking water, foods, food packaging materials, and other consumer products. Several PFAS 
have been identified as endocrine-disrupting chemicals based on their ability to interfere with 
normal reproductive function and hormonal signaling. Experimental models and epidemiologic 
studies suggest that PFAS exposures target the ovary and represent major risks for women’s 
health.  
Rationale/Objectives: This review summarizes human population and toxicological studies on 
the association between PFAS exposure and ovarian function.  
Search methods: A comprehensive review was performed by searching PubMed. Search terms 
included an extensive list of PFAS and health terms ranging from general keywords (e.g., 
ovarian, reproductive, follicle, oocyte) to specific keywords (including menarche, menstrual 
cycle, menopause, primary ovarian insufficiency/premature ovarian failure, steroid hormones), 
based on the authors’ knowledge of topic and key terms. 
Outcomes: Clinical evidence demonstrates the presence of PFAS in follicular fluid and their 
ability to pass through the blood-follicle barrier. Although some studies found no evidence 
associating PFAS exposure with disruption in ovarian function, numerous epidemiologic studies 
have identified associations of higher PFAS exposure with later menarche, irregular menstrual 
cycles, longer cycle length, earlier age of menopause, and reduced levels of estrogens and 
androgens, mostly in cross-sectional study designs. Adverse effects of PFAS on ovarian 
folliculogenesis and steroidogenesis have been confirmed in experimental models. Based on 




hormone synthesis through activating peroxisome proliferator-activated receptors, disrupt gap 
junction intercellular communication between oocyte and granulosa cells, induce thyroid 
hormone deficiency, antagonize ovarian enzyme activities involved in ovarian steroidogenesis, 
or inhibit kisspeptin signaling in the hypothalamus.  
Wider implications: The published literature supports associations between PFAS exposure and 
adverse reproductive outcomes; however, the evidence remains insufficient to infer a causal 
relationship between PFAS exposure and ovarian disorders. Thus, more research is warranted. 
PFAS are of significant concern because these chemicals are ubiquitous and persistent in the 
environment and in humans. Moreover, susceptible groups, such as fetuses and pregnant women, 
may be exposed to harmful combinations of chemicals that include PFAS. However, the role 
environmental exposures play in reproductive disorders has received little attention by the 
medical community. To better understand the potential risk of PFAS on human ovarian function, 
additional experimental studies using PFAS doses equivalent to the exposure levels found in the 
general human population and mixtures of compounds are required. Prospective investigations in 
human populations are also warranted to ensure temporality of PFAS exposure and health 
endpoints and to minimize the possibility of reverse causality.  
Key words: Perfluoroalkyl and polyfluoroalkyl substances (PFAS), endocrine-disrupting 





According to the definition adopted by the Endocrine Society Scientific Statement, an 
endocrine-disrupting chemical (EDC) is “a compound, either natural or synthetic, which, through 
environmental or inappropriate developmental exposures, alters the hormonal and homeostatic 
systems that enable the organism to communicate with and respond to its environment” 
(Diamanti-Kandarakis et al., 2009). A variety of EDCs are used in industrial and consumer 
applications, such as solvents and lubricants (e.g., polychlorinated biphenyls), flame retardants 
(e.g., polybrominated diethyl ethers), pesticides (e.g., dichlorodiphenyltrichloroethane and 
chlorpyrifos), and plasticizers (e.g., phthalates and bisphenol-A) (Burger et al., 2007; Caserta et 
al., 2011). Among them, perfluoroalkyl and polyfluoroalkyl substances (PFAS) have received 
unprecedented attention recently due to nationwide drinking water contamination and 
widespread use that impacts up to 110 million residents in the United States (Environmental 
Working Group, 2018). 
PFAS comprise a large family of man-made fluorinated chemicals that are ubiquitous 
environmental toxicants to which humans are exposed on a daily basis (Trudel et al., 2008). At 
least one type of PFAS chemical was detected in the blood of nearly every person sampled in the 
U.S. National Biomonitoring Program (Centers for Disease Control, 2019). Many consumer 
products contain specific members of this family of chemicals, such as  non-stick cookware 
(Teflon) (Bradley et al., 2007; Ewan Sinclair et al., 2007); food packaging materials (Begley et 
al., 2005; Schaider et al., 2017; Trier et al., 2011); stain- and water-resistant coating for clothing, 
furniture, and carpets (Scotchgard and Gore-Tex) (Hill et al., 2017; Lee et al., 2017); and 
cosmetics and personal care products (Boronow et al., 2019; Danish EPA, 2018). PFAS are also 




bases for crash and fire training (Butenhoff et al., 2006; Kantiani et al., 2010; Kissa, 2011; 
Trudel et al., 2008).  
Because PFAS are remarkably widespread in drinking water and groundwater in the 
United States and globally, especially on and near industrial sites, fire-fighting facilities and 
military installations, they pose a serious and immediate threat to the communities where the 
source of drinking water have been contaminated with PFAS. Although government and 
regulatory bodies have been working towards regulations that limit the production of 
perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA), two primary PFAS 
compounds that have been the most extensively manufactured (USEPA, 2016a,  2016b), the 
phase out and ban of PFOA and PFOS has led to an increased usage of alternative PFAS 
chemicals (Ateia et al., 2019). Consequently, there is an urgent need to raise the awareness of the 
potential threat of PFAS to human health. 
PFAS have been identified as contaminants of concern for reproductive toxicity (Jensen 
and Leffers, 2008). Observational studies have shown that PFAS exposure could delay menarche 
(Lopez-Espinosa et al., 2011), disrupt menstrual cycle regularity (Zhou et al., 2017), cause early 
menopause (Taylor et al., 2014) and premature ovarian insufficiency (Zhang et al., 2018), and 
alter the levels of circulating sex steroid hormones (Barrett et al., 2015). The ovary is the site of 
folliculogenesis and is responsible for the proper maturation of oocytes. It is also the principle 
site of sex hormone steroidogenesis. Experimental studies have shown that PFAS exposure was 
associated with the depletion of ovarian reserve (i.e. the number of ovarian follicles and oocytes) 
(Bellingham et al., 2009; Chen et al., 2017; Domínguez et al., 2016; Du et al., 2019; Feng et al., 
2015,  2017; Hallberg et al., 2019; López-Arellano et al., 2019), and inhibition steroidogenic 




Disruption of this finely controlled network may have physiologic impacts beyond the 
reproductive system, affecting the overall health of girls and women. 
Growing evidence has suggested that ovaries may be a potential target for PFAS toxicity: 
however, a comprehensive review of experimental and human studies for the effects of PFAS on 
normal ovarian function has not previously been reported. In this review, we summarize the 
sources and pathways of PFAS, describe the processes of ovarian folliculogenesis and 
steroidogenesis, review the state of the science regarding associations between PFAS exposures 
and ovarian function in experimental and epidemiological studies, identify gaps in the current 
data and outline directions for future research.  
2. Methods 
A thorough search was carried out for relevant articles in order to ensure a 
comprehensive review on PFAS exposure and ovarian function. We searched PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed) through August 2019. The following search terms were 
used, including PFAS search terms: perfluoroalkyl, polyfluoroalkyl, perfluorinated, 
fluorocarbons, perfluorobutanoic acid, perfluoropentanoic acid, perfluorohexanoic acid, 
perfluoroheptanoic acid, perfluorooctanoic acid, perfluorononanoic acid, perfluorodecanoic acid, 
perfluoroundecanoic acid, perfluorododecanoic acid, perfluorobutane sulfonic acid, 
perfluoroheptane sulfonic acid, perfluorooctane sulfonic acid, perfluorooctane sulfonamide, 
PFBA, PFPeA, PFHxA, PFHpA, PFOA, PFDeA, PFUnA, PFDoA, PFBS, PFHpS, PFOS, 
PFOSA; and outcome search terms: ovary, follicle, oocyte, menarche, menstrual cycle, 
menopause, primary ovarian insufficiency, premature ovarian failure, steroid hormones, 
polycystic ovarian syndrome, and ovarian cancer. In addition, we manually reviewed the 




3. Basic principles of PFAS 
3.1 Nomenclature 
The term PFAS refers to perfluoroalkyl and polyfluoroalkyl substances, a large group of 
man-made chemicals with the distinguishing structure of a chain of carbon atoms (forming an 
“alkyl”) that has at least one fluorine atom bound to a carbon. Details of PFAS terminology, 
classification and origins can be found elsewhere (Buck et al., 2011; Interstate Technology 
Regulatory Council, 2017). Note that use of non-specific acronyms, such as perfluorinated 
compound (PFC), should be avoided in the scientific publications as it has hampered clear 
communications in researchers, practitioners, policy makers and the public.  
Perfluoroalkyl substances are fully fluorinated  molecules in which every hydrogen atom 
bonded to a carbon in the alkane backbone (carbon-chain) is replaced by a fluorine atom, except 
for the carbon at one end of the chain that has a charged functional group attached. The carbon-
fluorine bond is extremely strong and renders these chemicals highly resistant to complete 
degradation. The basic chemical structure of perfluoroalkyl substances can be written as 
CnF2n+1 − R, where “CnF2n+1” defines the length of the perfluoroalkyl chain tail with n>2, and 
“R” represents the attached functional group head (as shown in Figure 1). PFOA and PFOS (so-
called C8 compounds) have been the most extensively produced and studied PFAS compounds. 
Perfluoroalkyl acids (PFAAs) are some of the most basic PFAS molecules and are essentially 
non-degradable. PFAAs contain three major groups on the basis of the functional group at the 
end of the carbon chain: perfluoroalkyl carboxylic acids (PFCAs), perfluoroalkane sulfonic acids 
(PFSAs), and perfluoroalkyl phosphonates (PFPAs) or perfluoroalkyl phosphinates (PFPiAs).  




fluorine substitution in the alkane backbone: at least one carbon must not be bound to a fluorine 
atom and at least two carbons must be fully fluorinated. The fluorotelomer substances are a 
subset of polyfluoroalkyl substances because they are oligomers with low molecular weight 
produced by a telomerization reaction. Some important examples fluorotelomer substances are 
fluorotelomer alcohol (FTOH) and perfluorooctane sulfonamidoethanol (FOSE). Since 
polyfluoroalkyl substances have a carbon that is lacking fluorine substitution, this weaker bond 
increases potential for degradation (Buck et al., 2011). For example, FTOH and FOSE can be 
transformed biologically or abiotically to PFOA and PFOS.  
In addition to the descriptions above, PFAS can also exist as polymers. These PFAS 
polymers are large molecules formed by joining many identical small PFAS monomers. Current 
information indicates that the non-polymer PFAS constitute the greatest risk for environmental 
contamination and toxicity, although some PFAS polymers can be degradable to basic PFAS.  
3.2 Sources of human exposure 
Previous studies have evaluated daily exposure in populations around the world (Ericson 
et al., 2008; Fromme et al., 2007; Haug et al., 2010; Heo et al., 2014; Ostertag et al., 2009; 
Renzi et al., 2013; Tittlemier et al., 2007; Trudel et al., 2008; Zhang et al., 2010). Although it is 
difficult to compare concentrations among populations because of differences in participant 
characteristics (e.g. age, sex, and geographical locations), the ranges of PFAS serum 
concentrations are remarkably similar worldwide. Exposure to PFAS in the general population is 
at lower levels compared to those affected by occupational exposure or local contaminations 
(ATSDR, 2018). Multiple sources of potential exposure to PFAS have been previously identified 
in the general population. These sources include diet (Domingo and Nadal, 2017; Haug et al., 




(Domingo and Nadal, 2019; Hu et al., 2016; Post et al., 2009; Thompson et al., 2011), air and 
dust (Fromme et al., 2015; Goosey and Harrad, 2012; Haug, et al., 2011; Karásková et al., 2016; 
Piekarz et al., 2007), and consumer products (Begley et al., 2005; Boronow et al., 2019; Bradley 
et al., 2007; Ewan Sinclair et al., 2007; Hill et al., 2017; Lee et al., 2017; Schaider et al., 2017; 
Trier et al., 2011). The widespread production of PFAS, their use in common commercial and 
household products, their improper disposal, and their resistance to degradation has led to daily 
human exposures via oral ingestion, inhalation, and dermal contact. Different sources and 
pathways of human exposure are summarized in Table 1.  
The highest exposures to PFAS are often from dietary intake, particularly to PFOS and 
PFOA (Domingo and Nadal, 2017; Haug, Huber, Becher, et al., 2011; Tittlemier et al., 2007; 
Trudel et al., 2008; Vestergren and Cousins, 2009). Fish and shellfish generally exhibit the 
highest PFAS concentrations and detection rates among all types of foodstuffs (Domingo and 
Nadal, 2017; Jian et al., 2017). Other potential dietary sources of PFAS include dairy products, 
eggs, beverages and vegetables (Chen et al., 2018; Domingo et al., 2012; Eriksson et al., 2013; 
Felizeter et al., 2014; Gebbink et al., 2015; Haug et al., 2010; Heo et al., 2014; Herzke et al., 
2013; Noorlander et al., 2011; Vestergren et al., 2012; Zhang et al., 2010). However, these 
foodstuffs have generally low concentrations and low detection frequencies compared to fish and 
shellfish (Jian et al., 2017). In addition, food can become contaminated with PFAS through 
transfer from food packaging and/or processing (Schaider et al., 2017) because PFAS are used as 
in grease- and water-repellent coatings for food-contact materials and non-stick cookware 
(Begley et al., 2005).  
Drinking water is also a common source of PFAS in humans (Domingo and Nadal, 




various countries (Boone et al., 2019; Jin et al., 2009; Mak et al., 2009; Quinete et al., 2009; 
Quiñones and Snyder, 2009; Takagi et al., 2008; Thompson et al., 2011; Wilhelm et al., 2010). 
Recently, Boone et al. measured concentrations in source (untreated) and treated drinking water 
sampled from 24 states across the United States (Boone et al., 2019): Seventeen PFAS analytes 
were detected in all samples and summed concentrations ranged from <1-1102 ng/L, with one 
drinking water treatment plant (DWTP) exceeding the health advisory of 70 ng/L for PFOA and 
PFOS set by the United States Environmental Protection Agency (U.S. EPA).  
Some PFAS polymers such as FTOHs were frequently used for impregnation treatment 
of furniture and floor coverings, and as intermediates in manufacturing various household 
products (e.g. paints, carpet, and cleaning agents). These neutral PFAS, mainly FTOHs, FOSA, 
and FOSEs, are volatile compounds that are easily released into indoor environments (air and 
dust) due to their low water solubility and high vapor pressure (Haug, et al., 2011; Langer et al., 
2010; Yao et al., 2018). Perfluoroalkyls have also been detected in indoor air and dust (Barber et 
al., 2007; Kubwabo et al., 2005; Strynar and Lindstrom, 2008). In the study of 67 houses in 
Canada, carpeted home had higher concentrations of PFOA, PFOS and PFHxS in dust, possibly 
due to the use of stain-repellent coatings (Kubwabo et al., 2005). The use of aqueous firefighting 
foams at military installations and the production of fluorochemicals at industrial facilities have 
resulted in widespread contamination in soil and sediment (Anderson et al., 2016; Xiao et al., 
2015). Many consumer products, such as ski waxes, leather samples, outdoor textiles, and 
cosmetics products including hair spray and eyeliner, also contain PFAS (Danish EPA, 2018; 
Kotthoff et al., 2015).  
Previous literature has estimated the relative contributions of different exposures routes 




2011; Trudel et al., 2008; Vestergren and Cousins, 2009). Oral ingestion from diet and drinking 
water has been proposed as the largest source of exposure to PFOA and PFOS (around 90%) 
compared with inhalation or dermal contact (Gebbink et al., 2015; Haug, et al., 2011; Lorber and 
Egeghy, 2011; Vestergren and Cousins, 2009). For PFOA, Trudel et al. reported ingestion of 
food from PFOA-containing packaging materials (56%), inhalation of indoor air and dust (14%), 
and hand-to-mouth transfer of house dust (11%), as significant pathways (Trudel et al., 2008). 
Other pathways proposed to be less important included ingestion of food prepared with PTFE-
coated cookware, dermal contact from clothes and other consumer products (Trudel et al., 2008).  
3.3 Transport and clearance of PFAS in the human body 
Whereas most persistent organic pollutants such as polychlorinated biphenyls (PCBs) and 
brominated flame retardants (BFRs) are lipophilic, the substitution of carbon-hydrogen bonds for 
the strongest carbon-fluorine counterparts coupled with a charged functional group confers 
unique dual hydrophobic and lipophobic surfactant characteristics to PFAS molecules (Banks 
and Tatlow, 1994; Kissa, 2011). Most of the available data on transport and clearance of PFAS is 
based on studies with PFAAs (primarily PFOA and PFOS). In contrast to other persistent organic 
pollutants, PFAAs are not stored in adipose tissue but undergo extensive enterohepatic 
circulation. The presence of PFAAs has been confirmed primarily in liver and serum (Falk et al., 
2015; Pérez et al., 2013).  
The hydrophobic nature of fluorine-containing compounds can also lead to increased 
affinity for proteins (Jones et al., 2003). Once consumed, PFAAs tend to partition to the tissue of 
highest protein density, with approximately 90% to 99% of these compounds in the blood bound 
to serum albumin (Han et al., 2003; Ylinen and Auriola, 1990). Due to the ability of albumin to 




PFAAs can easily be transported into growing follicles. PFAAs have been detected in human 
follicular fluid, and could alter in vivo oocyte maturation and follicle development (Heffernan et 
al., 2018; Petro et al., 2014).  
The primary route of elimination of PFAAs is through the kidney in the urine (Han et al., 
2008). Other important clearance pathways include menstruation (Ding et al., 2020; Harada et 
al., 2005; Park et al., 2019; Taylor et al., 2014), pregnancy (Monroy et al., 2008), and lactation 
(Bjermo et al., 2013). Sex hormones have been identified as a major factor in determining renal 
clearance of PFAAs. Kudo et al. examined the role of sex hormones and transport proteins on 
renal clearance and concluded that, in ovariectomized female rats, estradiol could facilitate 
transporting of PFAAs across the membranes of kidney tubules into the glomerular filtrate, 
resulting in lower serum concentrations (Kudo et al., 2002).  
Serum concentrations of PFOA, PFOS, PFHxS and PFNA appear to be higher in males 
than in females across all age groups (Calafat et al., 2007). Wong et al. found that approximately 
30% of the PFOS elimination half-life difference between females and males was attributable to 
menstruation (Wong et al., 2014a). The differences by sex narrows with aging, suggesting that 
PFAS may reaccumulate after cessation of menstrual bleeding in postmenopausal women 
(Dhingra et al., 2017; Ruark et al., 2017; Wong et al., 2014b). Decreased serum concentrations 
have also been shown in premenopausal versus postmenopausal women and, analogously, in 
men undergoing venesections for medical treatment (Lorber et al., 2015).  
PFAAs are considered metabolically inert and remain in the human body for many years. 
Estimation of human elimination half-life (or population halving time) for PFOA, PFOS, PFHxS 




et al., 2020; Eriksson et al., 2017; Glynn et al., 2012; Li et al., 2018; Olsen et al., 2007,  2012; 
Spliethoff et al., 2008; Wong et al., 2014a; Worley et al., 2017; Yeung et al., 2013b,  2013a; 
Zhang et al., 2013). Comparing the estimated half-lives of PFAS among populations is difficult 
as they differ by sampling time intervals, duration of exposure, sex and age of study subjects. 
Despite these challenges, most of the aforementioned studies reported that the half-life in 
humans of PFOA is around 2-3 years, and of PFOS is approximately 4-5 years.  
4. Mechanistic evidence for ovarian toxicity of PFAS 
4.1 Effects of PFAS on folliculogenesis 
The ovary is the female gonad and an important endocrine organ. The ovaries consist of a 
surface epithelium surrounding the ovary, a dense underlying connective tissue (tunica 
albuginea), an outer cortex, and an inner medulla. The cortex appears dense and granular due to 
the presence of ovarian follicles, corpora lutea and stroma. The medulla is highly vascular with 
abundant blood vessels, lymphatic vessels, and nerves. The main functions of the ovary include 
production, maturation and release of the female gamete (oocyte), and synthesis of female sex 
steroid and peptide hormones that regulate reproductive and non-reproductive function. 
Environmental exposures can exhaust the oocyte pool and cause depletion of follicular cells, 
leading to earlier age at menopause, premature ovarian failure and infertility (Vabre et al., 2017). 
The processes of oogenesis and follicle development, and the effects of PFAS exposure on 
folliculogenesis, are summarized in Figure 2.    
4.1.1 Effects of PFAS on oogenesis 
PFAS exposure has been shown to disrupt the earliest stage of folliculogenesis by 




al., 2019). The potential mechanisms include activation of peroxisome proliferator-activated 
receptor (PPAR) signaling pathways, disruption of intercellular communication between oocytes 
and granulosa cells, and induction of oxidative stress.  
PPARs are family of nuclear hormone receptors that have been identified as key players 
in the mode of action for PFAS-induced reproductive toxicity (Desvergne and Wahli, 1999). All 
three known PPAR family members – α, β/δ and γ – are expressed in the ovary (Dauça et al., 
2014). The PPAR-α and PPAR-β/δ isoforms are expressed primarily in thecal and stromal cells 
in the ovary, while the PPAR-γ isoform is detected strongly in granulosa cells and the corpus 
lutea (Komar et al., 2001). The ability of PFAS to interact with nuclear PPARs has been put 
forward as an explanation for metabolic disturbances associated with PFAS exposure, mainly 
through PPAR-α. In addition, PPAR-γ has been found to inhibit the expression of genes 
involved in the meiosis of oocytes (e.g. endothelin-1 and nitric oxide synthase) (Komar, 2005), 
implicating a role in female gamete development.  
A recent study reported that administration of 10 μg/mL PFNA on bovine oocytes in 
vitro for 22 hours has a negative effect on oocyte developmental competence during their 
maturation (Hallberg et al., 2019). This decrease in oocyte survival was attributed to PPAR-α  
(Hallberg et al., 2019), leading to the disturbance of lipid metabolism and increased lipid 
accumulation in the ovaries (Bjork and Wallace, 2009; Wan et al., 2012). Lending further 
support, another study showed that excessive lipids in the ooplasm correlated with impaired 
oocyte developmental competence and low oocyte survival rates (Prates et al., 2014). Because 
PFAS can bind and activate PPARs and play an important role in PPAR signaling during ovarian 
follicle maturation and ovulation, it is plausible that persistent activation of ovarian PPARs 




In addition to the impact on PPAR signaling, PFAS exposure could alter cell-cell 
communication within a follicle. Because the interior of an ovarian follicle is avascular, cell-cell 
communication among granulosa cells and between granulosa cells and the oocyte is critically 
dependent on bidirectional transfer of low molecular weight nutrients, signaling molecules, and 
waste products via gap junction intercellular communication (Clark et al., 2018). When treated 
with an aqueous solution with 0, 12.5, 25 and 59 μM PFOS in vitro for a 44-hour maturation 
period, the number of live oocytes and the percentage of matured oocytes decreased in porcine 
ovaries (Domínguez et al., 2016). Similarly, fetal murine oocytes exposed to 28.2 and 112.8 μM 
PFOA in vitro for 7 days  exhibited increased apoptosis and necrosis (López-Arellano et al., 
2019). These effects are attributed due to inhibition of gap junction intercellular communication 
between oocytes and granulosa cells (Domínguez et al., 2016; López-Arellano et al., 2019).  
PFAS may also induce oxidative stress with increased generation of reactive oxygen 
species (ROS) production, increased DNA damage, and decreased total antioxidant capacity 
(Wielsøe et al., 2015). Pregnant mice administered 10 mg PFOA/kg/day from gestational days 1-
7 or 1-13 exhibited inhibited superoxide dismutase and catalase activity, increased generation of 
ROS, and increased expression of p53 and Bax proteins (important in apoptotic cell death) in the 
maternal ovaries (Chen et al., 2017; Feng et al., 2015). Similarly, another study reported 
significantly increased ROS production in rats exposed to PFOA, which interfered with the 
activities of complexes I, II, III in the mitochondrial respiratory chain and led to oocyte apoptosis 




4.1.2 EFFECTS OF PFAS ON FOLLICLE DEVELOPMENT 
Studies in laboratory rodents indicate that PFAS alters the formation and/or function of 
ovarian follicular cells at several stages of development. Adult female mice exposed to 0.1 mg 
PFOS/kg/day by gavage for 4 months had a decreased number of preovulatory follicles and 
increased number of atretic follicles (Chen et al., 2017; Feng et al., 2015). Moreover, the PFOS-
exposed mice had depressed serum levels of estradiol and progesterone. Notably, PFOS reduced 
the mRNA expression of steroidogenic acute regulatory protein (Star), which codes for the StAR 
protein that transports cholesterol from the outer to the inner mitochondrial membrane, a critical 
step in steroid hormone biosynthesis: this effect on Star was proposed as the cause of deficits in 
follicle maturation and ovulation (Feng et al., 2015). Similar findings were reported for pregnant 
mice exposed to 2.5, 5 and 10 mg PFOA/kg/day from gestational day 1–7 or 1-13, with 
decreased number of corpora lutea accompanied by decreased mRNA expression of Star in the 
maternal ovaries (Chen et al., 2017; Feng et al., 2015). 
In female rats exposed as neonates to 0.1 and 1 mg PFOA/kg/day, or 0.1 and 10 mg 
PFOS/kg/day, there was a significant reduction in the numbers of ovarian primordial follicles, 
growing follicles and corpora lutea (Du et al., 2019). The ovarian effects of the prior study were 
accompanied by down-regulated mRNA expression of KiSS-1 metastasis-suppressor (Kiss1) and 
KISS1 receptor (Kiss1r), and a decrease in kisspeptin fiber intensities in the hypothalamus. 
Because kisspeptin signaling has a critical role in regulation of the ovarian cycle as well as 
initiation of puberty (Gaytán et al., 2009; Hu et al., 2017), the PFOA and PFOS perturbation of 
follicular development may have resulted from disruption of kisspeptin signaling in the 




Pregnant mice administered oral doses of 200 and 500 mg/kg/day of perfluorobutane 
sulfonate (PFBS) on days 1-20 of gestation gave birth to female offspring that exhibited 
numerous symptoms of disrupted ovarian function: depressed ovarian size and weight, depressed 
size and weight, decreased number of ovarian follicles (all stages), delayed vaginal opening, 
delayed onset of estrus, prolonged diestrus, and reduced serum levels of estradiol (Feng et al., 
2017). In addition, the PFBS exposure disrupted thyroid hormone synthesis consistent with 
hypothyroxinemia, as indicated by depressed serum levels of the thyroid hormones 
triiodothyronine (T3) and thyroxine (T4) in the dams on gestation day 20 as well as in the female 
offspring (Feng et al., 2017). Mounting evidence from animal (Chang et al., 2008; Lau et al., 
2003; Thibodeaux et al., 2003) and human studies (Dallaire et al., 2009; Wang et al., 2014) 
suggests that levels of thyroid hormones decrease with increased PFAS concentrations. Thyroid 
hormones play a critical role in ovarian follicular development and maturation as well as in the 
maintenance of other physiological functions (Fedail et al., 2014; Wakim et al., 1994). It is 
possible that thyroid hormone insufficiency could affect follicle development via an influence on 
the production of follicular fluid, inhibin, estrogens, and other cytokines (Dijkstra et al., 1996; 
Tamura et al., 1998).  
4.2 Effects of PFAS on ovarian steroidogenesis  
Another primary function of the ovary is ovarian steroidogenesis -- the production and 
secretion of sex steroid hormones. Ovarian steroidogenesis relies on a strict coordination of both 
theca cells and granulosa cells and the addition of hypothalamus and anterior pituitary gland (as 
shown in Figure 3) (Hillier et al., 1994).  
Thecal cells produce androgens (androstenedione, A4; and testosterone, T) via the 




theca cell cytoplasm via the StAR protein. P450 cholesterol side-chain cleavage enzyme 
(CYP11A1) then catalyzes the conversion of cholesterol to pregnenolone. Pregnenolone is then 
converted to a precursor androgen, dehydroepiandrosterone (DHEA) that involves the enzyme 
17α-hydroxylase-17, 20-desmolase (CYP17A1), or progesterone via 3β-hydroxysteroid 
dehydrogenase (3β-HSD). Progesterone and DHEA are then converted to an androgen, A4, via 
CYP17A1 or 3β-HSD, respectively. The final androgenic steroid produced in the theca cell is T 
using the enzyme 17β-hydroxysteroid dehydrogenase (17β-HSD).  
A4 and T are androgen end-products of theca cell steroidogenesis and migrate across the 
basal lamina of the follicle to granulosa cells. In preovulatory follicles, granulosa cells proliferate 
and undergo differentiation to produce increasingly large amounts of 17β-estradiol (E2). Theca 
cells contain LH receptors (LHRs), and upon receptor binding, LH stimulates the transcription of 
theca-derived genes that encode the enzymes required for the conversion of cholesterol to 
androgens. Granulosa cells contain FSH receptors (FSHRs), and in response to FSH binding, the 
transcription of granulosa-derived genes that encode the enzymes necessary for the conversion of 
androgens to estrogens is stimulated. 
Endocrine disruption may occur at the molecular and cellular level by interference with 
steroid hormone biosynthesis in ovaries (Figure 3). PFAS can modulate the endocrine system by 
up- or down-regulation of expression of proteins responsible for cholesterol transport and 
ovarian steroidogenesis. Oral exposure to PFDoA at 3 mg/kg/day from postnatal day 24 for 28 
days significantly down-regulated the mRNA expression of ovarian luteinizing 
hormone/choriogonadotropin receptor (Lhcgr), Star, Cyp11a1, and Hsd17b3in pre-pubertal 
female rats, which led to a decrease in E2 production (Shi et al., 2009). Chronic exposure of 




reduced mRNA expression of Star mediated by reduced histone acetylation (Feng et al., 2015). 
Given that PFAS exposure does not change the substrate (cholesterol) supply in the ovaries 
(Rebholz et al., 2016), a decrease in Star mRNA levels might account for a reduction in transport 
of cholesterol as a necessary precursor for ovarian steroidogenesis.  
Another possible mechanism of action of PFAS as endocrine disruptors is through 
activation of PPARs. Exposure of isolated porcine ovarian cells in vitro to 1.2 μM PFOS or 
PFOA for 24 hours inhibited LH-stimulated and FSH-simulated secretion of progesterone, 
estradiol, and androstenedione in granulosa cells (Chaparro-Ortega et al., 2018). PPAR-γ can 
inhibit the expression of aromatase, the enzyme for the conversion of androgens to estrogens, by 
disrupting the interaction of nuclear factor-kappa B (NF-κB) (Fan et al., 2005). Rak-Mardyla and 
Karpeta showed that the activation of PPAR-γ caused lower expression and decreased enzymatic 
activity of CYP17 and 17β-HSD in porcine ovarian follicles (Rak-Mardyła and Karpeta, 2014), 
and thus decreased levels of progesterone and A4.  
PFAS are also known to have weak estrogenic activity, and as with other weak estrogens, 
exposure to a combination of E2 and these compounds produced anti-estrogenic effects (Liu et 
al., 2007). Studies have reported contradictory results using in vitro screening systems to assay 
for hormone activity by ER- or AR-mediated transactivation in the human breast 
adenocarcinoma cell lines MCF-7 and MVLN (Behr et al., 2018; Kjeldsen and Bonefeld-
Jørgensen, 2013; Maras et al., 2006; Wang et al., 2012), human adrenal carcinoma cell H295R 
(Behr et al., 2018; Du, Hu, et al., 2013; Du, Huang, et al., 2013; Wang et al., 2015), human 
placental choriocarcinoma cell JEG-3 (Gorrochategui et al., 2014), rat Leydig cells (Biegel et al., 




Hu, et al., 2013; Yao et al., 2014). It remains unclear whether PFAS affect estrogen or androgen 
receptor signaling at concentrations relevant to human exposure.     
Nonetheless, because gonadotropin (GnRH) neurons in the hypothalamus do not express 
ER, they are regulated by E2 and T primarily from kisspeptin neurons in the arcuate nucleus 
(ARC) and anteroventral periventricular nucleus (AVPV) that send projections to GnRH neurons 
(Roa et al., 2009). E2 and T down-regulate Kiss1 mRNA in the ARC and up-regulate its 
expression in the AVPV. Thus, kisspeptin neurons in the ARC may participate in the negative 
feedback regulation of GnRH secretion, whereas kisspeptin neurons in the AVPV contribute to 
generating the preovulatory GnRH surge in the female. In vivo evidence demonstrated that 
exposure of adult female mice to PFOS at 10 mg/kg/day for 2 weeks led to diestrus prolongation 
and ovulation reduction through suppression of AVPV-kisspeptin neurons, but not via ARC-
kisspeptin neurons in the forebrain (Wang, Bai, et al., 2018). PFAS may impair ovulation and 
reproductive capacity through suppression of the activation of ER-mediated AVPV-kisspeptin 
expression.  
5. Epidemiologic evidence linking PFAS exposure and ovarian outcomes  
Ovarian folliculogenesis and steroidogenesis are essential processes for normal 
reproductive health. Increasing evidence suggests that PFAS could adversely affect numerous 
aspects of these processes. Specifically, exposures to PFOA and PFOS have been shown to 
impact ovarian steroidogenesis (Table 2), delay onset of menarche (Table 3), disrupt menstrual 
cycle regularity (Table 4), accelerate ovarian aging (Table 5), and may affect other chronic 
conditions such as polycystic ovarian syndrome (PCOS) and ovarian cancer (Table 6). Other 




5.1 Sex hormones 
Exposure to PFAS has been shown to disrupt ovarian steroidogenesis and steroidogenic-
controlled processes. Although the literature on other PFAS chemicals is scant, epidemiologic 
evidence suggests that exposure to PFOS is associated with steroidogenic defects. Specifically in 
the C8 Health Project, PFOS exposure had a significant and negative relationship with serum E2 
levels among women aged 42-65 years without a history of hormone contraceptive use (Knox et 
al., 2011). The parent Energy Balance and Breast Cancer Aspects (EBBA-I) study sampled 
serum from healthy, naturally cycling women aged 25-35 years and found that, among 
nulliparous women but not parous women, PFOS exposure was negatively associated with serum 
E2 and progesterone (P) levels (Barrett et al., 2015). Similarly, Zhang et al. suggested that PFOS 
exposure may lead to decreased serum E2 and prolactin (PRL) levels and increased FSH levels 
among premature ovarian insufficiency (POI) patients (Zhang et al., 2018). McCoy et al. also 
found a negative correlation between PFOS concentrations and E2 levels among women 
undergoing in vitro fertilization (McCoy et al., 2017). Moreover, Heffernan et al. observed a 
significant and negative association between PFOS exposure and free androgen index (FAI) 
among healthy women without PCOS (Heffernan et al., 2018).   
In contrast, no associations with hormone levels have been reported for PFOA exposure 
(Barrett et al., 2015; Heffernan et al., 2018; Knox et al., 2011; McCoy et al., 2017; Zhang et al., 
2018). PFOS and PFOA were also not related to serum T levels among women 12-80 years of 
age from the NHANES 2011-2012 (Lewis et al., 2015). In utero exposure to PFOA and PFOS 
had no impact on serum levels of total T, sex hormone binding globulin (SHBG), FAI, DHEA, 





Other PFAS may also have the potential to disturb homeostasis of the endocrine system, 
although the evidence remains inconclusive. Heffernan et al. found a positive association 
between PFNA exposure and A4 in both PCOS cases and controls, and a positive association 
between PFHxS exposure and total T in healthy women (Heffernan et al., 2018). Zhang et al. 
indicated that PFHxS exposure may increase FSH levels and decrease E2 levels in POI patients 
(Zhang et al., 2018). No significant associations were observed in cross-sectional studies 
conducted among naturally cycling women in the EBBA-I study (Barrett et al., 2015), general 
women in NHANES (Lewis et al., 2015), or women receiving in vitro fertilization (IVF) 
(McCoy et al., 2017).  
Compared to adults, adolescents may be more susceptible to PFAS toxicity. Serum 
concentrations of PFOA, PFUnA, and PFOS were inversely associated with serum levels of 
SHBG, FSH, and T, respectively, in adolescents aged 12-17 years but not in young adults (Tsai 
et al., 2015).  Similarly, girls aged 6-9 years who enrolled in the C8 Health Project also had 
lower serum T levels with higher exposure to PFOS (Lopez-Espinosa et al., 2016). Although no 
association was observed for PFOA and PFOS exposures with E2 or T in Chinese adolescent 
girls, serum T levels decreased by 1.2% (95% CI: -2.2%, -0.1%) with an 1 ng/mL increase in 
serum PFDoA concentrations (Zhou et al., 2016).  
5.2 Onset age of menarche  
Delayed menarche is a common condition defined as the absence of physical signs of 
puberty by an age ≥2-2.5 standard deviations above the population mean age of menarche 
(typically 13 years in girls) (Palmert and Dunkel, 2012). Emerging evidence suggests that later 
menarche may be linked to negative physiological outcomes, and cardiovascular disease in 




to PFAS and timing of menarche have yielded inconsistent results with some studies finding no 
association (Christensen et al., 2011; Kristensen et al., 2013; Lopez-Espinosa et al., 2011). The 
latter study, a cross-sectional study of 2931 girls 8-18 years of age from the C8 Health Project, 
reported  that PFOA and PFOS serum concentrations were associated with later age at menarche, 
specifically 130 and 138 days of delay comparing the highest quartile of concentrations vs. the 
lowest, respectively (Lopez-Espinosa et al., 2011).  
In addition, concern exists regarding in utero exposure to PFAS due to high vulnerability 
in this early-life stage. A Danish birth cohort established in 1988-1989 followed up 267 female 
offspring when they were ~20 years of age in 2008-2009. The study found that women with in 
utero exposure to higher concentrations of PFOA reached menarche 5.3 (95% CI: 1.3, 9.3) 
months later compared with the reference group of lower PFOA concentrations; while no 
associations were observed for PFOS (Kristensen et al., 2013). In contrast, a study of 218 girls 
reporting early menarche (before age 11.5 years) and 230 controls (at or after age 11.5 years) 
born between 1991 and 1992 in the United Kingdom showed no association of earlier age at 
menarche with exposure to PFOSA, EtFOSAA, MeFOSAA, PFOS, PFHxS, PFOA, or PFNA 
(Christensen et al., 2011).  
5.3 Menstrual cycle characteristics 
Disturbances of menstrual cycle manifest in a wide range of presentations. The key 
characteristics include menstrual cycle regularity, cycle length, and the amount of flow, but each 
of these may exhibit considerable variability. Epidemiologic data on the possible effects of PFAS 
on menstrual cycle regularity originate primarily from cross-sectional studies (Lyngsø et al., 
2014; Zhou et al., 2017). Lyngsø et al. reported a statistically significant association between 




(95%CI: 1.0-3.3) when comparing the highest tertile of exposure with the lowest, in 1623 fertile 
women enrolled in the Inuit-endocrine (INUENDO) cohort from 3 countries (Greenland, Poland 
and Ukraine); whereas no significant results were detected for PFOS (Lyngsø et al., 2014). 
Moreover, a cross-sectional analysis of 950 Chinese women revealed that increased exposures to 
PFOA, PFOS, PFNA and PFHxS were associated with higher odds of irregular and longer 
menstrual cycle but lower odds of menorrhagia (Zhou et al., 2017). Interestingly, women with 
higher concentrations of PFOA, PFNA and PFHxS were more likely to experience 
hypomenorrhea (Zhou et al., 2017).  
The relationship of PFOA and PFOS with menstrual irregularity was detected in a subset 
of 1240 pregnant women randomly selected from the Danish National Birth Cohort (DNBC); 
women had higher exposure to PFOA and PFOS tended to report having irregular period (Fei et 
al., 2009). Lum et al. used data from 501 couples from Michigan and Texas upon their 
discontinuing contraception for purposes of becoming pregnant who enrolled in a prospective 
cohort, the Longitudinal Investigation of Fertility and the Environment (LIFE) Study (Lum et al., 
2017). Menstrual cycles were 3% longer among women in the second versus the lowest tertile of 
PFDeA serum concentrations, but 2% shorter for women in the highest versus the lowest tertile 
of PFOA concentrations; while no associations were observed with PFOS (Lum et al., 2017). 
When examining the effects of prenatal exposure, a recent prospective study found no 
associations between maternal exposure to PFOA and PFOS and menstrual cycle length or 
number of ovarian follicles in their offspring (Kristensen et al., 2013). 
5.4 Ovarian aging 
Premature ovarian insufficiency (POI) represents a gynecological disorder characterized 




years with the presence of oligo/amenorrhea for at least 4 months in combination with elevated 
FSH levels. It should be noted that POI is the transitional stage from normal ovarian function to 
complete loss of ovarian function. A case-control study of 240 Chinese women found that high 
exposures to PFOA, PFOS and PFHxS were associated with increased risks of POI; however, no 
associations were observed for PFNA, PFDeA, PFUnA, PFDoA, PFHpA, and PFBS (Zhang et 
al., 2018).  
Beyond the problem of infertility in POI patients, diminished ovarian reserve and 
extended steroid hormone deficiency during ovarian aging have far-reaching health implications. 
Earlier age at natural menopause  has been associated with an increased risk of overall mortality 
(Jacobsen et al., 2003; Mondul et al., 2005; Ossewaarde et al., 2005), cardiovascular disease 
(Atsma et al., 2006; Hu et al., 1999) and cardiovascular death (de Kleijn et al., 2002; Mondul et 
al., 2005; van der Schouw et al., 1996), low bone mineral density (Parazzini et al., 1996) and 
osteoporosis (Kritz-Silverstein and Barrett-Connor, 1993), and other chronic conditions (Shuster 
et al., 2010). Quality of life may be significantly decreased while risks of sexual dysfunction and 
neurological disease may be increased later in life (McEwen and Alves, 1999; Rocca et al., 2009; 
Van Der Stege et al., 2008).  
A study of the National Health and Nutrition Examination Survey (NHANES) 
participants found that higher PFAS concentrations were associated with earlier menopause: a 
hazard ratio (HR) of natural menopause was 1.42 (95% CI: 1.08, 1.87) comparing PFHxS serum 
concentrations in tertile 2 versus tertile 1, and 1.70 (95% CI: 1.36, 2.12) in tertile 3 versus tertile 
1; positive dose-response relationships were also detected for PFOA, PFOS, PFNA and PFHxS 
with hysterectomy (Taylor et al., 2014). Additionally, a cross-sectional study of the C8 Health 




increased with increasing exposure quintiles of PFOA and PFOS, particularly in women aged 42-
65 years (Knox et al., 2011).  
These epidemiologic studies of PFAS and age at menopause were cross-sectional 
analyses in which the outcome was ascertained through an interview at the same time as a blood 
sample was collected to determine serum PFAS concentrations. It raises the question of reverse 
causation, in that measured PFAS concentrations increased with years since menopause, possibly 
due to the cessation of PFAS excretion via menstruation (Taylor et al., 2014). Using a 
retrospective cohort of women recruited during 2005-2006, Dhingra et al. found no significant 
association between PFOA exposure (using either estimated year-specific serum concentrations 
during 1951 and 2011, or measured serum concentrations) and natural menopause incidence 
(Dhingra et al., 2016).  
5.5 Other conditions 
PCOS is a common endocrine disorder among women of reproductive age, leading to 
several health complications including menstrual dysfunction, infertility, hirsutism, acne, 
obesity, metabolic syndrome, and an increased risk of type-2 diabetes and cardiovascular disease 
(Norman et al., 2007). A study of 180 infertile PCOS cases and 180 healthy controls showed a 
significant and positive dose-response relationship between PFDoA serum concentrations and 
risks of PCOS-related infertility; however, no significant associations were observed for PFBS, 
PFHpA, PFHxS, PFOA, PFOS, PFNA, PFDeA, or PFUA (Wang, Zhou, et al., 2019). In regard 
to cancer, only a few studies have evaluated associations between PFAS exposure and increased 
risks of ovarian cancer (Barry et al., 2013; Vieira et al., 2013). Neither of these studies observed 
a significant association but the number of cases in each study was small. Thus, the evidence is 





Findings from in vitro and in vivo studies suggests that PFAS exposure can target the 
ovary to adversely affect its two essential functional processes, i.e., folliculogenesis and 
steroidogenesis.  PFAS exposure may alter follicle and oocyte development and diminish ovarian 
reserve (Bellingham et al., 2009; Chen et al., 2017; Domínguez et al., 2016; Du et al., 2019; 
Feng et al., 2015,  2017; Hallberg et al., 2019; López-Arellano et al., 2019). Potential 
mechanisms include PPAR activation, disruption of gap junction intercellular communication, 
oxidative stress, and thyroid hormone disruption. Limited experimental evidence published to 
date also suggests PFAS can be a disruptor of ovarian steroidogenesis with independent actions 
on both theca and granulosa cells (Chaparro-Ortega et al., 2018; Shi et al., 2009; Wang, Bai, et 
al., 2018). In addition to PPAR signaling pathways, endocrine disruption may also be facilitated 
by acting directly on gene coding for enzymes responsible for cholesterol transport and ovarian 
steroidogenesis, and a loss of kisspeptin signaling in the hypothalamus that can impact ovarian 
function.  
In general, experimental studies were limited by the use of doses that exceed the range of 
estimated human exposure. For example, it is calculated that North American and European 
consumers had a daily uptake dose of PFOA in the range of 3-220 ng/kg bw and PFOS of 1 to 
130 ng/kg bw (Trudel et al., 2008). The lowest concentrations of PFOS and PFOA used in 
studies of animal models investigating follicle development was 0.1 mg/kg bw/day (=105 ng/kg 
bw/day) (Chen et al., 2017; Feng et al., 2015).  
In epidemiologic studies, the associations between PFAS exposure and ovarian function 
across different populations and difference ranges of exposure levels were inconsistent. Despite 




compounds is associated with later menarche (Kristensen et al., 2013; Lopez-Espinosa et al., 
2011), irregular and longer menstrual cycle (Chen et al., 2017; Fei et al., 2009; Lum et al., 2017; 
Lyngsø et al., 2014; Zhou et al., 2017), increased risks of POI (Zhang et al., 2018), and earlier 
onset of menopause (Knox et al., 2011; Taylor et al., 2014).  
Methodologic problems, however, limit the causal interpretation of these findings. The 
observed associations between PFAS exposure and delayed menarche could be explained by 
reverse causation rather than a toxic effect of these substances, in that the physiological changes 
during reproductive growth and maturation in girls may have a considerable influence on serum 
PFAS concentrations (Wu et al., 2015). It is also possible that the observed associations of PFAS 
and early onset of menopause in cross-sectional studies might be due to reverse causation related 
to the presence or volume of menstrual bleeding. Furthermore, information on the timing of 
menarche, menstrual cycle length and age at menopause were based on self-reports, and recalled 
data may have been imprecise particularly for users of hormonal contraceptives (Must et al., 
2002; Small et al., 2007). Relationships between PFAS exposure and menstrual cycle length 
among contraceptive users may have been blurred by actions of exogenous hormones (Lum et 
al., 2017).  
Evidence from epidemiologic studies also suggests associations of PFAS exposure with 
lower E2 levels and higher FSH levels in female adults (Barrett et al., 2015; Heffernan et al., 
2018; Knox et al., 2011; McCoy et al., 2017; Zhang et al., 2018). This is consistent with the role 
of PFAS in accelerating ovarian aging. Compared to adults, girls may be more vulnerable 
because exposures to PFAS may lead to decreased serum levels of SHBG, FSH, and total T 
(Lopez-Espinosa et al., 2016; Tsai et al., 2015; Zhou et al., 2016). However, the associations 




also probably subject to reverse causation because sex steroid hormones could affect rates of 
renal clearance (Kudo et al., 2002). Higher ovarian hormone levels also tend to have a more 
proliferative endometrial lining (Clancy, 2009) and, by extension, heavier menstrual bleeding, 
which could contribute to greater clearance of PFAS in menstrual blood. Therefore, we cannot 
rule out the possibility that fluctuations in hormone levels might impact PFAS serum 
concentrations in women. Given the inconsistency in previous findings and lack of longitudinal 
evidence, no causal inferences can be drawn at this time based on this body of literature. 
7. Conclusions 
The possibility of an association between PFAS exposure and abnormal ovarian function 
has important implications for research and public health. The ovary is a primary regulator of 
reproductive and endocrine function as well as general health in the female. Because millions of 
people worldwide are exposed to PFAS-contaminated drinking water, the public health 
consequences of a causal relationship could be serious. Methodologic problems limit the causal 
interpretation of associations between PFAS exposure and menstrual disorders in epidemiologic 
studies. Overall, there is insufficient evidence to determine a causal relationship between PFAS 
exposure and ovarian function. Experimental studies with doses relevant to human exposure and 
epidemiologic research with prospective study designs should be future research priorities.  
8. Specific aims 
   Menopause is a sensitive and critical time window in a woman’s life. The existing 
knowledge for understanding the impact of environmental pollutants on menopause is limited. 
This dissertation focused on PFAS which are persistent in the environment for years and can bio-




environmental ubiquity and their toxicity. However, few studies have addressed the role of 
PFASs on reproductive aging.  
The overall goal of my dissertation project was to explore how exposure to PFAS affects 
the timing of menopause and to fill research gaps in the evidence base. This area of study will 
provide a new window on population-level effects from chemical exposures, help shape clinical 
recommendations, as well as suggest public health prevention and intervention strategies. 
Aim 1: To describe the longitudinal changes in PFAS concentrations during the menopausal 
transition and evaluate whether time trends differed by reproductive aging (i.e. menstruation 
status), parity, or race/ethnicity. 
Aim 2: To examine the associations between PFAS exposures and incidence of natural 
menopause in the multi-racial/ethnic sample of women who were premenopausal at baseline with 
standard approximately annual clinic visits from 1999-2017.  
Sub-Aim 1: To assess whether the relationship differed by racial/ethnic groups.  
Sub-Aim 2: To identify subgroups exposed to different patterns of PFAS using the k-means 
clustering method and evaluate the combined effects of PFAS mixtures on menopause. 
Aim 3: To explore causal mediation of the relationship between exposure to PFAS, as indicated 
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Table I. 1 Sources and pathways of human exposure to PFAS. 
Sources Pathways 
Dietary sources 
  Fish and shellfish Environment/Ingestion 
  Drinking water Ingestion  
  Food-packaging materials Ingestion 
  Non-stick cookware Ingestion 
  Others (including dairy products, eggs,  
  beverages and vegetables) 
Ingestion 
Non-dietary sources 
  Indoor air Inhalation 
  Indoor dust Inhalation/Ingestion 
  Soil and sediment Environment 
  Impregnation spray (for furniture and carpet) Inhalation/Dermal absorption 
  Cosmetics Dermal absorption 
  Other consumer products (including ski  



































































PFOA: no association 
PFOS: only in 
women >42-51 years,  
(-) -13.4 (P<.0001); 
and >51 years,  




















































































with OC use, 




chronic illness (e.g. 






Day -7 to -
1 for E2 
and day +2 








PFOA: no association 
PFOS:  
(-) -0.025 (-0.043, -
0.007) 
2) ln(P) 
PFOA: no association 
PFOS:  






























































































PFOA: (-) 3.5 (0.2), 
3.5 (0.3), 3.4 (0.3), 
3.0 (0.3) 
PFOS: no association 
2) FSH: no 
association 
3) T 
PFOA: no association 
PFOS: (-) 4.0 (0.2), 
4.0 (0.2), 3.9 (0.2), 
3.6 (0.4) 
4) E2: no association 
Among young adults, 
no association 
Age, gender, 


























the p75 vs. 
p25 of 
ln(PFAS) 
PFOA: no association 
PFOS:  
(-) -6.6% (-10.1%, -
2.8%) 


























from seven public 
schools who had no 
personal or family 





per 1 ng/mL 
increase in 
PFAS 



























Including women at 
the Coastal Fertility 








PFOA: no association 





























































PFOS: no association 
2) SHBG: no 
association 
3) ln(FAI)  
PFOA: no association 
PFOS: (-) -0.61 
(0.26) 
4) A4: no association 














































Among POI cases, 
1) ln(FSH) 
PFOA: no association 
PFOS: (+) 0.3 (0.2-
0.4) 
2) ln(LH): no 
association 
3) ln(E2) 




PFOA: (+) 0.2 (0.01-
0.3) 










Abbreviations: AMH, anti-Mullerian hormone; A4, androstenedione; BMI, body mass index; DHEA, dehydroepiandrosterone; ETS, environmental tobacco smoke; E2, estradiol; 
FAI, free androgen index, was calculated as 100×total T/SHBG; FSH, follicle-stimulating hormone; GM, geometric mean; IQR, interquartile range; NA, not available; NM, not 
measured; OR, odds ratio; P, progesterone; PCOS, polycystic ovarian syndrome; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; POI, premature ovarian 

























Girls with age of 
menarche before 11.5 
years and controls with 
age of menarche later 
than 11.5 years from 
the Avon Longitudinal 
Study of Parents and 
Children conducted 






















PFOA/PFOS: no association Birth order, 








Girls enrolled in the C8 
Health Project from the 
Mid-Ohio Valley in the 
US during 2005-2006 

















1) Being postmenarcheal 
PFOA: (-) 0.57 (0.37-0.89). 
PFOS: (-) 0.55 (0.35-0.87). 
 









enrolled in a Danish 
population-based cohort 
from 1988-1989 with 
follow-ups in 2008-
2009 













β (95%CI) in 
the highest 
tertile vs. the 
lowest (the 
reference) 
PFOA: (+) 5.3 (1.3-9.3) 







 Abbreviations: BMI, body mass index; IQR, interquartile range; OR, odds ratio; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; 95%CI, 95% confidence 























































PFOA: 9.0% vs. 15.0%  



























1) Cycle length, 
day 
 
2) Number of 






by OC use 































1) Longer cycle with 
cycle length ≥32 
days 
 
2) Shorter cycle with 
cycle length ≤24 
days 
 
3) Irregular cycle 










1) Longer cycle 
PFOA: (+) 1.8 (1.0-3.3). 
PFOS: no association 
 
2) Shorter cycle 
PFOA/PFOS: no association  
 
3) Irregular cycle 




































PFOA: (-) 0.98 (0.96-1.00) 



















1) Longer periods 
with cycle 




1) Longer periods 
PFOA: (+) 2.0 (1.2-3.1). 
PFOS: no association 
Age, BMI, 







(28-32) (10.1-18.8) (7.6-15.4)  
2) Irregular periods 




3) Menorrhagia as 
self-reported heavy 











2) Irregular periods 
PFOA: (+) 2.0 (1.2-3.2). 
PFOS: no association 
 
3) Menorrhagia 
PFOA: (-) 0.2 (0.1-0.5). 
PFOS: (-) 0.3 (0.1-0.6). 
 
4) Hypomenorrhea 
PFOA/PFOS: no association 
menarche, and 
parity 
Abbreviations: AF, acceleration factor; BMI, body mass index; IQR, interquartile range; OR, odds ratio; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; 





































Valley in the 
US during 
2005-2006 




Natural menopause OR (95%CI) in the 
highest quintile vs. 
the lowest (the 
reference) 
stratified by age 
groups (18-42 
years, >42-51 







PFOA: (+) 1.4 (1.1-1.8) 
PFOS: (+) 1.4 (1.1-1.8) 
 
>51 years 
PFOA: (+)1.7 (1.3-2.3) 















from the US 








HR (95%CI) in the 
highest tertile vs. 
the lowest (the 
reference) 
1) Natural menopause 
PFOA: (+) 1.4 (1.1-1.8) 
PFOS: no association 
 
2) Hysterectomy 
PFOA: (+) 2.8 (2.1-3.7) 






















3334 ≥40  P40, 60 
17.8-33.6 
NM Natural menopause HR (95% CI) in 
the highest quintile 











Case-control Women with 






















POI as an elevated 
FSH level >25IU/L 
on two occasions >4 
weeks apart and 
oligo/amenorrhea for 
≥4 months 
OR (95%CI) in the 
highest tertile vs. 
the lowest (the 
reference) 
PFOA: (+) 3.8 (1.9-7.5) 





Abbreviations: AF, acceleration factor; IQR, interquartile range; NM, not measured; OR, odds ratio; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; POI, 








Study design Population, 
























DuPont from the 
US during 2005-
2006 and 













NM Ovarian cancer HR (95%CI) per 
ln-unit increase in 
PFAS 









living near the 
DuPont plant 


























from China in 
2014 




PCOS OR (95%CI) in the 
highest tertile vs. 
the lowest (the 
reference) 
No association Age, BMI, 
household income, 
education, 
employment, age at 
menarche, 
menstrual volume 
Abbreviations: NM, not measured; OR, odds ratio; PCOS, polycystic ovarian syndrome; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; 95%CI, 95% 




Table I. 7 Epidemiologic evidence on the effects of other PFAS compounds. 
1st author, 
Year 
Study design Population, location, 














Case-control Girls with age of 
menarche before 11.5 
years and controls 
with age of menarche 
later than 11.5 years 
from the Avon 
Longitudinal Study 
of Parents and 
Children conducted 
during 1991-1992 in 
the UK 
448 8-13 Median (IQR) 
maternal exposure 





PFHxS, 1.6 (1.2-2.2) 
PFNA, 0.6 (0.5-0.8) 
 
Early menarche 







No association Birth order, 
maternal age at 
delivery 










950 ~30 Median (IQR) 
PFHxS, 0.7 (0.6-0.9) 
PFNA, 1.4 (1.0-1.9) 
1) Longer cycle 
with cycle length 
>35 days 
2) Irregular cycle 
with ≥7 days in 
difference between 
cycles 
3) Menorrhagia as 
self-reported heavy 






in the highest 
quartile vs. the 
lowest (the 
reference) 
1) Longer cycle 
PFHxS: (+) 2.1 (1.3-
3.5) 
PFNA: (+) 1.7 (1.0-2.7) 
2) Irregular cycle 
PFHxS: (+) 2.1 (1.3-
3.5) 
PFNA: no association 
3) Menorrhagia 
PFHxS: (-) 0.3 (0.1-
0.7) 
PFNA: (-) 0.4 (0.2-0.9) 
4) Hypomenorrhea 
PFHxS: (+) 3.6 (1.5-
8.6) 
PFNA: no association 
Age, BMI, 














from the US 
501 18-
40 
Median (IQR) among 




PFDeA, 0.4 (0.2-0.6) 
PFNA, 1.2 (0.8-1.7) 
Relative difference 
in menstrual cycle 
length 
AF (95%CI) in 
the highest 
tertile vs. the 
lowest (the 
reference) 





Case-control Women with overt 
POI and healthy 
controls from China 
240 20-
40 
Median (IQR) in 
controls: 
PFHpA, 0.2 (0.1-0.3) 
POI as an elevated 
FSH level >25IU/L 
on two occasions 
OR (95%CI) 
in the highest 
tertile vs. the 
PFHpA: no association 
PFNA: no association 








PFNA, 1.8 (1.3-2.7) 
PFDeA, 1.7 (1.0-2.6) 
PFDoA, 0.17 (0.1-
0.2) 
PFUnA, 1.3 (0.8-1.9) 
PFBS, 0.05 (0.04-0.1) 
PFHxS, 0.3 (0.2-0.4) 
>4 weeks apart and 
oligo/amenorrhea 
for ≥4 months 
lowest (the 
reference) 
PFDoA: no association 
PFUnA: no association 
PFBS: no association 








General adult women 
in NHANES 1999-
2010 from the US 
2732 20-
65 
Median (IQR) in 
premenopausal 
women: 
PFHxS, 1.0 (0.6-1.8) 





in the highest 
tertile vs. the 
lowest (the 
reference) 
1) Natural menopause 
PFHxS: (+) 1.7 (1.4-
2.1) 
PFNA: (+) 1.5 (1.1-1.9) 
2) Hysterectomy 
PFHxS: (+) 3.5 (2.7-
4.5) 











Healthy women with 
natural cycling 
enrolled in the parent 
Energy Balance and 
Breast Cancer 














PFNA, 0.6 (0.2-2.9) 
Saliva E2 and P, 
ln(pmol/L) 
 
Day -7 to -1 for E2 


















Women in NHANES 









PFNA, 0.7;  
40-<60:PFHxS, 0.9; 
PFNA, 0.8;  
60-<80:PFHxS, 1.5; 
PFNA, 1.1. 
Serum T, pmol/L  Percent change 





age groups  
































1) SHBG: no 
association 
2) FSH 
PFNA: no association 
PFUnA: only in girls 
12-17 years, (-) 1.6 
Age, gender, 








(0.3), 1.6 (0.2), 1.4 
(0.2), 1.2 (0.2) 
3) T: no association 







Girls enrolled in the 
C8 Health Project 
during 2005-2006 
1123 6-9 Median (IQR) 
PFHxS, 7.0 (3.8-13.8) 
PFNA, 1.7 (1.3-2.4) 




(95%CI) in the 
p75 vs. p25 of 
ln(PFAS) 






Girls enrolled in the 
Genetics and 
Biomarkers study for 
Childhood Asthma 





PFBS, 0.5 (0.4-0.5) 
PFHxS, 1.2 (0.5-3.0) 
PFHxA, 0.2 (0.1-0.3) 
PFNA, 0.9 (0.6-1.1) 
PFDeA, 1.0 (0.8-1.2) 
PFDoA, 3.1 (0.9-6.2) 
PFTeA, 4.5 (0.3-18.4) 
Serum E2 and T, 
pmol/L 





Only for PFDoA, 



























Plasma E2, pg/mL Correlation 
coefficient (P 
value) 
No association NA 
Heffernan 
2018 
Case-control Women with PCOS 
and age- and BMI-
matched controls 
recruited from the 




PFHxS, 1.0 (0.2-10.2) 
PFNA, 0.6 (0.2-1.8) 
Serum T, and 
SHBG, ln(pmol/L); 
FAI; 
Serum A4 and E2, 
pmol/L 
 
Luteal phase  
β (SE) per ln-





Among PCOS cases, 
only for A4 and  
PFNA: (+) 1.71 (0.65) 
Among controls, 
only for ln(T),  
PFHxS: (+) 0.50 (0.17) 




Case-control Women with overt 
POI and 120 healthy 





Median (IQR) in 
controls 
PFHxS, 0.3 (0.2-0.4) 
 
Serum FSH, LH, 









Among POI cases, 
1) ln(FSH)  
(+) 0.16 (0.04-0.28) 
2) ln(LH): no 
association 
3) ln(E2) 
(-) -0.19 (-0.37- -0.02) 
4)ln(PRL): no 
association 
5)ln(T): no association 
Among controls, 











Case-control Infertile women 
diagnosed with 
PCOS and healthy 










PFNA, 0.5 (0.3-0.9) 
PFDeA, 0.5 (0.3-0.8) 
PFUnA, 0.4 (0.3-0.6) 
PFDoA, 0.24 (0.2-
0.27) 
PCOS OR (95%CI) 
in the highest 
tertile vs. the 
lowest (the 
reference) 
PFBS: no association 
PFHxS: no association 
PFHpA: no association 
PFNA: no association 
PFDeA: no association 
PFUnA: no association 









Abbreviations: AMH, anti-Mullerian hormone; A4, androstenedione; BMI, body mass index; DHEA, dehydroepiandrosterone; EtFOSAA, 2-(N-Ethylperlfuorooctane 
sulfonamide) acetic acid; E2, estradiol; FAI, free androgen index, was calculated as 100×total T/SHBG; FSH, follicle-stimulating hormone; GM, geometric mean; 
IQR, interquartile range; MeFOSAA, 2-(N-Methylperfluorooctane sulfonamido) acetic acid; NHANES, National Health And Nutrition Examination Survey; NM, not 
measured; OR, odds ratio; P, progesterone; PCOS, polycystic ovarian syndrome; PFBS, perfluorobutane sulfonic acid; PFDeA, perfluorodecanoic acid; PFDoA, 
perfluorododecanoic acid; PFHpA, perfluoroheptanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOSA, perfluorooctane 
sulfonamide; PFUnA, perfluoroundecanoic acid; POI, premature ovarian insufficiency; PRL, prolactin; p60 and 90, 60th and 90th percentiles; SHBG, sex hormone-






Figure I. 1 The chemical structures of perfluoroalkyl substances. a. The basic chemical structure of perfluoroalkyl substances, where 
“𝐶𝑛𝐹2𝑛+1” represents the length of the perfluoroalkyl chain and “𝑅” defines the functional group. b. The general chemical structures 
of perfluoroalkyl carboxylic acids (PFCAs) with the functional group of –COOH. c. The general chemical structures of 
perfluoroalkane sulfonic acids (PFSAs) with the functional group of -𝑆𝑂3𝐻. d-i. The chemical structures of commonly detected 
perfluoroalkyl substances, including liner and branched perfluorooctane sulfonic acid (PFOS), linear and branched perfluorooctane 
carboxylic acid (PFOA), perfluohexane sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA). Note that branched PFOA and 
PFOS isomers may have different rearrangements from the linear form, often mono-substituted, di-substituted, or cyclic structural 





Figure I. 2 PFAS disrupt folliculogenesis. The upper part of the figure is about follicle development and the text box shows the effects 
of PFAS on the number of follicles at that stage of development. The part below displays the process of oogenesis and text boxes 
outline the major effects of PFAS at that stage of oocyte development and maturation. GJIC=gap junction intercellular 





Figure I. 3 PFAS alter ovarian steroidogenesis. Ovarian steroidogenesis requires the cooperative 
interactions of the theca and granulosa cells within the follicles. This figure is a simplified 
overview of the two-cell ovarian steroidogenesis model, with black text boxes indicating PFAS 
targets from the experimental literature. ARC=arcuate nucleus; AVPV=anteroventral 
periventricular nucleus; cAMP=cyclic adenosine monophosphate; CYP11A1=cholesterol side 
chain cleavage enzyme; CYP17A1=17α-hydroxylase-17, 20-desmolase; CYP19A1=cytochrome 
P450 aromatase; ERα=estrogen receptor α; FSH=follicle-stimulating hormone; FSHR=follicle-
stimulating hormone receptor; GnRH=gonadotropin-releasing hormone; GnRHR=gonadotropin-
releasing hormone receptor; 3β-HSD=3β-hydroxysteroid dehydrogenase; 17β-HSD=17β-
hydroxysteroid dehydrogenase; LH=luteinizing hormone; LHR=luteinizing hormone receptor; 
PKA=protein kinase A; StAR=steroid acute regulatory protein. 
  
This chapter has been published on Environmental International.  
Ding N, Harlow SD, Batterman S, Mukherjee B, Park SK. Longitudinal trends in perfluoroalkyl 
and polyfluoroalkyl substances among multiethnic midlife women from 1999 to 2011: The 
Study of Women′s Health Across the Nation. Environ Int 2020;135:105381.  
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Chapter II. Longitudinal Trends in Perfluoroalkyl and Polyfluoroalkyl Substances among 







Background: Limited information exists regarding longitudinal trends in midlife  women’s 
exposure to per- and polyfluoroalkyl substances (PFAS). Further, little is known about how 
patterns of exposure differ by race/ethnicity and reproductive characteristics including parity and 
menopause.  
Objective: We aimed to examine temporal variations in serum PFAS concentrations among 
midlife women from the Study of Women’s Health Across the Nation.  
Methods: Serum concentrations of 11 PFAS compounds were measured in 75 White, Black and 
Chinese women with blood samples collected in 1999-2000, 2002-2003, 2005-2006, and 2009-
2011. Rates of changes in PFAS concentrations were calculated assuming a first-order 
elimination model. Associations between PFAS concentrations and race/ethnicity, menstruation 
and parity were evaluated with linear mixed models, adjusting for age, body mass index and 
study site. 
Results: Serum concentrations of linear-chain perfluorooctanoic acid (n-PFOA), linear- and 
branched-chain perfluorooctane sulfonic acid (n-PFOS and Sm-PFOS) decreased significantly (-
6.0%, 95% CI: -8.3%, -3.6% per year for n-PFOA; -14.8%, 95% CI: -17.3%, -12.3% per year for 
n-PFOS; -16.9%, 95% CI: -19.1%, -14.6% per year for Sm-PFOS); whereas perfluorononanoic 
acid (PFNA) increased (16.0%, 95% CI: 10.6%, 21.6% per year). Detection rates of 
perfluorodecanoic acid (PFDeA) and perfluoroundecanoic acid (PFUA) doubled. Temporal 
trends varied significantly by race/ethnicity. Chinese women tended to have consistently higher 
PFNA concentrations at each follow-up visit, compared with White and Black women. Serum 





Menstruating women consistently had lower concentrations. Parity was associated with lower 
concentrations at baseline but the differences between nulliparous and parous women became 
smaller over time. 
Conclusions: Our results suggest longitudinal declines in serum concentrations of legacy PFAS 
and increases in serum concentrations of emerging compounds from 1999 to 2011 in midlife 
women. Temporal trends in PFAS concentrations are not uniform across race/ethnicity and parity 
groups.  
Keywords: Perfluoroalkyl and polyfluoroalkyl substances; Biomonitoring; Midlife women; 





1. Introduction  
Per- and polyfluoroalkyl substances (PFAS) are anthropogenic compounds that have been 
widely used since the discovery of polytetrafuoroethylene (commonly known as Teflon) 
(Kotthoff et al., 2015; Prevedouros et al., 2006). Due to the strong electronegativity and small 
atomic size of fluorine, the perfluoroalkyl moiety imparts unique water- and oil-repellency, and 
thermal and chemical stability to these compounds, compared to their hydrocarbon counterparts. 
Many consumer products contain specific members of this family of chemicals, such as nonstick 
cookware, weatherproof clothing, surface protectants, carpets, greaseproof food packaging, 
aqueous film-forming foams, and etc. (Begley et al., 2005; Butenhoff et al., 2006; Kantiani et 
al., 2010; Kissa, 2011; Trudel et al., 2008).  
PFAS are of particular concern as these compounds have been linked to hepatocellular 
damage (Darrow et al., 2016), chronic kidney disease (Shankar et al., 2011) and metabolic 
disorders (Liu et al., 2018; Sun et al., 2018), and have also been identified as potential 
reproductive toxicants (Jensen and Leffers, 2008). Perfluorooctanoic acid (PFOA) and 
perfluorooctane sulfonic acid (PFOS) (so-called C8 compounds) have been the most extensively 
produced and studied chemicals. Epidemiological studies have shown associations between 
exposure to elevated concentrations of PFOA and PFOS with menstrual cycle irregularity 
(Lyngsø et al., 2014; Zhou et al., 2017), premature ovarian insufficiency and accelerated ovarian 
aging (Knox et al., 2011; Taylor et al., 2014; Zhang et al., 2018), steroidogenic defects (Barrett 
et al., 2015), and infertility (Bach et al., 2016). Given the toxicity, persistence and 
bioaccumulation of PFAS, government and regulatory bodies in some parts of the world have 
been working towards agreements and regulations to limit the production of PFOA and PFOS 





Stockholm Convention, 2016; US EPA, 2000,  2016). At the same time, several other PFAS have 
increased steadily in the general population (Calafat et al., 2007). Therefore, the quantitation of 
multiple PFAS in human serum is important to adequately assess human exposure and associated 
health risks.  
Previous human biomonitoring studies primarily focused on repeated cross-sectional data 
and have shown declines in PFOS, PFOA and their precursors (Calafat et al., 2006,  2007; Kato, 
Wong, et al., 2011; Liu et al., 2015; Olsen et al., 2012). To date, few published studies have 
reported longitudinal trends in the United States (Kato et al., 2014; Wu et al., 2015). These 
longitudinal studies (Kato et al., 2014; Wu et al., 2015) included only two recorded time points 
within a short time frame (~6-12 months) among pregnant women in Ohio and children and 
adults in California, respectively. Given that many PFAS are slowly eliminated, e.g., half-lives 
can exceed 2 years, it is important to have multiple measurements over a relatively long follow-
up period to adequately describe within-person changes.  
Understanding the health effects of common exposures is challenging as exposures may 
vary by participant characteristics such as race/ethnicity and geography. Serum concentrations 
also cannot easily be related to probable ongoing background exposures in midlife women, since 
factors such as menstruation and parity may not properly be accounted for in female elimination 
rates. To improve our understanding of exposure to PFAS in midlife women, we describe the 
longitudinal changes in PFAS concentrations during the menopausal transition and evaluate 
whether time trends differed by reproductive aging (i.e. menstruation status), parity, or 
race/ethnicity. The present study was based on four repeated measurements of serum PFAS 
concentrations collected 1999 through 2011 in a cohort of 75 multiethnic midlife women aged 






2.1 Study populations. Participants were drawn from the Study of Women’s Health Across the 
Nation (SWAN), a multicenter, multi-ethnic, community-based cohort of midlife women. 
Detailed study designs were described elsewhere (Sowers et al., 2000). Briefly, 3,302 women 
were recruited at baseline during 1996-1997 from 7 study sites in the United States (Boston, MA; 
Chicago, IL; southeast Michigan, MI; Los Angeles, CA; Newark, NJ; Oakland, CA; Pittsburgh, 
PA). Each site recruited White women and women from a specified minority group (black in 
Boston, Chicago, southeast Michigan, and Pittsburgh; Chinese in Oakland; Japanese in Los 
Angeles; Hispanic in Newark). Baseline eligibility criteria for enrollment into the longitudinal 
cohort included the following: aged 42 to 52 years, having an intact uterus and at least one ovary, 
not currently using exogenous hormones affecting ovarian functions, having a menstrual period 
in the previous 3 months, and self-identified with a site’s designated racial/ethnic group.  
The SWAN Multi-Pollutant Study (MPS) was initiated in 2016 to examine multiple 
environmental chemical exposures, including PFAS, polychlorinated biphenyls (PCBs), 
organochlorine pesticides, polybrominated diphenyl ethers (PBDEs), metals, phenols, phthalates, 
and organophosphate pesticide among midlife women. A schematic diagram of the SWAN MPS 
sampling procedure is shown in Supplemental Table II.1. Repository samples available from 
the third follow-up visit (V03, 1999-2000) were used for environmental exposure assessments. 
Of 2,694 women enrolled at V03, we excluded women from Chicago (n=368) and Newark 
(n=278) because urine samples were not available in these two sites. We additionally excluded 
648 women with insufficient serum or urine samples at V03 or insufficient urine samples at V06 
(for the assessment of non-persistent phenols and phthalates), yielding the sample size of 1400. 





We also designed a pilot project at the SWAN V03 (1999-2000), V06 (2002-2003), V09 
(2005-2006) and V12 (2009-2011) to examine temporal trends in a panel of persistent organic 
pollutants, including PCBs, PBDEs, and PFAS. Of 1,400 participants with serum samples 
available at V03, we picked three study sites (Boston, MA in the East; southeast Michigan in the 
Midwest; Oakland, CA in the West), to capture temporal variations in different race/ethnic 
groups and geographical locations with limited resources. Because the menopausal transition and 
related body composition changes may impact chemical distributions of persistent organic 
pollutants, we then conducted random sampling to get a subsample of women (n=75) with 4 
follow-up visits at V03, V06, V09 and V12 (n=300 observations in total) stratified on changes in 
waist circumferences and race/ethnicity. The sampling procedure of this pilot project is given in 
Supplemental Figure II.2.  
Characteristics among 1,400 participants at V03 were compared to those included in the 
temporal trend study. Women who were followed until V12 had a higher level of education 
(P<0.05, Supplemental Table II.2). No significant differences were found for other socio-
demographic factors (P>0.05, Supplemental Table II.2) or for PFAS serum concentrations at 
the baseline (P>0.05, Supplemental Table II.3). In addition, waist circumference changes did 
not impact the temporal trends of PFAS concentrations (data not shown).  
2.2 PFAS measurements. We obtained serum samples from 75 women at SWAN V03 
(1999/2000), V06 (2002/2003), V09 (2005/2006), and V12 (2009/2011). Serum samples were 
sent to the Division of Laboratory Sciences, National Center for Environmental Health, Centers 





Perfluoroalkyl acids (PFAAs) are some of the most simple PFAS molecules, which are 
essentially non-degradable. The PFAAs contain two major groups, perfluoroalkyl carboxylic 
acids (PFCAs) and perfluoroalkane sulfonic acids (PFSAs). PFCAs included PFOA, 
perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDeA), perfluoroundecanoic acid 
(PFUA), and perfluorododecanoic acid (PFDoA). PFSAs included perfluorohexane sulfonic acid 
(PFHxS), and PFOS. PFOA and PFOS may be present as mixtures of linear- (n-) and branched- 
(sm-) chain isomers depending on the manufacturing process used. A linear isomer is composed 
of carbon atoms bonded to only one or two carbons, which form a straight backbone. A branched 
isomer consists of at least one carbon atom bonded to more than two carbon atoms. Note that 2-
(N-ethyl-perfluorooctane sulfonamide) acetate (EtFOSAA) and 2-(N-methyl-perfluorooctane 
sulfonamide) acetate (MeFOSAA) are perfluoroalkane sulfonamide acetic acids (FASAAs) 
which belong to polyfluorinated compounds and act as intermediate environmental 
transformation products of PFOS. Chemical names and formulas of PFAS analyzed in this study 
are shown in Supplemental Table II.1. 
We measured PFHxS, n-PFOS, sum of Sm-PFOS, EtFOSAA, MeFOSAA, n-PFOA, sum 
of Sb-PFOA, PFNA, PFDeA, PFUA, and PFDoA in 1 mL of serum, using an online solid phase 
extraction-high performance liquid chromatography-isotope dilution-tandem mass spectrometry 
(on-line SPE-HPLC-MS/MS) method (Kato, Basden, et al., 2011) that allows for selective 
analyses of serum. The limits of detection (LODs) were determined during  method validation by 
running 5 repeated measurements of low-level standards spiked onto calf serum (Taylor, 1981) 
and then calculating the standard deviation of the instrument response. The limit of detection was 






In parallel with sample analyses, the following quality control (QC) procedures were 
conducted: (a) standard reference materials (SRMs) and spike and surrogate recoveries were 
tested periodically; (b) linearity and drift checks were performed with each sample batch; (c) 
internal standards consisting of deuterated standards are used on each sample; (d) duplicates 
were analyzed in each batch; (e) method detection limits (MDLs) for each target compound were 
determined for each matrix; and (f) blanks (instrumental, field and laboratory) were run with 
each sample batch. Each sample run contained 9 calibration standards, two low-concentration 
QCs (QCL), two high-concentration QCs (QCH), three serum blanks, and two reagent blanks. 
All solvents and other materials contacting samples are proved to be clean, as confirmed using 
blanks. The coefficient of variation was 5.9-12.1% for the low QC pools; and 5.9-10.6% for the 
high QC pools. 
2.3 Covariates. Time-independent covariates included race/ethnicity, study site, and baseline 
age, measured body mass index, and parity. Parity, which represents the sum of the number of 
live births and stillbirths, was classified into nulliparous or parous. Time-varying variables 
included menstruation status. Menstruation was determined from self-administered 
questionnaires. At each visit women were asked: “Did you have any menstrual bleeding since 
your last study visit?” All these variables were fully observed in the study sample. 
2.4 Comparison with NHANES data. We used the NHANES 1999-2010 data to compare 
temporal trends in PFAS between our study and the contemporary US representative population. 
Only women with the same age range at each cycle matched to our longitudinal follow-up visits 
were included in the analyses. Thus, participants included in the comparison were 91 women 
aged 45-56 years from NHANES 1999-2000, 119 women aged 48-59 years from NHANES 





68 years from NHANES 2009-2010 (a total of 566).  Survey-weighted medians and interquartile 
ranges were computed at each cycle.  
2.5 Statistical analysis. The concentrations of 11 PFAS were described using geometric mean 
(GM), geometric standard deviation (GSD), median, interquartile range (IQR), 95th and 99th 
percentiles, and range. For measurements below the LODs, the values were substituted with 
LOD/√2. An intra-class correlation coefficient (ICC) was calculated to assess reliability of 




⁄ , where 𝜎𝐵
2 is 
the between-subject variation and 𝜎𝑊
2 is the within-subject variance.  An ICC is very useful for 
analyzing continuous measures. A high ICC indicates that differences in PFAS serum 
concentration between subjects have greater variability than that within subjects over the study 
period (Enderlein, 2007).  
PFAS chemicals that were detected in at least 70% of the samples were included in the 
trend analysis. Under the assumption of a first-order elimination model, halving time (T1/2) for 
PFAS were calculated by 
ln (2)
𝛽⁄ , where 𝛽 was the fixed effect coefficient of time; 
(𝑒𝛽 − 1) × 100%  was expressed as the excretion constant rate. Repeated measure analysis of 
variance (ANOVA) tests were conducted to compare serum PFAS concentrations by participant 
characteristics.  
In the adjusted analyses, linear mixed models (LMMs) were fitted with random intercepts 
to calculate effect estimates and standard errors (SEs) for assessment of time-varying PFAS 
serum concentrations by participant characteristics. PFAS concentrations were modeled as a 





natural logarithmic transformation was applied to serum PFAS concentrations to approximate a 
normal distribution. Both crude analyses and analyses with adjustment for age at baseline, 
race/ethnicity, study site (Santoro et al., 2011), BMI at baseline, parity, and menstrual bleeding 
were conducted. To explore temporal variations by covariates, interactions terms between time 
and these covariates were included in the regressions of SWAN follow-up visits. Likelihood ratio 
tests were used to compare models with and without interaction terms to determine whether time 
trajectories differed by these factors.  
Given the limited sample size we used the most parsimonious adjusted model as shown 
below,  
𝑃𝐹𝐴𝑆𝑖𝑗 = 𝛽0 + 𝛽1𝑉06𝑖 + 𝛽2𝑉09𝑖 + 𝛽3𝑉12𝑖 + 𝛽4𝑀𝑒𝑛𝑠𝑡𝑟𝑢𝑎𝑡𝑖𝑛𝑔𝑖𝑗 + 𝛽5𝑊ℎ𝑖𝑡𝑒𝑖 + 𝛽6𝐶ℎ𝑖𝑛𝑒𝑠𝑒𝑖
+ 𝛽7𝑃𝑎𝑟𝑜𝑢𝑠𝑖 + 𝛽8𝑉06𝑖 × 𝑊ℎ𝑖𝑡𝑒𝑖 + 𝛽9𝑉09𝑖 × 𝑊ℎ𝑖𝑡𝑒𝑖 + 𝛽10𝑉12𝑖 × 𝑊ℎ𝑖𝑡𝑒𝑖
+ 𝛽11𝑉06𝑖 × 𝐶ℎ𝑖𝑛𝑒𝑠𝑒𝑖 + 𝛽12𝑉09𝑖 × 𝐶ℎ𝑖𝑛𝑒𝑠𝑒𝑖 + 𝛽13𝑉12𝑖 × 𝐶ℎ𝑖𝑛𝑒𝑠𝑒𝑖
+ 𝛽14𝑉06𝑖 × 𝑃𝑎𝑟𝑜𝑢𝑠𝑖 + 𝛽15𝑉09𝑖 × 𝑃𝑎𝑟𝑜𝑢𝑠𝑖 + 𝛽16𝑉12𝑖 × 𝑃𝑎𝑟𝑜𝑢𝑠𝑖
+ 𝛽𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠𝑖 + 𝑏0𝑗 + 𝜀𝑖𝑗,  
where 𝑃𝐹𝐴𝑆𝑖𝑗  is serum concentrations for the ith subject with the jth observation;  𝑋
× 𝑌 is the interaction term between X and Y;  𝑉06 is SWAN visit 06 during 2002
− 2003, 𝑉09 is SWAN visit 09 during 2005 − 2006, and 𝑉12 is SWAN visit 12 during 2009
− 2011;  Covariates include age at baseline, BMI at baseline, and study site. 
Statistical analyses were conducted by R 3.4.4 (R Core Team (2018). R Foundation for 






3. Results  
3.1 Participant characteristics. Characteristics of 75 women at SWAN V03 (1999/2000), V06 
(2002/2003), V09 (2005/2006) and V12 (2009/2011) are described in Table II.1. The average 
age of participants was 49 years (range = 45 to 56 years) at V03, the baseline period for this 
analysis, in 1999-2000. The median (IQR) BMI was 26.1 (22.7-32.0) kg/m2 at baseline and did 
not change much during the follow-up visits. All 75 women lived in the same place during the 
follow-up visits. Among participants, 25.3% resided in southeast Michigan, 30.7% in Boston, 
and 44.0% in Oakland; 49.3% were White, 25.3% were Black and 25.3% were Chinese. 89.3% 
of participants experienced menstrual bleeding since their last visit at V03 (on average, 
approximately 12 months after V02) decreasing to 4.0% at V12. Sixteen percent were 
nulliparous at V03 and no one became pregnant or breastfed during the follow-up visits.   
3.2 Longitudinal trends of serum PFAS concentrations from 1999 to 2011. Distributions of 
serum PFAS concentrations across follow-up visits are displayed for selected compounds with 
detection rates >70% in Figure II.1 and presented for all the PFAS analytes in Supplemental 
Table II.4. Over 70% of the serum samples had detectable concentrations above LODs at each 
time point for n-PFOA, n-PFOS, Sm-PFOS, PFHxS, and PFNA. Substantial decreases were 
observed in median concentrations of n-PFOA (3.30 to 2.60 ng/mL; P=0.001), n-PFOS (17.00 to 
7.50 ng/mL; P<.0001), and Sm-PFOS (6.20 to 2.50 ng/mL; P<.0001) during 1999 and 2011. 
Over 98% of the samples had detectable EtFOSAA and MeFOSAA at V03 while the detectable 
percentages decreased to 1.33% and 50.67%, respectively, during the follow-up visits. PFHxS 






In contrast to other PFAS, PFNA showed increase steeply (0.50 to 1.30 ng/mL), 
comparing V03 (1999/2000) to V12 (2009/2011) (P<.0001). PFDeA and PFUA concentrations 
increased during 1999-2011 with a detection rate of 89.3% and 66.7% at V12, respectively, from 
42.7% and 36% at V03. Fewer than 20% of the samples had detectable levels of Sb-PFOA and 
PFDoA. Intraclass correlation coefficients ranged 0.16 to 0.48, indicating low similarity and 
highly variable values from the same subject over time.  
On average, serum concentrations of n-PFOA, n-PFOS, Sm-PFOS and PFHxS were 
estimated to be decreased by 6.0% (95% CI: -8.3%, -3.6%), 14.8% (95% CI: -17.3%, -12.3%), 
16.9% (95% CI: -19.1%, -14.6%) and 6.2% (95% CI: -9.1%, -3.2%) per year, respectively, as 
shown in Table II.2. The halving time was estimated to be 11.2 (95% CI: 8.0-19.0) years for n-
PFOA, and 4.3 (95% CI: 3.6-5.3), 3.7 (95% CI: 3.3-4.4) and 10.8 (95% CI: 7.2-21.5) years and 
for n-PFOS, Sm-PFOS and PFHxS, respectively. On the contrary, PFNA increased by 16.0% 
(95% CI: 10.6%, 21.6%) during follow-up visits with a doubling time of 4.7 (95% CI: 3.5-6.9) 
years. Adjustment for age at baseline, race and study site and menstruation did not account for 
temporal variations of PFAS serum concentrations, except for PFNA, of which the time effects 
became insignificant (P=0.12). 
3.3 Comparison with NHANES data. Comparisons of the present study with the contemporary 
NHANES data of general U.S. women with the same age range are displayed in Supplemental 
Figure II.3. Both showed serum concentrations of PFOA, PFOS, PFHxS, and PFNA with 
detection rates>70%. SWAN participants had lower median concentrations over time, but the 
spread of IQRs in SWAN and the NHANES datasets generally overlapped. Both had decreasing 
trends of PFOA, PFOS and PFHxS, and increasing trends of PFNA. Detection rates of PFDeA 





shown). Neither showed detectable concentrations of PFDoA. 
3.4 Determinants of temporal changes in PFAS concentrations. Unadjusted median (IQR) log-
transformed serum concentrations of n-PFOA, n-PFOS, Sm-PFOS, PFHxS and PFNA by 
race/ethnicity, menstruation status and parity over time are displayed in Figures II.2-II.4. In the 
unadjusted analyses, temporal trends differed significantly by race/ethnicity for n-PFOA 
(P=0.007), n-PFOS (P=0.02), and PFHxS (P=0.04) but not for Sm-PFOS (P=0.13) and PFNA 
(P=0.19). Menstruating women had lower PFAS concentrations and the differences remain 
almost the same over time during the follow-up visits (P=0.31 for n-PFOA, P=0.29 for n-PFOS, 
P=0.80 for Sm-PFOS, P=0.36 for PFHxS, and P=0.07 for PFNA). Nulliparous women had 
higher serum PFAS concentrations at baseline but the time trajectories of n-PFOA and n-PFOS 
had changed significantly during the follow-up visits (P=0.03 for n-PFOA, P=0.03 for n-PFOS). 
In contrast, the trajectories of other PFAS did not differ by parity (P=0.19 for Sm-PFOS, P=0.99 
for PFHxS, and P=0.28 for PFNA).  
Figure II.5 depicts the adjusted trends of n-PFOA, n-PFOS, Sm-PFOS, PFHxS and 
PFNA across the four visits stratified by race/ethnicity, menstrual bleeding and parity, 
controlling for age at baseline, study site, and BMI at baseline (see effect estimates and standard 
errors from mixed regression models in Supplemental Table II.5).  
Race/ethnicity was an independent predictor of PFAS concentrations and their trends 
over time. For n-PFOA, women had significantly lower concentrations from baseline to V12, but 
trends differed significantly by race/ethnicity (P for interaction=0.001). White women had the 
highest exposures to n-PFOA at baseline; however, time mitigated the racial/ethnic differences. 





racial/ethnic groups had significantly lower concentrations at V12 compared to V03, but White 
women had a more rapid decline from baseline to V12, compared with that of Chinese and Black 
(P for interaction=0.0007). Temporal trends of Sm-PFOS and PFHxS also differed significantly 
by race/ethnicity (P for interaction=0.03 and 0.008, respectively), with racial/ethnic differences 
decreased over time. However, PFNA serum concentrations did not change significantly over 
time across racial/ethnic groups (P for interaction=0.13) but Chinese women showed consistently 
higher concentrations  compared to other racial/ethnic groups (P=0.03 at baseline for 
race/ethnicity).  
Compared to women without menstrual bleeding since the last visit, menstruating women 
had 16.4% (95% CI: -26.7%, -4.7%), 18.3% (95% CI: -31.9%, -1.9%), 13.4% (95% CI: -22.8%, 
-2.9%) lower serum concentrations of n-PFOA, PFNA, and Sm-PFOS, respectively, during 
follow-up visits. n-PFOS or PFHxS were not associated with menstruation status (P=0.14 and 
0.15, respectively). Interaction terms between time and menstrual bleeding were not significant.   
In addition, serum concentrations of n-PFOA, n-PFOS and Sm-PFOS also varied 
significantly across parity. Concentrations decreased by -40.5% (95% CI: -58.5%, -14.6%) for n-
PFOA, -47.7% (95% CI: -65.6%, -20.7%) for n-PFOS, and -45.5% (95% CI: -64.0%, -17.4%) 
for Sm-PFOS, comparing parous to nulliparous women at baseline; whereas the differences 
became significantly smaller for n-PFOA and n-PFOS (P for interaction=0.02 for n-PFOA, and 
0.008 for n-PFOS) over time, but did not change for Sm-PFOS (P for interaction=0.21). No 
significant differences by parity status were observed for PFHxS (P=0.50) and PFNA (P=0.31) 
at baseline, or during follow-up visits (P for interaction= 0.95 for PFHxS, and 0.47 for PFNA). 
Further adjustment for education, employment status, and difficulty paying for basics did not 






This study updates the existing knowledge on human exposure to PFAS. It provides 
valuable data on midlife women’s exposure to PFAS as they transition through menopause and 
temporal trends of PFAS serum concentrations, which have rarely been reported before. This 
study also provides new evidences on the contribution of race/ethnicity, menstruation, and parity 
to the temporal variations of PFAS concentrations. 
4.1 Longitudinal trends of serum PFAS concentrations from 1999 to 2011. Overall, serum 
concentrations of legacy compounds, including n-PFOA, n-PFOS, Sm-PFOS, EtFOSAA and 
MeFOSAA peaked at baseline. In contrast, increasing trends were observed for PFNA, PFUA, 
and PFDeA from 1999 to 2011.  
Along with a recent study summarizing PFAS data in NHANES (Calafat et al., 2007), 
our findings indicated effectiveness of deliberate efforts to reduce the production of PFOA, 
PFOS and its precursors in the United States. Unlike the majority of legacy PFAS, the current 
study and previous studies have suggested increases in serum concentrations of other long-chain 
PFAS, including PFNA (Calafat et al., 2006,  2007; Kato, Wong, et al., 2011; Spliethoff et al., 
2008), PFUA (Calafat et al., 2006,  2007; Kato, Wong, et al., 2011; Spliethoff et al., 2008), and 
PFDeA (Calafat et al., 2006,  2007; Kato, Wong, et al., 2011; Spliethoff et al., 2008).These 
increasing trends indicate an ongoing exposure. For example, PFNA was found to be present in 
several commonly used consumer products, e.g. paper-based food contact materials and textiles 
(Kotthoff et al., 2015). In addition, PFNA and PFUA are believed to be manufactured through a 
transformation of fluorotelomer olefins (Buck et al., 2011), which could be formed by telomere-





was related to internal metabolisms (e.g. cessation of menstruation) in midlife women. However, 
the routes of exposure and control mechanisms for these compounds remain obscure, as the main 
exposure pathway for PFCAs varies according to exposure scenarios (Gebbink et al., 2015).  
No significant changes were observed for serum PFHxS concentrations among the 
midlife women. However, PFHxS was the second most abundant PFSAs next to PFOS during 
2003 and 2011. Previous research indicates that higher prevalence of PFHxS could be associated 
with increased use of stovetop Teflon cookware (Hu et al., 2018), preheated 
packaged/microwavable foods (Hu et al., 2018; Wu et al., 2015), as well as indoor dust (Wu et 
al., 2015) and lower vacuuming frequency (Siebenaler et al., 2017). 
4.2 Differential changes in PFAS concentrations by race/ethnicity from 1999-2011. 
Race/ethnicity has previously been correlated with PFAS exposures (Boronow et al., 2019; 
Calafat et al., 2007; Park et al., 2019). Although serum concentrations of n-PFOA, n-PFOS, and 
Sm-PFOS have declined over all, to our knowledge no longitudinal study to date had assessed 
whether temporal changes in serum PFAS concentrations differ by race/ethnicity. The present 
study addresses this gap. Our findings suggest that temporal trends in PFAS exposure are not 
uniform across racial/ethnic groups, and subpopulations with higher initial PFAS exposures often 
experienced the greater change over the study period. For example, we observed a more rapid 
decline in n-PFOA and n-PFOS concentrations among White women, who had higher baseline 
concentrations compared with other racial/ethnic groups, possibly reflecting differences in 
consumer product use. A scenario-based risk assessment study (Trudel et al., 2008) reported that 
in female adults, the most dominant source of PFOA exposure was likely from consumer 
products including impregnation spray, treated carpets in homes, and coated food contact 





Substantial declines in serum concentrations of n-PFOA and n-PFOS among White women 
might result from changes in product preferences and food consumption. Conversely, White 
women had a slight increase in PFHxS serum concentrations in 2009-2011. Another recent  
study of middle-aged women also found that White women with higher serum concentrations of 
PFHxS compared with Black, likely attributable to exposure from dental floss with Oral-B Glide 
(Boronow et al., 2019).  
Unlike other racial/ethnic groups, Chinese women had increasing exposures to PFHxS 
since 2002, and consistently higher serum concentrations of PFNA during the follow-up visits. 
However, little is known about potential sources of exposure in Chinese populations. 
Socioeconomic characteristics, lifestyle factors or genetics may account for the observed 
disparities. Compared to White women, both Black and Chinese had lower education attainment, 
less physical activity; Black women had more difficulty paying for basics; Chinese women had 
more fish intake (Supplemental Table II.6). Although biomonitoring studies are useful for 
documenting population exposures to environmental chemicals, they are limited in their ability 
to identify the contribution of specific sources to personal exposure. Nonetheless, our 
understanding of sources of PFAS exposure remains incomplete, however, these findings prompt 
follow-up in future studies.  
4.3 PFAS concentrations by parity. Parity was a significant determinant of PFAS serum 
concentrations, especially with parous women having lower concentrations of n-PFOA, n-PFOS 
and Sm-PFOS than nulliparous women. This is the first study examining longitudinal trends of 
PFAS serum concentrations by parity in midlife women. Previous studies found that nulliparous 
women had higher PFAS maternal concentrations (Berg et al., 2014; Brantsæter et al., 2013; Fei 





infants or to the placenta through the umbilical cord (Beesoon et al., 2011; Hanssen et al., 2010; 
Kato et al., 2014). Blood loss during delivery might also decrease maternal body burden of PFAS 
(Lorber et al., 2015). After birth, PFAS may gradually re-accumulate in women, and as a result 
the differences at baseline narrowed over time (Fei et al., 2009). On the other hand, given the 
longer half-life of long-chain PFAS (e.g. PFNA) they might not be easily excreted during 
delivery.  
4.4 PFAS concentrations by menstruation status. This study strengthens the evidence that 
PFAS concentrations are influenced by menstruation status. Menstruating women tended to have 
lower serum concentrations compared to those without. The results are consistent with a previous 
pharmacokinetics modeling, in which Wong et al. found that approximately 30% of the PFOS 
elimination half-life difference between females and males (Wong et al., 2014). Decreased serum 
concentrations have been shown in premenopausal versus postmenopausal women (Dhingra et 
al., 2017; Taylor et al., 2014) and, analogously, in men undergoing venesections for medical 
treatment (Lorber et al., 2015). Given that approximately 90% to 99% of these compounds in the 
blood are bound to serum albumin (Han et al., 2003; Ylinen and Auriola, 1990), blood loss 
through menstruation may  be an important elimination pathway.  
Kudo et al. examined the role of sex hormones and transport proteins on the renal 
clearance and concluded that: in ovariectomized female rats, 1) estradiol could facilitate 
transporting PFOA across the membranes of kidney tubules into the glomerular filtrate; 2) 
treatments with testosterone reduced the clearance of PFOA (Kudo et al., 2002). This conforms 
to humans. Zhang et al. study reported that the rate of renal elimination was 0.024 mL/day/kg 
among women >50 years while 0.043 mL/day/kg among women ≤50 years (Zhang et al., 2013). 





change of PFAS serum concentrations among midlife women during menopausal transition. 
4.5 Strengths and limitations. Our study is limited by its small sample size. We do not have 
sufficient power to examine the changes over time stratified by participant characteristics. 
Instead, we relied on the tests of statistical interactions between time and covariates. We also 
oversampled Chinese women to better capture racial/ethnic differences. In addition, we did not 
have information on important sources of exposure including food contact materials, 
microwavable or packaged food consumption, or use of carpet treatment procedures because no 
such information was available in this cohort. We were also unable to fully assess the impact of 
genetics and lifestyle factors which may account for racial/ethnic disparities. Future study with a 
larger sample size would provide a clearer picture of the complex relationships between 
race/ethnicity in PFAS exposure. Lastly, our study participants were 75 midlife women from 
three geographic locations, so results might not be generalizable to people living in other areas. 
The study sample is not representative of the base population of the SWAN Multipollutant 
Study. Women who have completed all 4 visits and provided serum samples were eligible. Also, 
by design, only women from Oakland, South Michigan, and Boston were included in selection. 
A major strength of this study was the opportunity to include persons from different 
geographical locations in the United States, and Chinese, whose exposures have not been 
characterized. The repeated measurements also allow for examination of longitudinal intra-
individual changes in PFAS serum concentrations. As the ICCs for repeated measurements were 
relatively low, indicating that one single serum measurement may not be enough to provide a 






In summary, our results depict longitudinal declines in legacy PFAS (i.e. PFOA and 
PFOS), as well as their branched isomers and precursors MeFOSAA and EtFOSAA among 
midlife women living in the US during 1999-2011. The findings are consistent with reduced 
environmental exposures since 2000-2002. We also identified differential patterns of exposure 
by race/ethnicity, which can provide useful information for developing hypotheses about 
possible sources of exposure that, especially for PFHxS and PFNA, are poorly understood. 
Additional analyses should be performed nationwide to examine whether similar racial/ethnic 
disparities exist across different regions of the country and which compounds (e.g. behaviors, 
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Table II. 1 Characteristics of participants in the Study of Women’s Health Across the Nation (SWAN) 1999-2011. 
SWAN visit V03 V06 V09 V12 
Year of sample collection 1999-2000 2002-2003 2005-2006 2009-2011 
No. of participants 75 75 75 75 
Age at interview1, years 49.4 (47.1-51.2) 52.5 (50.1-54.2) 55.4 (53.2-57.3) 59.6 (57.8-62.1) 
Body mass index 1, kg/m2 26.1 (22.7-32.0) 
Study site  
   Southeast Michigan 19 (25.3%) 
   Boston, MA 23 (30.7%) 
   Oakland, CA 33 (44.0%) 
Race/ethnicity  
   Black 19 (25.3%) 
   White 37 (49.3%) 
   Chinese 19 (25.3%) 
Menstrual bleeding since last visit 67 (89.3%) 46 (61.3%) 23 (30.7%) 3 (4.0%) 
Parity  
    Nulliparous 12 (16.0%) 






Table II. 2 Halving or doubling time for serum PFAS1 concentrations among 75 women (300 observations in total) in SWAN 1999-
2011. 
 n-PFOA n-PFOS Sm-PFOS PFHxS PFNA 
Unadjusted 
Percent change per year -6.0% -14.8% -16.9% -6.2% 16.0% 
95% CI -8.3%, -3.6% -17.3%, -12.3% -19.1%, -14.6% -9.1%, -3.2% 10.6%, 21.6% 
p-value <.0001 <.0001 <.0001 <.0001 <.0001 
Halving or doubling time, year 11.2 4.3 3.7 10.8 -4.7 
95% CI 8.0, 19.0 3.6, 5.3 3.3, 4.4 7.2, 21.5  -6.9, -3.5 
Adjusted2 
Percent change per year -6.9% -12.0% -14.7% -6.3% 4.7% 
95% CI -10.0%, -3.7% -15.4%, -8.4%  -17.7%, -11.6% -10.2%, -2.1% -1.2%, 10.8% 
p-value <.0001 <.0001 <.0001 0.004 0.12 
Halving or doubling time, year 9.6 5.4 4.4 10.7 -15.3 
95% CI 6.6, 18.3 4.1, 7.9 3.6, 5.6 6.4, 32.9 -58.4, 6.7  
1PFAS with serum concentrations above limit of detection more than 60% were included in the analyses. 







Figure II. 1 Concentrations of selected PFAS with detection rates >70% analyzed in repeated 
serum samples of women (n=75) across the United States for four SWAN visits. Boxes represent 
the 25th-75th percentiles, horizontal lines represent the median, and whiskers indicate 5th and 95th 
percentiles, respectively. Note that a log scale is used for Y axis. The limits of detection were 0.1 
ng/mL for all PFAS analytes. Abbreviations: n-PFOA, linear-chain perfluorooctanoic acid; 
PFNA, perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; n-PFOS, linear-chain 






Figure II. 2 Serum concentrations of selected PFAS with detection rates >70% by race/ethnicity in women (n=75) across the United 
States for four SWAN visits. Boxes represent the 25th-75th percentiles, horizontal lines represent the median, and whiskers indicate 5th 
and 95th percentiles, respectively. Repeated measure analysis of variance tests was conducted to compare temporal variations of PFAS 
concentrations by racial/ethnic groups: P=0.007 for n-PFOA; P=0.02 for n-PFOS; P=0.13 for Sm-PFOS; P=0.04 for PFHxS; and 
P=0.19 for PFNA. Note that a log scale is used for Y axis. The limits of detection were 0.1 ng/mL for all PFAS analytes. 
Abbreviations: n-PFOA, linear-chain perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; 









Figure II. 3 Serum concentrations of selected PFAS with detection rates >70% by menstruation status (i.e. whether had menstrual 
bleeding since last visit) in women (n=75) across the United States for four SWAN visits. Boxes represent the 25th-75th percentiles, 
horizontal lines represent the median, and whiskers indicate 5th and 95th percentiles, respectively. Repeated measure analysis of 
variance tests was conducted to compare temporal variations of PFAS concentrations by menstruation status: P=0.31 for n-PFOA; 
P=0.29 for n-PFOS; P=0.80 for Sm-PFOS; P=0.36 for PFHxS; P=0.07 for PFNA. Note that a log scale is used for Y axis. The 
limits of detection were 0.1 ng/mL for all PFAS analytes. Abbreviations: n-PFOA, linear-chain perfluorooctanoic acid; PFNA, 
perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; n-PFOS, linear-chain perfluorooctane sulfonic acid; Sm-PFOS, sum of 











Figure II. 4 Serum concentrations of selected PFAS with detection rates >70% by parity status (nulliparous or parous) in women 
(n=75) across the United States for four SWAN visits. Boxes represent the 25th-75th percentiles, horizontal lines represent the median, 
and whiskers indicate 5th and 95th percentiles, respectively. Repeated measure analysis of variance tests was conducted to compare 
temporal variations of PFAS concentrations by parity group: P=0.03 for n-PFOA; P=0.03 for n-PFOS; P=0.19 for Sm-PFOS; 
P=0.99 for PFHxS; P=0.28 for PFNA. Note that a log scale is used for Y axis. The limits of detection were 0.1 ng/mL for all PFAS 
analytes. Abbreviations: n-PFOA, linear-chain perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexane 








Figure II. 5 Predicted temporal trends of log-transformed n-PFOA, n-PFOS, Sm-PFOS, PFHxS and PFNA serum concentrations at 
SWAN V03 (1999/2000), V06 (2002/2003), V09 (2005/2006) and V12 (2009/2011), stratified by race/ethnicity, menstruation status 
and parity. The models were adjusted for age at baseline, study site and body mass index at baseline, based on fixed effects estimated 
from mixed regression models. Abbreviations: n-PFOA, linear-chain perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, 











Figure II.5 Continued Predicted temporal trends of log-transformed n-PFOA, n-PFOS, Sm-PFOS, PFHxS and PFNA serum 
concentrations at SWAN V03 (1999/2000), V06 (2002/2003), V09 (2005/2006) and V12 (2009/2011), stratified by race/ethnicity, 
menstruation status and parity. The models were adjusted for age at baseline, study site and body mass index at baseline, based on 
fixed effects estimated from mixed regression models. Abbreviations: n-PFOA, linear-chain perfluorooctanoic acid; PFNA, 
perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; n-PFOS, linear-chain perfluorooctane sulfonic acid; Sm-PFOS, sum of 








Figure II.5 Continued Predicted temporal trends of log-transformed n-PFOA, n-PFOS, Sm-PFOS, PFHxS and PFNA serum 
concentrations at SWAN V03 (1999/2000), V06 (2002/2003), V09 (2005/2006) and V12 (2009/2011), stratified by race/ethnicity, 
menstruation status and parity. The models were adjusted for age at baseline, study site and body mass index at baseline, based on 
fixed effects estimated from mixed regression models. Abbreviations: n-PFOA, linear-chain perfluorooctanoic acid; PFNA, 
perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid; n-PFOS, linear-chain perfluorooctane sulfonic acid; Sm-PFOS, sum of 





Supplemental Table II. 1 Perfluoroalkyl and polyfluoroalkyl substances (PFAS) analyzed in the 
serum samples. 
Analyte (Long Name) Analyte Formula 
2-(N-ethyl-perfluorooctane sulfonamide) acetate ET-PFOSA-ACOH C12H8F17NO4S 
2-(N-methyl-perfluorooctane sulfonamide) acetate ME-PFOSA-ACOH2 C11H6F17NO4S 
n-perfluorooctanoate n-PFOA C8HF15O2 
branched perfluorooctanoates1 Sb-PFOA C8HF15O2 
perfluorohexane sulfonate PFHxS C6HF13O3S 
perfluorododecanoate PFDOA C12HF23O2 
perfluoroundecanoate PFUA C11HF21O2 
perfluorodecanoate PFDeA C10HF19O2 
branched perfluorooctane sulfonate2 Sm-PFOS C8HF17O3S 
n-perfluorooctane sulfonate n-PFOS C8HF17O3S 
perfluorononanoate PFNA C9HF17O2 
1Sb-PFOA include perfluoro-3-methylheptanoic acid, perfluoro-4-methyheptanoic acid, 
perfluoro-5-methyheptanoic acid, perfluoro-6-methyheptanoic acid, perfluoro-4,4-
dimethylhexanoic acid, perfluoro-5,5-dimethylhexanoic acid, perfluoro-3,5-dimethylhexanoic 
acid, and perfluoro-4,5-dimethylhexanoic acid. 
2Sm-PFOS include perfluoro-3-methylheptane sulfonate, perfluoro-4-methylheptane sulfonate, 





Supplemental Table II. 2 Comparisons of characteristics between study participants at SWAN 




  Unweighted (n=75) Weighteda (n=345) 
Socio-demographic 
characteristics 
Mean (SD) or N 
(%) 
Mean (SD) or N 
(%) 
Mean (95% CI) 
or % (95% CI) 
Age at interview, years 49.5 (2.6) 49.4 (2.4) 49.4 (48.8-50.0) 
Education    
    High school or less 252 (18.1%) 9 (12.0%) 9.0% (2.0%-16.0%) 
    Some college 448 (32.2%) 20 (26.7%) 28.8% (17.1%-
40.5%) 
    College degree or 
higher 
693 (49.7%) 46 (61.3%) 62.2% (50.0%-
74.4%) 
Employed 1,213 (86.6%) 70 (93.3%) 91.7% (84.3%-
99.1%) 
Difficulty paying for 
basics (V00)  
   
    Very difficult 89 (6.5%) 5 (6.9%) 7.8% (0.7%-14.9%) 
    Somewhat difficult 347 (25.2%) 16 (22.2%) 20.9% (10.5%-
31.2%) 
    Not at all difficult 942 (68.3%) 51 (70.8%) 71.3% (59.9%-
82.7%) 
Study sites    
    Michigan 257 (18.4%) 19 (25.3%) 25.0% (14.2%-
35.7%) 
    Boston 233 (16.6%) 23 (30.7%) 29.0% (17.5%-
40.5%) 
    Oakland 309 (22.1%) 33 (44.0%) 46.0% (33.1%-
58.8%) 
    Los Angeles 366 (26.1%) NA NA 
    Pittsburgh 235 (16.8%) NA NA 
Race/ethnicity    
    Black 308 (22.0%) 19 (25.3%) 24.9 (14.0%-35.8%) 
    White 708 (50.6%) 37 (49.3%) 47.0% (34.2%-
59.7%) 
    Japanese 207 (14.8%) NA NA 
    Chinese 177 (12.6%) 19 (25.3%) 28.1% (16.2%-
40.0%) 
Physical activityb     7.8 (1.7) 7.7 (2.0) 7.9 (7.5-8.4) 
Biomarkers Mean (SD) or % Mean (SD) or % Mean (95% CI) 
or % (95% CI) 
Body mass index, 
kg/m2 





Percent body fat, % 
(V06) 
37.3 (7.9) 37.0 (7.7) 36.9 (34.9-38.8) 
Total body water, kg 
(V06) 
33.6 (5.5) 33.7 (5.0) 34.0 (32.6-35.4) 
Estradiol, pg/mL 65.8 (81.4) 64.8 (78.6) 69.2 (48.7-89.7) 
Daily dietary intake 
(V00) 
Mean (SD) or % Mean (SD) or % Mean (95% CI) 
or % (95% CI) 
Protein, g 70.1 (26.8) 71.1 (29.2) 70.9 (63.4-78.3) 
Fiber, g 12.9 (6.2) 13.0 (6.2) 13.4 (11.7-15.1) 
Total calorie, kcal 1816.8 (695.1) 1841.5 (760.3) 1851.5 (1643.4-
2059.6) 
Tuna     
   Never 414 (29.9%) 23 (31.1%) 31.4% (19.5%-
43.3%) 
   2 times per month 356 (25.7%) 18 (24.3%) 23.1% (12.5%-
33.6%) 
   4 times per month 324 (23.4%) 14 (18.9%) 20.2% (9.8%-30.6%) 
   12 times per month 167 (12.1%) 9 (12.2%) 13.4% (4.4%-22.4%) 
   23 times per month 78 (5.6%) 6 (8.1%) 8.3% (1.6%-15.0%) 
   Once per day 38 (2.8%) 4 (5.4%) 3.6% (0-7.8%) 
   Twice per day 6 (0.4%) NA NA 
   30 times per week NA NA NA 
Shellfish     
   Never 568 (41.1%) 32 (43.2%) 42.1% (29.4%-
54.8%) 
   2 times per month 409 (29.6%) 21 (28.4%) 25.8% (14.7%-
36.9%) 
   4 times per month 263 (19.0%) 11 (14.9%) 16.8% (6.9%-26.7%) 
   12 times per month 88 (6.4%) 7 (9.5%) 10.9% (2.7%-19.0%) 
   23 times per month 35 (2.5%) 1 (1.4%) 2.2% (0-6.5%) 
   Once per day 16 (1.2%) 2 (2.7%) 2.3% (0-6.2%) 
   Twice per day 2 (0.1%) NA NA 
   30 times per week 1 (0.1%) NA NA 
Other fish     
   Never 365 (26.4%) 20 (27.0%) 29.6% (17.9%-
41.4%) 
   2 times per month 315 (22.8%) 12 (16.2%) 14.4% (6.3%-22.4%) 
   4 times per month 332 (24.0%) 17 (23.0%) 24.2% (13.0%-
35.5%) 
   12 times per month 236 (17.1%) 14 (18.9%) 16.6% (7.2%-26.1%) 
   23 times per month 96 (6.9%) 9 (12.2%) 11.3% (3.4%-19.2%) 
   Once per day 29 (2.1%) 2 (2.7%) 3.9% (0-9.2%) 
   Twice per day 4 (0.3%) NA NA 





Fried fish or fish 
sandwich  
   
   Never 715 (51.7%) 48 (64.9%) 62.1% (49.8%-
74.5%) 
   2 times per month 259 (18.7%) 10 (13.5%) 16.5% (6.6%-26.4%) 
   4 times per month 195 (14.1%) 8 (10.8%) 9.5% (2.5%-16.5%) 
   12 times per month 138 (10.0%) 5 (6.8%) 8.5% (1.0%-16.0%) 
   23 times per month 60 (4.3%) 2 (2.7%) 1.9% (0-4.7%) 
   Once per day 14 (1.0%) 1 (1.4%) 1.5% (0-4.5%) 
   Twice per day 1 (0.1%) NA NA 
   30 times per week 1 (0.1%) NA NA 
Menstruation % % % (95% CI) 
Menstrual bleeding 
since last visit 
1,206 (86.1%) 67 (89.3%) 88.6% (80.2%-
96.9%) 
a Descriptive statistics were calculated after taking into account sampling weights from stratified 
random sampling. We created a population of 345 women which were the same as the sampling 
frame at the selection of study subjects into the pilot project. 
b Physical activity was assessed with a modified version of the Kaiser Physical Activity Survey 
(KPAS) as per Ainsworth et al. 2000 at visit 03. Adapted from the Baecke physical activity 
questionnaire (Baecke et al. 1982), the KPAS assesses activity levels during the previous 12 
months in 3 distinct domains: active living (e.g. frequency of television viewing (reverse coded), 
active transportation such as walking to work); household/caregiving (e.g. housework, 
childcare); and sports/exercise (e.g. participation in recreational activity). Domain-specific 
activity indices were calculated from mostly ordinal Likert scale categorical responses, with 





Supplemental Table II. 3 Comparisons of serum PFAS concentrations between study 
participants at SWAN V03 (1999/2000) (n=1,400) and those in the PFAS temporal variation 
sub-study at V03 (n=75). 
Serum concentrations, 
ng/mL 










Linear PFOA 99.9% 4.08 (1.82) 100% 3.46 (1.90) 
































PFDoA 3.8% <LOD 4.0% <LOD 




a Descriptive statistics were calculated after taking into account sampling weights from stratified 
random sampling. We created a population of 345 women which were the same as the sampling 
frame at the selection of study subjects into the pilot project. 





Supplemental Table II. 4 Summary of PFAS serum concentrations (ng/mL) measured in 
SWAN PFAS temporal trend sub-study. 
 SWAN V03 SWAN V06  SWAN V09  SWAN V12 ICC 
Year of sample 
collection 
1999-2000 20002-2003 2005-2006 2009-2011  
No. of participants 75 75 75 75  
Serum PFAS concentrations, ng/mL  
Total PFOA 0.47 
   GM (GSD)  3.63 (1.89) 3.36 (1.92) 2.88 (1.74) 2.60 (1.56)  









   95th percentile 14.00 9.97 6.67 4.77  
   99th percentile 35.87 26.77 11.27 7.07  
   Min, max 0.77-35.87 0.37-26.77 0.47-11.27 0.57-7.07  
Linear PFOA 0.18 
   Percent detected 100% 100% 100% 100%  
   GM (GSD)  3.46 (1.90) 3.27 (1.96) 2.80 (1.78) 2.52 (1.59)  









   95th percentile 12.30 9.90 6.60 4.70  
   99th percentile 35.80 26.70 11.20 7.00  
   Min, max 0.7-35.8 0.3-26.7 0.4-11.2 0.5-7.0  
Branched PFOA NAb 
   Percent detected 17.33% 0% 0% 0%  
   GM (GSD)  0.10 (2.38) <LOD <LOD <LOD  
   Median (IQR) <LOD <LOD <LOD <LOD  
   95th percentile 1.00 <LOD <LOD <LOD  
   99th percentile 1.70 <LOD <LOD <LOD  
   Min, max <LOD-1.7 <LOD <LOD <LOD  
Total PFOS 0.46 
   GM (GSD)  24.04 (1.91) 23.37 (1.89) 13.81 (1.95) 10.18 (1.93)  
   Median (IQR) 22.80 








   95th percentile 96.20 78.40 43.30 32.90  
   99th percentile 177.80 103.60 53.70 57.00  
   Min, max 6.1-177.8 6.1-103.6 2.7-53.7 1.3-57.0  
Linear PFOS 0.33 
   Percent detected 100% 100% 100% 100%  
   GM (GSD)  17.21 (1.90) 17.17 (1.88) 10.03 (1.97) 7.46 (2.03)  





 (7.30, 15.70) 
7.50 
 (4.90, 11.00) 
 
   95th percentile 63.50 58.80 29.80 29.40  
   99th percentile 141.50 67.30 48.00 53.50  
   Min, max 4.3-141.5 5.1-67.3 1.0-48.0 0.8-53.5  





   Percent detected 100% 100% 100% 100%  
   GM (GSD)  6.55 (2.05) 5.95 (2.00) 3.55 (2.00) 2.50 (1.79)  
   Median (IQR) 6.20  
(4.30, 9.40) 
6.10 






   95th percentile 32.50 23.70 9.60 6.70  
   99th percentile 63.00 36.30 21.50 7.80  
   Min, max 1.2-63.0 1.0-36.3 0.8-21.5 0.5-7.8  
EtFOSAA NAb 
   Percent detected 98.67% 65.33% 2.67% 1.33%  
   GM (GSD)  1.21 (2.91) 0.23 (2.83) 0.07 (1.23) 0.07 (1.28)  
   Median (IQR) 1.10  
(0.60, 2.40) 
0.30 
 (<LOD, 0.50) 
<LOD <LOD  
   95th percentile 7.70 1.70 0.07 0.07  
   99th percentile 112.50 3.70 0.30 0.60  
   Min, max <LOD-112.5 <LOD-3.7 <LOD-0.3 <LOD-0.6  
MeFOSAA     0.48 
   Percent detected 100% 62.67% 80% 50.67%  
   GM (GSD)  1.42 (1.99) 0.29 (3.58) 0.30 (2.43) 0.18 (2.64)  









   95th percentile 5.00 1.90 1.10 0.80  
   99th percentile 6.60 8.40 1.60 1.10  
   Min, max 0.3-6.6 <LOD-8.4 <LOD-1.6 <LOD-1.1  
PFHxS     0.40 
   Percent detected 98.67% 98.67% 93.33% 97.33%  
   GM (GSD)  1.47 (2.30) 1.31 (2.39) 1.01 (2.69) 1.07 (2.25)  
   Median (IQR) 1.50 








   95th percentile 6.30 5.30 3.80 4.20  
   99th percentile 11.20 8.90 5.70 5.10  
   Min, max <LOD-11.2 <LOD-8.9 <LOD-5.7 <LOD-5.1  
PFDEA     0.36 
   Percent detected 42.67% 32% 89.33% 89.33%  
   GM (GSD)  0.13 (2.11) 0.13 (2.59) 0.33 (1.99) 0.37 (2.12)  
   Median (IQR) <LOD 
 (<LOD, 0.30) 
<LOD 
 (<LOD, 0.30) 
0.40 




   95th percentile 0.40 0.70 0.80 1.20  
   99th percentile 0.70 8.40 2.00 2.30  
   Min, max <LOD-0.7 <LOD-8.4 <LOD-2.0 <LOD-2.3  
PFUA     0.44 
   Percent detected 36% 26.67% 46.67% 66.67%  
   GM (GSD)  0.12 (2.07) 0.11 (2.22) 0.15 (2.42) 0.22 (2.43)  
   Median (IQR) <LOD  
(<LOD, 0.30) 
<LOD 
 (<LOD, 0.20) 
<LOD 









   95th percentile 0.50 0.60 0.70 0.80  
   99th percentile 0.50 1.10 1.00 1.00  
   Min, max <LOD-0.5 <LOD-1.1 <LOD-1.0 <LOD-1.0  
PFDOA     NAb 
   Percent detected 4% 2.67% 0% 1.33%  
   GM (GSD)  <LOD <LOD <LOD <LOD  
   Median (IQR) <LOD <LOD <LOD <LOD  
   95th percentile <LOD <LOD <LOD <LOD  
   99th percentile 0.20 0.20 <LOD 0.20  
   Min, max <LOD-0.2 <LOD-0.2 <LOD <LOD-0.2  
PFNA     0.16 
   Percent detected 97.33% 77.33% 100% 100%  
   GM (GSD)  0.54 (1.80) 0.36 (2.80) 1.06 (1.51) 1.22 (1.55)  
   Median (IQR) 0.50  
(0.40, 0.80) 
0.50 




 (0.90, 1.60) 
 
   95th percentile 1.30 1.30 2.20 2.40  
   99th percentile 1.60 2.40 2.70 3.50  
   Min, max <LOD-1.6 <LOD-2.4 0.4-2.7 0.3-3.5  
Abbreviations: GM, geometric mean; GSD, geometric standard deviation; IQR, interquartile 
range. 
P value estimated using Kruskal-Wallis test to assess temporal variations of serum PFAS 
concentrations. 
a Values below level of detection (LOD) were replaced by LOD/√2. 
b ICC cannot be estimated because serum congener concentrations can barely be detected in at 







Supplemental Table II. 5 Effect estimates (standard errors) from linear mixed regressions on log (serum PFAS1 concentrations) 
among 75 women with 300 observations in SWAN 1999-2011. 
Predictor n-PFOA n-PFOS Sm-PFOS PFHxS PFNA 
Intercept 1.70 (0.24)*** 3.63 (0.28)*** 2.34 (0.28)*** 0.78 (0.38)* -0.43 (0.28) 
Age at baseline2 0.02 (0.02) 0.05 (0.03) 0.04 (0.03) 0.06 (0.04) 0.03 (0.02) 
BMI at baseline3 0.002 (0.009) -0.003 (0.01) 0.01 (0.01) -0.02 (0.01) 0.007 (0.009) 
Period      
   1999/2000 Ref Ref Ref Ref Ref 
   2002/2003 -0.13 (0.18) -0.16 (0.18) -0.21 (0.16) -0.19 (0.24) -0.51 (0.27) 
   2005/2006 -0.59 (0.19)** -0.72 (0.18)*** -0.78 (0.16)*** -0.40 (0.25) 0.49 (0.27) 
   2009/2011 -0.91 (0.19)*** -1.15 (0.19)*** -1.30 (0.16)*** -0.59 (0.25)* 0.48 (0.28) 
Menstruation      
   No Ref Ref Ref Ref Ref 
   Yes -0.18 (0.07)** -0.10 (0.07) -0.15 (0.06)* -0.13 (0.09) -0.20 (0.09)* 
Race/ethnicity      
   Black Ref Ref Ref Ref Ref 
   Chinese -0.31 (0.24) 0.05 (0.29) -0.16 (0.19) -0.17 (0.39) 0.56 (0.26)* 
   White 0.25 (0.18) 0.006 (0.21) 0.29 (0.21) 0.36 (0.28) 0.08 (0.20) 
Parity      
    Nulliparous Ref Ref Ref Ref Ref 
    Parous -0.52 (0.18)** -0.65 (0.21)** -0.61 (0.21)** -0.19 (0.28) -0.21 (0.20) 
Site      
    Michigan Ref Ref Ref Ref Ref 
    Boston 0.26 (0.15) -0.10 (0.18) 0.16 (0.19) -0.12 (0.24) 0.17 (0.14) 
    Davis 0.05 (0.19) -0.21 (0.23) 0.05 (0.23) -0.28 (0.31) -0.15 (0.18) 
Period × Race/ethnicity      
    2002/2003 × Chinese 0.03 (0.16) 0.11 (0.15) 0.11 (0.14) 0.09 (0.21) -0.05 (0.23) 
    2005/2006 × Chinese 0.26 (0.16) 0.13 (0.15) 0.18 (0.14) 0.41 (0.21)* -0.17 (0.23) 
    2009/2011 × Chinese 0.49 (0.16)** 0.08 (0.15) 0.23 (0.14) 0.59 (0.21)** -0.08 (0.23) 
    2002/2003 × White -0.11 (0.14) -0.07 (0.14) -0.04 (0.12) -0.0003 (0.19) -0.45 (0.20)* 
    2005/2006 × White -0.15 (0.14) -0.31 (0.14)* -0.17 (0.12) -0.16 (0.18) -0.22 (0.20) 





Period × Parity      
    2002/2003 × Parous 0.08 (0.16) 0.17 (0.15) 0.08 (0.14) 0.02 (0.21) 0.34 (0.23) 
    2005/2006 × Parous 0.34 (0.16)* 0.29 (0.15) 0.14 (0.14) -0.09 (0.21) 0.25 (0.23) 
    2009/2011 × Parous 0.43 (0.16)** 0.50 (0.15)** 0.27 (0.14)* -0.05 (0.21) 0.23 (0.23) 
1PFAS with serum concentrations above limit of detection more than 70% were included in the analyses. 
2Age at baseline was centered at 50 years. 
3BMI at baseline was centered at 25 kg/m2. 





Supplemental Table II. 6 Baseline characteristics of study participants at SWAN V03 
(1999/2000) by race/ethnicity. 
 Total (n=75) White (n=37) Black (n=19) Chinese 
(n=19) 
 Mean (SD) or 
N (%) 
Mean (SD) or 
N (%) 
Mean (SD) or 
N (%) 
Mean (SD) or 
N (%) 
Age at interview, years 49.4 (2.4) 48.8 (2.4) 50.1 (2.5) 49.8 (2.1) 
Education     
    High school or less 9 (12.0%) 2 (5.4%) 2 (10.5%) 5 (26.3%) 
    Some college 20 (26.7%) 9 (24.3%) 9 (47.4%) 2 (10.5%) 
    College degree or 
higher 
46 (61.3%) 26 (70.3%) 8 (42.1%) 12 (63.2%) 
Employed 70 (93.3%) 36 (97.3%) 17 (89.5%) 17 (89.5%) 
Difficulty paying for 
basics  
    
    Very difficult 5 (7.0%) 2 (5.7%) 3 (16.7%) 0 
    Somewhat difficult 16 (22.2%) 9 (25.7%) 4 (22.2%) 3 (15.8%) 
    Not at all difficult 51 (70.8%) 24 (68.6%) 11 (61.1%) 16 (84.2%) 
Study sites     
    Michigan 19 (25.3%) 8 (21.6%) 11 (57.9%) 0 
    Boston 23 (30.7%) 15 (40.5%) 8 (42.1%) 0 
    Oakland 33 (44.0%) 14 (37.8%) 0 19 (100%) 
Physical activity     7.7 (2.0) 8.2 (1.8) 7.2 (2.4) 7.4 (1.7) 
Body mass index, kg/m2 28.0 (7.1) 27.2 (5.8) 33.2 (9.1) 24.3 (4.1) 
Menstrual bleeding since 
last visit 
67 (89.3%) 33 (89.2%) 17 (89.5%) 17 (89.5%) 
Daily dietary intake     
Protein, g 71.1 (29.2) 67.6 (25.4) 83.1 (37.5) 66.0 (24.7) 
Fiber, g 13.0 (6.2) 12.7 (5.7) 13.1 (6.5) 13.7 (7.1) 
Total calorie, kcal 1841 (760) 1722 (624) 2223 (1024) 1691 (583) 
Fish     
   <1 per week 23 (31.1%) 15 (41.7%) 6 (31.6%) 2 (10.5%) 
   1-2 per week 24 (32.4%) 12 (33.3%) 3 (15.8%) 9 (47.4%) 







Supplemental Figure II. 1 The study designs of the Study of Women’s Health Across the 















Supplemental Figure II. 3 Median (interquartile range) of serum PFAS concentrations (ng/mL) of measured in SWAN among women (n=75) aged 45-56 years 
at V03(1999-2000), V06 (2002-2003), V09 (2005-2006), and V12 (2009-2010);and  in NHANES 1999-2000 (n=91) among women aged 45-56 years, 2003-2004 






Supplemental Figure II. 4 Serum concentrations of selected PFAS with detection rates >70% by study site in women (n=75) across 
the United States for four SWAN visits. Boxes represent the 25th-75th percentiles, horizontal lines represent the median, and whiskers 
indicate 5th and 95th percentiles, respectively. Note that a log scale is used for the Y axis. The limits of detection were 0.1 ng/mL for 
all PFAS analytes. Abbreviations: n-PFOA, linear-chain perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, 









Chapter III. Associations between Perfluoroalkyl Substances and Incident Natural 






Previous epidemiologic studies of per- and polyfluoroalkyl substances (PFAS) and menopausal 
timing conducted in cross-sectional settings were limited by reverse causation because PFAS 
serum concentrations increase after menopause. 
Objectives  
To investigate associations between PFAS serum concentrations and incident natural menopause.  
Design and Setting 
A prospective cohort of midlife women, the Study of Women’s Health Across the Nation, from 
1999 to 2017. 
Participants 
1120 multi-racial/ethnic premenopausal women (White, Black, Chinese and Japanese) aged 45-
56 years in 1999-2000. 
Methods 
Serum PFAS concentrations were quantified by online solid phase extraction-high performance 
liquid chromatography-isotope dilution-tandem mass spectrometry. The final menstrual period 
was determined during the annual follow-up visits. Cox proportional hazards models were used 





Participants contributed 5466 person-years of follow-up, and 578 had incident natural 
menopause. Compared to the lowest tertile, women at the highest tertile of baseline serum 
concentrations had adjusted HR for natural menopause of 1.26 (95%CI: 1.02-1.57) for n-
perfluorooctane sulfonic acid (n-PFOS) (Ptrend=0.03), 1.27 (95%CI: 1.01-1.59) for branched-
PFOS (Ptrend=0.03), and 1.31 (95%CI: 1.04-1.65) for n-perfluorooctanoic acid (Ptrend=0.01). 
Women were classified into four clusters based on their overall PFAS concentrations as 
mixtures: low, low-medium, medium-high, and high. Compared to the low cluster, the high 
cluster had a HR of 1.63 (95% CI: 1.08-2.45), which is interpreted as 2.0 years earlier experience 
of natural menopause.  
Conclusion 
This study suggests that select PFAS serum concentrations are associated with earlier natural 





Menopause marks the cessation of ovarian function, and its timing has physiologic 
impacts beyond the reproductive system, affecting the overall health of midlife women 
(Snowdon et al., 1989; Wise et al., 1996). Earlier age at the final menstrual period (FMP) has 
been associated with an increased risk of overall mortality (Jacobsen et al., 2003; Mondul et al., 
2005; Ossewaarde et al., 2005), cardiovascular disease (Atsma et al., 2006; Hu et al., 1999), 
cardiovascular death (de Kleijn et al., 2002; Mondul et al., 2005; van der Schouw et al., 1996), 
low bone mineral density (Parazzini et al., 1996) and osteoporosis (Kritz-Silverstein and Barrett-
Connor, 1993), and other chronic conditions (Shuster et al., 2010). Ovarian aging reflects the 
combined effects of  genetic factors, socio-demographics, lifestyle and health characteristics (de 
Bruin et al., 2001; Gold et al., 2001,  2013). Although the etiology of premature menopause 
(before age 40 years) and early menopause (before age 45 years) is not fully understood, 
accumulating evidence has suggested that certain environmental exposures may play an 
important role in the acceleration of ovarian aging (Diamanti-Kandarakis et al., 2009; Grindler et 
al., 2015; Vabre et al., 2017).  
Per- and polyfluoroalkyl substances (PFAS) are a family of anthropogenic 
environmentally persistent chemicals, some of which also persist in the human body, that have 
been widely used in many industrial and consumer products, such as non-stick cookware 
(Bradley et al., 2007; Ewan Sinclair et al., 2007), food packaging (Begley et al., 2005; Schaider 
et al., 2017; Trier et al., 2011), outdoor apparel (Hill et al., 2017; Lee et al., 2017), and aqueous 
film-forming foams (Butenhoff et al., 2006; Kantiani et al., 2010; Kissa, 2011; Trudel et al., 
2008a). These compounds, especially the most studied perfluorooctanoic acid (PFOA) and 




with the potential to cause reproductive disturbances (Jensen and Leffers, 2008; Kar et al., 2017). 
The potential for reproductive impact is supported by findings from animal toxicology studies 
with effects on female reproduction, including altered ovarian function, histopathological 
changes in the reproductive tract and ovarian cell steroidogenesis (Chaparro-Ortega et al., 2018a; 
Dixon et al., 2012; Zhao et al., 2012), likely through the activation of various transcriptional 
factors, such as peroxisome proliferator-activated receptors (PPARs) (Andersen et al., 2008; 
White et al., 2011). However, extrapolations of findings from animal studies to the potential 
effects of PFAS on human ovarian health are clearly limited, given the species-specific 
toxicokinetics, metabolism and tissue distributions of PFAS (Lau et al., 2007).  
Although three human studies have examined the associations of natural menopause with 
PFOS, PFOA, perfluorononanoic acid (PFNA) and perfluorohexane sulfonic acid (PFHxS), the 
results have been inconsistent. A cross-sectional study of mid-Ohio Valley residents found that 
earlier age at natural menopause was associated with higher concentrations of PFOA and PFOS 
(Knox et al., 2011); whereas using data from the National Health and Nutrition Examination 
Survey (NHANES), Taylor et al. observed a significant relationship of earlier natural menopause 
with PFHxS but not with PFOA, PFOS, PFNA (Taylor et al., 2014). These studies also raised 
concerns about reverse causation, in that it is unclear whether PFAS exposure contributed to 
earlier menopause, or cessation of PFAS excretion via cessation of menstruation led to increased 
serum concentrations of PFAS in women (Dhingra et al., 2017; Konkel, 2014; Ruark et al., 
2017; Taylor et al., 2014).  
A retrospective cohort study reported no association between PFOA exposure and natural 
menopause [43].  That study relied on recalled information on age at menopause that had 




of FMP without longitudinal observations of menstrual cycles (Santoro and Johnson, 2019). 
Potential recall bias may have reduced the accuracy of reported age at natural menopause and 
presumably biased the study results toward the null (Dhingra et al., 2016). Annual interviews can 
determine relatively accurate estimates of FMP, and a prospective cohort design with a large, 
diverse population can provide insights regarding causality that can be more generalizable.  
We, therefore, examined the associations between PFAS exposures and incidence of 
natural menopause in the multi-racial/ethnic sample of women who were premenopausal at 
baseline from a prospective cohort, i.e., the Study of Women’s Health Across the Nation 
(SWAN). Women were followed every year from 1999-2010 and every other year from 2011-
2017. We also assessed whether the relationship differed by racial/ethnic groups and evaluated 
the combined effects of PFAS mixtures on natural menopause.  
2. Materials and methods 
Study design 
The SWAN cohort, a multi-racial/ethnic, longitudinal study, was designed to characterize 
physiological and psychosocial changes that occur during the menopausal transition to observe 
their effects on subsequent risk factors for age-related chronic diseases, as previously described 
(Sowers et al., 2000). A total of 3,302 premenopaal women aged 42-52 years at baseline were 
recruited from seven study sites, including Boston, MA; Chicago, IL; Detroit, MI; Los Angeles, 
CA; Newark, NJ; Oakland, CA; Pittsburgh, PA. Eligible participants had to have an intact uterus, 
at least one menstrual period in the prior three months, and not have taken hormone medications 
within the prior three months. Participants self-identified as non-Hispanic White women or one 




each site. Data and specimens were collected every year from 1999-2010 and every other year 
from 2011-2017. The institutional review board at each participating site approved the study 
protocol, and all participants provided written, signed informed consent. 
The SWAN Multi-Pollutant Study (MPS) was initiated in 2016, using the SWAN follow-
up visit 03 (V03, 1999-2000) as the baseline to examine the potential health effects of multiple 
environmental chemicals, including PFAS, polychlorinated biphenyls, organochloride pesticides, 
polybrominated diphenyl ethers, metals, phenols, phthalates, and organophosphate pesticide 
among midlife women. The study design of the SWAN MPS is shown in Supplemental Figure 
III.1. We used repository serum and urine samples collected at SWAN V03, considered the MPS 
baseline for environmental exposure assessments. Of 2,694 women enrolled at SWAN V03, we 
did not include women from Chicago (n=368) and Newark (n=278), because urine samples were 
not available at these two sites. An additional 648 women were excluded due to insufficient 
volumes of serum or urine samples. Of the remaining1,400 participants with serum samples 
available at the SWAN-MPS baseline, we excluded 232 women who had already reached natural 
menopause and 48 women who had had a hysterectomy and/or oophorectomy at the MPS 
baseline, resulting in a final analytic sample of 1120 women with 6586 observations and 5466 
person-years of follow-up through 2017. Additional details of the study design are described 
elsewhere (Park et al., 2019).  
Ascertainment of natural menopause incidence 
The age at the natural FMP was determined from annual interviews indicating 12 months 
of amenorrhea since the last menstrual period for no other causes (including hysterectomy, 




had a menstrual bleed followed by at least 12 consecutive months that were both HT-free and 
bleed-free, her FMP was ascertained. If a woman missed at least three consecutive visits prior to 
the first post-menopause visit, the FMP date was set to missing.  
Measurements of PFAS serum concentrations 
Baseline MPS serum samples were sent to the Division of Laboratory Sciences, National 
Center for Environmental Health, Centers for Disease Control and Prevention (CDC). The CDC 
laboratory’s involvement did not constitute engagement in human-subjects research. Serum 
samples from subsequent SWAN visits were not analyzed because serum concentrations of the 
target analytes are relatively stable over time (Ding et al., 2019). We measured perfluorohexane 
sulfonic acid (PFHxS), n-PFOS, sum of branched isomers of PFOS (Sm-PFOS), n-PFOA, sum 
of branched PFOA (Sb-PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid 
(PFDA), perfluoroundecanoic acid (PFUnDA), and perfluorododecanoic acid (PFDoA) in 0.1 
mL of serum, using an online solid phase extraction-high performance liquid chromatography-
isotope dilution-tandem mass spectrometry method (Kato, Basden, et al., 2011). The analytic 
methods and quality control procedures have been described elsewhere (Ding et al., 2019). The 
coefficient of variation of low- and high-quality controls ranged from 6% to 12%. The limit of 
detection (LOD) was 0.1 ng/mL for all the analytes. Concentrations below the LODs were 
substituted with LOD/√2.  
Assessments of covariates 
Annual visits included an in-person interview, self-administered questionnaires, and 
measurements of weight and height. All questionnaires were translated into Spanish, Cantonese 




Socio-demographic variables included race/ethnicity, study site, and educational 
attainment from the screening questionnaire. Race/ethnicity was classified into self-identified 
Black, Chinese, Japanese, or White. We categorized education as high school or less, some 
college, or college degree or higher. Baseline time-invariant health-related variables included 
prior oral contraceptive and other exogenous hormone use, and body mass index (BMI) at 
baseline. We did not consider time-varying BMI in case of over-adjustment bias because PFAS 
might contribute to weight gain (Liu et al., 2018). 
Time-varying lifestyle variables included annual self-reported active smoke exposure and 
physical activity. Self-reported smoking status was classified as never smoked, former smoked 
only, or current smoking (Ferris, 1978). Physical activity was assessed using an adaptation of the 
Kaiser Physical Activity Survey (Sternfeld et al., 1999), which consists of 38 questions with 
primarily Likert-scale responses about physical activity in various domains, including 
sports/exercise, household/caregiving, and daily routine (defined as walking or biking for 
transportation and hours of television watching, which are reverse-coded). Domain-specific 
indices were derived by averaging the ordinal responses to questions in each domain, resulting in 
values from 1 to 5. Thus, the total physical activity score ranged from 3 to 15 with 15 indicating 
the highest level of activity.  
Statistical analyses 
Bivariate statistics were calculated for participant characteristics at baseline and PFAS 
serum concentrations stratified by racial/ethnic groups. Chi-square or Fisher’s exact statistics 
were computed for categorical variables; and analysis of variance (ANOVA) or Kruskal-Wallis 




initiating HT if no subsequent HT-free bleeding occurred, at the date of hysterectomy or bilateral 
oophorectomy, or at the last menstrual period at the end of data collection if it occurred before 12 
months of amenorrhea, on the date of death or on the date of the participants’ last follow-up 
visits. Of the 1120 participants, 578 had an observed date at the natural FMP. The remaining 542 
were censored for one of the following reasons: hysterectomy and/or oophorectomy before 
having ≥12 months of amenorrhea (n=69); had an unknown FMP date because of HT use 
(n=451); or end of data collection before ≥12 months of amenorrhea (n=22). 
Hazard ratios (HRs) and 95% confidence intervals (CIs) of natural menopause incidence 
were estimated by Cox proportional hazard (PH) regression. We used time since baseline as the 
time scale. Serum PFAS concentrations were also categorized into tertiles. HRs and 95% CIs 
were calculated comparing the medium and the highest tertiles of PFAS concentrations to the 
lowest tertiles (the reference group). To assess the linear trend of the associations between PFAS 
exposures and incident natural menopause, tertiles of PFAS concentrations were used as 
continuous variables in the regression models. We also tested the log-linear relationships using 
log-transformed PFAS concentrations (log-transformed with base 2). In this case, HRs and 95% 
CIs were interpreted as effects of a two-fold increase in PFAS serum concentrations. Covariates 
considered in multivariate adjustments included baseline age (continuous), race/ethnicity (White, 
Black, Chinese, Japanese), educational attainment (high school or less, some college, college 
graduate, or post-college), time-varying parity status (nulliparous, or parous), time-varying 
smoking status (never, former, or current smoker), time-varying physical activity, prior HT use 
at baseline, and baseline BMI. To examine effect modifications by race/ethnicity, we used 
statistical interaction terms between PFAS exposure and race/ethnicity. Chinese and Japanese 




People are exposed to multiple and often inter-correlated chemicals. Efforts to study 
chemical mixtures in isolation can thus result in underestimated environmental effects (Wang, 
Mukherjee, and Park, 2019; Wang, Mukherjee, et al., 2018). To identify subgroups 
corresponding to distinct MPS baseline PFAS concentration profiles, a nonparametric portioning 
method, k-means clustering, was used to find an optimal number of clusters and assign 
membership to each cluster for each participant (Jain, 2010). The k-means clustering was 
conducted using PROC FASTCLUS procedures. All PFAS serum concentrations were log-
transformed and standardized to z scores to make the distributions normal and comparable before 
the k-means analysis. The number of clusters was chosen based on cubic clustering criterion, 
pseudo F statistic (i.e., the ratio of between-cluster variance to within-cluster variance), r-squared 
statistics, and interpretability. Participant characteristics differed significantly by k-means 
clusters (Supplemental Table III.1). It is possible that there is uncertainty in classifying women 
based on their overall concentration patterns. Therefore, we utilized inverse probability treatment 
weighting method to account for confounding due to differences in distributions of these 
characteristics among clusters (96). HRs of natural menopause incidence were estimated for 
women with different clusters. We estimated conservative 95% CIs based on the robust variance 
estimator. All the analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, 
North Carolina). 
Sensitivity analyses 
HT use or loss to follow up masked the actual FMP date. We therefore conducted 
multiple imputations with chain equations for missing FMP age using a comprehensive list of 
covariates related to timing of menopause (see the list of covariates in the Supplemental Table 




perfectly, we used ten sets of imputations to account for uncertainty, and the pooled results were 
computed using PROC MIANALYZE.    
Hysterectomy and/or oophorectomy was a competing risk in our analyses. Previous 
studies have suggested that exposures to PFOS, PFOA, and PFNA were associated with 
increased risk of endometriosis (Campbell et al., 2016). Many women undergo a hysterectomy to 
help alleviate intolerable symptoms of endometriosis. Because such surgery would mask the age 
at which a woman would have become menopausal in the absence of surgery, the competing risk 
may preclude women from participation due to no longer being at risk of reaching the natural 
FMP. To examine the potential impact of this competing risk on our results, we excluded women 
who had hysterectomy in the sensitivity analyses. Lastly, we excluded 29 women who reached 
their natural menopause since baseline to minimize the possibility of reverse causation bias. 
3. Results 
Study participants 
The median (interquartile range, IQR) age of the 1120 premenopausal women was 48.9 
(47.0-50.8) years with a range of 45-56 years at baseline (1999-2000) (Table 1). Most women 
had at least some college education. Educational attainment differed significantly by 
race/ethnicity, with Black women more likely to receive a high school education or less 
(p<0.0001) compared to other racial/ethnic groups. Less than 40% of the women had ever 
smoked; a higher proportion of Black women were current smokers compared to the other 
racial/ethnic groups (p<0.0001). Physical activity also differed significantly by race/ethnicity, 
with White women having higher activity scores (p<0.0001). BMI at baseline was significantly 




Chinese and Japanese women were more likely to be nulliparous (p<0.0001) and to report prior 
use of HT at baseline (p=0.0005).  
PFOS and PFOA were the PFAS detected at the highest concentrations (Supplemental 
Table III.3). The median (interquartile range, IQR) serum concentration was 17.1 (12.2-24.5) 
ng/mL for n-PFOS, 7.2 (4.6-10.8) ng/mL for Sm-PFOS, and 4.0 (2.8-5.7) ng/mL for n-PFOA, 
1.5 (0.9-2.3) ng/mL for PFHxS, 0.6 (0.4-0.8) ng/mL for PFNA. PFUnDA, PFDoA, PFDA, and 
Sb-PFOA were detected in fewer than 40% of baseline samples, and thus they were not 
considered further in these analyses. Significant racial/ethnic differences were observed in serum 
PFAS concentrations: White women had the highest concentrations of n-PFOA; Black women 
had the highest concentrations of n-PFOS, and Sm-PFOS; Chinese and Japanese women had the 
lowest PFHxS concentrations; White, Chinese and Japanese women had a higher detection rate 
of PFNA, and significantly higher median concentrations compared to Black women.  PFAS 
were positively correlated amongst each other with Spearman ρs ranging from 0.35-0.82 
(Supplemental Figure III.2). 
Associations between PFAS and incident natural menopause  
n-PFOS, Sm-PFOS, n-PFOA and PFNA were associated with earlier age at natural FMP 
(Table 2). After multivariate adjustment for age at baseline, race/ethnicity, study site, education, 
parity, BMI at baseline, and time-varying physical activity and smoking status, and prior 
hormone use at baseline, comparing the highest to the lowest tertiles, the HR for natural 
menopause was 1.26 (95% CI: 1.02-1.57) for n-PFOS (ptrend =0.03), 1.27 (95% CI: 1.01-1.59) for 
Sm-PFOS (ptrend=0.03), and 1.31 (95% CI: 1.04-1.65) for n-PFOA (ptrend =0.01). The relationship 




menopause was 1.12 (95% CI: 1.01-1.24) per doubling increase in PFNA serum concentrations. 
No significant association with age of menopause was found for PFHxS in either trend 
(ptrend=0.24) or log-linear analyses (p=0.15). Adjusted survival curves by tertiles of PFAS 
concentrations are presented in Supplemental Figures III.3-III.7. The predicted age at natural 
menopause in women with tertile 1, tertile 2, and tertile 3 of serum concentrations was: 52.6 
years, 52.3 years and 51.6 years for n-PFOS; 52.6 years, 51.9 years and 51.7 years for Sm-PFOS; 
52.7 years, 51.9 years and 51.6 years for n-PFOA; 52.7 years, 51.8 years and 51.8 years for 
PFNA; and 52.4 years, 51.9 years and 51.8 years for PFHxS.     
When we examined interaction terms between PFAS concentrations and race/ethnicity, 
significant associations with incidence of natural menopause were observed for PFNA and n-
PFOA among White women but not in other racial/ethnic groups (Figure 1). The HR for White 
women was 1.23 (95% CI: 1.06-1.44) and 1.33 (95% CI: 1.13-1.56) per doubling increase in 
serum concentrations of n-PFOA and PFNA, respectively, after covariate adjustment. The 
associations in Black or Asian women did not reach statistical significance. Neither did the 
results for n-PFOS, Sm-PFOS and PFHxS (Supplemental Figure III.8).  
In sensitivity analyses, the pooled effect estimates from 10 imputations of age at FMP 
were largely unchanged, while the 95% CIs became narrower (Table 3). However, the 
significant associations between PFNA concentration and natural menopause disappeared. In the 
competing risks analyses, 67 women (303 observations) who had hysterectomy and/or 
oophorectomy were excluded from the analyses, but effect estimates remained similar 
(Supplemental Table III.4). Exclusion of 29 women who reached natural menopause in the six 
months since baseline did not change results (Supplemental Table III.5), diminishing the 




Mixture effects of PFAS on incident natural menopause 
Participants were classified into clusters based on their overall PFAS concentrations 
profiles using the k-means method (Supplemental Figure III.9). Women were classified into 
four clusters based on serum PFAS concentrations, including “low”, “low-medium”, “medium-
high”, and “high” overall concentration patterns. Women in the “low” concentration group had 
the lowest overall concentrations of PFAS, while those classified into the “high” group exhibited 
the highest concentrations. After adjusting for confounding, women in the high concentration 
group were 1.63 (95% CI: 1.08-2.45) times more likely to reach natural menopause earlier, 1.31 
(95% CI: 0.94-1.83) for medium-high group and 1.30 (95% CI: 0.97-1.74) for low-medium 
group, compared to those in the low concentration group (Supplemental Table III.6). 
Participants in the high concentration group had an earlier onset of natural menopause compared 
to those in other groups (Figure 2). The predicted median age at natural menopause in the low 
concentration group was 52.8 years compared to 51.8 years, 52.0 years and 50.8 years for low-
medium, medium-high, and high concentration groups, respectively.  
4. Discussion 
In this 17-year prospective cohort of 1120 women with 5466 person-years of observation 
in annual follow-up visits, we found that higher baseline serum concentrations of n-PFOS, Sm-
PFOS, n-PFOA, and PFNA were significantly associated with an earlier age at natural FMP. 
PFHxS concentrations were not associated with incidence of natural menopause. The analysis of 
mixtures also suggested that the combined PFAS mixtures were associated with earlier onset of 
natural menopause. These results suggest that PFAS may play an important role in ovarian aging, 




Comparison with previous epidemiologic studies 
To date, evidence on the influence of PFAS exposure on the timing of menopause and 
ovarian aging has been limited and inconsistent, and has been primarily generated from cross-
sectional studies that could not establish causal relationships (Knox et al., 2011; Taylor et al., 
2014). Knox et al. found that higher concentrations of PFOA and PFOS were associated with 
earlier menopausal age in a cross-sectional study of women aged 18-65 years from the C8 Health 
Project (Knox et al., 2011). This study collected data from highly exposed communities and 
workers in six public water districts contaminated with PFOA from the DuPont Washington 
Works Plant near Parkersburg (Frisbee et al., 2009). Taylor et al. reported significant 
relationships between higher PFHxS concentrations and earlier menopause, but not for PFOA, 
PFOS and PFNA among the U.S. general women aged 20-65 years from NHANES (Taylor et 
al., 2014). Using estimated retrospective year-specific serum concentrations for 1951-2011 and 
PFOA concentrations measured in 2005-2006, no association was observed between earlier age 
at menopause with PFOA exposure in either retrospective or prospective cohort of C8 Science 
Panel (Dhingra et al., 2016). However,  reverse causation could not be ruled out as women 
appeared to have higher PFAS concentrations after menopause (Dhingra et al., 2017; Konkel, 
2014; Ruark et al., 2017; Taylor et al., 2014).  
Given that approximately 90% to 99% of PFAS in the blood are bound to serum albumin 
(Han et al., 2003; Ylinen and Auriola, 1990), menstrual bleeding could be an important 
elimination pathway in women. Wong et al.(Wong et al., 2014) found that menstruation could 
explain the PFOS elimination half-life difference between men and women. Therefore, 
previously observed associations identified in cross-sectional or retrospective designs (Dhingra 




aging on serum PFAS concentrations, rather than their adverse effects on ovarian reserve.  
To our knowledge, the current investigation is among the first of studies to evaluate the 
associations of exposures to various PFAS with the occurrence of natural menopause in a 
prospective cohort of multi-racial/ethnic midlife women. Our findings of PFOA and natural 
menopause are not in concordance with Dhingra et al. (Dhingra et al., 2016), the only other 
published study to our knowledge that has explored the associations between PFOA exposure 
and incident menopause. Adult women drawn from the C8 Health Project in 2005-2006 were 
interviewed in 2008-2011 to ascertain the timing of menopause, as part of the work of C8 
Science Panel (Dhingra et al., 2016). The different results obtained by the present study and 
Dhingra et al. (Dhingra et al., 2016) might be attributed to different sampling time intervals, 
sources and duration of exposures, as well as different demographics of the study participants. 
The availability of standardized and regular (approximately annual) visits to confirm menopausal 
status and ascertain age at the natural FMP is a major strength of SWAN and may account for the 
observed differences in the findings.  
No previous research of which we are aware has explored the mixture effects of PFAS on 
ovarian aging. PFAS are ubiquitous and environmentally persistent (Olsen et al., 2007). People 
may be normally exposed to multiple PFAS through drinking water, food intake, or use of 
consumer products (Domingo and Nadal, 2017,  2019). Understanding concentration patterns of 
multiple PFAS is an important first step before examining the association between PFAS 
mixtures and incident natural menopause. Results of mixture analyses showed a larger joint 
effect on ovarian aging compared with single PFAS. Along with our recent study of profiles of  
urinary concentrations of metal mixtures among midlife women (Wang, Mukherjee, Batterman, 




clusters in the population.  
This is also the first study of which we are aware to explore effect modification by 
race/ethnicity on the associations between PFAS exposure and natural menopause. Although 
environmental exposure in general is sometimes expected to be higher in racial minority groups 
and socioeconomically disadvantaged neighborhoods, the concentration patterns tended to 
depend on the PFAS. Serum concentrations of n-PFOA were found to be higher in White women 
and PFNA concentrations were relatively higher in White and Chinese women, whereas serum 
concentrations of n-PFOS and Sm-PFOS were higher in Black women. This is consistent with 
previous findings (Calafat, Kuklenyik, et al., 2007; Calafat, Wong, et al., 2007; Jain, 2014; Park 
et al., 2019). White women with higher n-PFOA and PFNA tended to have earlier natural 
menopause. 
PFOA is used as a surfactant and emulsifier in compounds used to coat a variety of food 
packaging materials, including microwave popcorn bags (Lau et al., 2007; Lindstrom et al., 
2011; State Water Resources Control Board, 2010) and is essential in manufacture of the 
fluoropolymer polytetrafluoroethylene (PTFE) used in non-stick coatings and waterproof fabrics 
(EFSA, 2016). Uses of PFOS included inks, varnishes, waxes, fire-fighting foams, and coating 
formulations (Paul et al., 2009). Use of consumer products may have contributed to more 
exposure to PFOA, while the most dominant source of PFOS exposure might have been intake of 
contaminated drinking water (Trudel et al., 2008b). Although production and use of some PFAS, 
including PFOA and PFOS, in the USA is on the decline, environmental exposures to many of 





Our study results showed no difference in the effects of n-PFOS and Sm-PFOS by 
racial/ethnic groups, possibly because of the exclusion of women with premature (before the age 
of 40 years) or early menopause (before age 45 years), or censoring of Black women who had 
surgical menopause had higher concentrations of n-PFOS and Sm-PFOS. Asian women with 
similar PFNA concentrations as White women did not reach their natural menopause earlier. 
Previous studies have shown increases in PFNA concentrations since 2000 (Calafat et al., 2006; 
Calafat, Kuklenyik, et al., 2007; Calafat, Wong, et al., 2007; Kato, Wong, et al., 2011; Spliethoff 
et al., 2008). Future studies with more recent PFNA measurements are needed to confirm our 
findings and better understand exposure trends. 
Biological evidence  
PFAS exposures have been associated with diminished ovarian reserve (i.e., the number 
of ovarian follicles and oocytes) (Bellingham et al., 2009; Chen et al., 2017; Domínguez et al., 
2016; Du et al., 2019; Feng et al., 2015,  2017; Hallberg et al., 2019; López-Arellano et al., 
2019). The mechanisms of PFAS-induced effects have widely been thought to occur through a 
peroxisome proliferator-activated receptor (PPAR) mechanism (Andersen et al., 2008; Elcombe 
et al., 2010; White et al., 2011). PPARs are expressed in the female hypothalamic-pituitary-
gonadal axis, and they act on critical processes for ovarian function. For example, PPARs may 
inhibit transactivation of the estrogen receptor (ER) through competition for estrogen response 
element (ERE) binding (Keller et al., 1995), down-regulate aromatase expression via nuclear 
factor-κB (NF-κB) pathway (Fan et al., 2005), and affect enzymatic activity in steroidogenesis 
(Rak-Mardyła and Karpeta, 2014; Toda et al., 2003).   




interfere with steroidogenic enzyme activities (Chaparro-Ortega et al., 2018b; Shi et al., 2009a; 
Wang, Bai, et al., 2018). Recently, it was also reported that PFNA and PFOA are weak 
xenoestrogens, inducing ERα-dependent transcriptional activation in vitro and in vivo 
(Benninghoff et al., 2011). As potential endocrine disruptors, PFAS might also suppress the 
effects of 17β-estradiol (E2) on estrogen-responsive gene expression (Henry and Fair, 2013; Shi 
et al., 2009b), reduce E2 production and alter the expression of major steroidogenic genes and 
regulator steroidogenic factors 1 (SF-1) (Du et al., 2013). Disruption of ER signaling pathways 
may contribute to adverse health effects, such as reproductive failure and acceleration of ovarian 
aging, thus supporting the notion that women may be particularly vulnerable to reproductive 
toxicity of PFAS. In addition, experimental studies suggest that PFOA may lead to minimal but 
significant histopathologic changes in the uterus, vagina, and cervix (Dixon et al., 2012).   
Strengths and limitations 
The primary strengths of this study included direct measurements of PFAS serum 
concentrations prior to menopause, prospectively determination of FMP date, and a large cohort 
of community-based midlife women from four racial/ethnic groups followed for up to 17 years. 
The reproductive toxicity of PFAS has not been previously characterized among Chinese and 
Japanese women, to our knowledge. The prospective design also minimized the possibility of 
reverse causation. Standard annual follow-up visits instead of one-time questionnaire provided 
reliable estimates of date of FMP. We also consider multiple factors simultaneously in the Cox 
PH model, censoring at initiation of HT use or at hysterectomy or oophorectomy, thus providing 
HRs for natural menopause for the independent relations of all exposure factors examined.  




limited to menstruating women, thus women with earlier menopause were excluded. This left-
truncation resulted in an overestimation of median age at FMP (Cain et al., 2011). Women who 
experienced menopause before baseline, especially those with premature menopause (before age 
40 years) or early menopause (before age 45 years) were not included in the cohort, which could 
bias our effect estimates towards the null. Second, more than 40% of the cohort was censored at 
the initiation of HT, before the participants were classified as post-menopausal. This could have 
resulted in an underestimation of the age at FMP because these women had higher education 
levels, which has been associated with later age at menopause. To minimize potential bias, we 
imputed their FMP age based on covariates related to the timing of menopause. Imputing age at 
menopause increased sample size and broadened generalizability to women with HT use and 
thus might have reduced bias. Finally, hysterectomy could be a competing risk of natural 
menopause. Hysterectomy can be undertaken for medical conditions (such as endometriosis or 
uterine fibroids, cancer or menorrhagia). We did not have data on the date of onset of these 
conditions and hence were unable to examine directly the potential effects of PFAS on cause-
specific subsets of menopause (either surgically or naturally occurring).  
5. Conclusions 
Our findings suggest that exposure to select PFAS was associated with earlier natural 
menopause. Women with highest tertiles of n-PFOS serum concentrations tended to have 1.0 
years earlier median time to natural menopause, and 0.9 years and 1.1 years earlier for Sm-PFOS 
and n-PFOA, respectively, compared to those in the lowest tertiles. High overall PFAS 
concentration patterns might contribute to 2.0 years earlier median time to natural menopause, 
compared to the low group. These estimates were roughly equivalent to or even larger than an 




PFAS widespread use and environmental persistence, their potential adverse effects remain a 
public health concern.  
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Table III. 1 Baseline (1999-2000) characteristics of multi-racial/ethnic midlife women by racial/ethnic groups in the Study of 














or n (%) 
Median (IQR) 
or n (%) 
Median (IQR) 
or n (%) 
Median (IQR) 
or n (%) 
Median (IQR) 
or n (%) 
 
Age, years 48.9 (47.0-50.8) 48.7 (47.0-50.8) 48.7 (46.8-50.7) 49.3 (47.3-50.7) 49.2 (47.4-50.9) 0.23 
Study site      NA 
    Southeast MI 202 (18.0%) 90 (15.6%) 112 (47.7%) 0 0  
    Boston, MA 182 (16.3%) 118 (20.4%) 64 (27.2%) 0 0  
    Oakland, CA      242 (21.6%) 100 (17.3%) 0 142 (100%) 0  
    Los Angeles, CA 299 (26.7%) 133 (23.1%) 0 0 166 (100%)  
    Pittsburgh, PA 195 (23.4%) 136 (23.6%) 59 (25.1%) 0 0  
Educational attainment      <0.0001 
    ≤High school 197 (17.7%) 69 (12.0%) 65 (28.0%) 35 (24.7%) 28 (16.9%)  
    Some college 350 (31.4%) 174 (30.3%) 90 (38.8%) 28 (19.7%) 58 (34.9%)  
    College 271 (24.3%) 137 (23.9%) 41 (17.7%) 43 (30.3%) 50 (30.1%)  
    Post-college 296 (26.6%) 194 (33.8%) 36 (15.5%) 36 (25.3%) 30 (18.1%)  
Parity      <0.0001 
    Nulliparous 215 (19.2%) 146 (25.3%) 21 (8.9%) 21 (14.8%) 27 (16.3%)  
    Parous 905 (80.8%) 431 (74.7%) 214 (91.1%) 121 (85.2%) 139 (83.7%)  
Prior hormone use  248 (22.1%) 151 (26.2%) 54 (23.0%) 21 (14.8%) 22 (13.3%) 0.0005 
Smoking status      <0.0001 
    Never smoker 720 (64.4%) 343 (59.5%) 134 (57.3%) 134 (94.4%) 109 (65.7%)  
    Former smoker 291 (26.0%) 187 (32.5%) 55 (23.5%) 7 (4.9%) 42 (25.3%)  
    Current smoker 107 (9.6%) 46 (8.0%) 45 (19.2%) 1 (0.7%) 15 (9.0%)  
Physical activity score 7.9 (6.6-9.0) 8.1 (6.9-9.3) 7.3 (6.4-8.6) 7.2 (6.0-8.5) 7.8 (6.7-8.9) <0.0001 
Body mass index, kg/m2 26.1 (22.7-31.5) 26.5 (22.9-31.7) 31.4 (26.5-37.9) 23.0 (20.9-25.0) 23.3 (21.5-26.2) <0.0001 
IQR, inter-quartile range. NA, not available. 
a Chi-square tests or Fisher’s exact tests were used for categorical variables; analysis of variance tests or Kruskal-Wallis tests were 




Table III. 2 Hazard ratios (HR) (95% confidence intervals, 95% CI) for incident natural menopause with tertile changes and per 
doubling increase in serum concentrations of n-PFOS, Sm-PFOS, n-PFOA, PFNA, and PFHxS. 
PFAS 
Tertile of PFAS concentrations p value 
 for 
trendc 










n-PFOS       
  Median (IQR), ng/mL 10.4 (8.1-12.2) 16.9 (15.6-18.7) 28.3 (24.2-37.8)    
  no. cases/person-years 183/1861 192/1883 203/1880    
  Model 1a Ref 1.04 (0.85-1.27) 1.19 (0.97-1.47) 0.09 1.06 (0.96-1.18) 0.26 
  Model 2b Ref 1.06 (0.86-1.31) 1.26 (1.02-1.57) 0.03 1.11 (0.99-1.23) 0.06 
Sm-PFOS       
  Median (IQR), ng/mL 3.8 (2.9-4.5) 7.1 (6.2-8.0) 13.0 (10.7-16.8)    
  no. cases/person-years 195/1842 194/1923 189/1858    
  Model 1a Ref 1.03 (0.84-1.27) 1.12 (0.90-1.39) 0.30 1.04 (0.95-1.14) 0.37 
  Model 2b Ref 1.11 (0.90-1.37) 1.27 (1.01-1.59) 0.03 1.08 (0.99-1.19) 0.09 
n-PFOA       
  Median (IQR), ng/mL 2.3 (1.8-2.8) 4.0 (3.5-4.5) 6.6 (5.6-8.6)    
  no. cases/person-years 183/1818 195/1936 200/1870    
  Model 1a Ref 1.15 (0.92-1.42) 1.29 (1.03-1.61) 0.02 1.06 (0.95-1.19) 0.27 
  Model 2b Ref 1.12 (0.90-1.40) 1.31 (1.04-1.65) 0.01 1.11 (0.99-1.24) 0.07 
PFNA       
  Median (IQR), ng/mL 0.3 (0.3-0.4) 0.5 (0.5-0.6) 0.9 (0.7-1.0)    
  no. cases/person-years 168/1930 181/1679 229/2015    
  Model 1a Ref 1.18 (0.95-1.46) 1.21 (0.99-1.49) 0.07 1.13 (1.02-1.25) 0.02 
  Model 2b Ref 1.18 (0.95-1.47) 1.20 (0.97-1.49) 0.10 1.12 (1.01-1.24) 0.04 
PFHxS       
  Median (IQR), ng/mL 0.8 (0.6-1.0) 1.5 (1.3-1.6) 3.0 (2.3-4.5)    
  no. cases/person-years 203/1957 168/1728 207/1939    
  Model 1a Ref 0.92 (0.75-1.13) 1.15 (0.94-1.41) 0.19 1.04 (0.97-1.13) 0.27 
  Model 2b Ref 1.05 (0.84-1.30) 1.11 (0.90-1.37) 0.33 1.03 (0.95-1.11) 0.50 
a Model 1 was adjusted for age at baseline, race/ethnicity, and study site. 
b Model 2 was additionally adjusted for education, parity, BMI at baseline, physical activity, smoking status, and prior hormone use at baseline.  




Table III. 3 Pooled hazard ratios (HR) (95% confidence intervals, 95% CI) for incident natural menopause with tertile changes and 
per doubling increase in serum concentrations of n-PFOS, Sm-PFOS, n-PFOA, PFNA, and PFHxS with 10 imputations. 
PFAS 












n-PFOS       
  Median (IQR), ng/mL 10.4 (8.1-12.2) 16.9 (15.6-18.7) 28.3 (24.2-37.8)    
  no. cases/person-yearsa 315/1487 322/1499 344/1483    
  Model 1b Ref 0.98 (0.84-1.16) 1.23 (1.05-1.46) 0.01 1.10 (1.01-1.20) 0.02 
  Model 2c Ref 0.99 (0.84-1.17) 1.26 (1.06-1.49) 0.01 1.11 (1.02-1.21) 0.02 
Sm-PFOS       
  Median (IQR), ng/mL 3.8 (2.9-4.6) 7.2 (6.2-8.1) 13.1 (10.9-17.2)    
  no. cases/person-yearsa 320/1496 331/1510 330/1463    
  Model 1b Ref 1.01 (0.86-1.19) 1.20 (1.01-1.43) 0.04 1.09 (1.01-1.17) 0.02 
  Model 2c Ref 1.02 (0.86-1.20) 1.25 (1.04-1.50) 0.01 1.11 (1.03-1.20) 0.009 
n-PFOA       
  Median (IQR), ng/mL 2.3 (1.8-2.8) 4.0 (3.5-4.5) 6.6 (5.6-8.6)    
  no. cases/person-yearsa 313/1448 334/1553 334/1468    
  Model 1b Ref 1.11 (0.94-1.30) 1.15 (0.98-1.35) 0.06 1.10 (1.01-1.20) 0.03 
  Model 2c Ref 1.14 (0.96-1.35) 1.23 (1.03-1.47) 0.02 1.10 (1.01-1.21) 0.02 
PFNA       
  Median (IQR), ng/mL 0.3 (0.3-0.4) 0.5 (0.5-0.6) 0.9 (0.7-1.0)    
  no. cases/person-yearsa 331/1522 295/1362 374/1585    
  Model 1b Ref 1.00 (0.85-1.19) 1.14 (0.96-1.34) 0.12 1.07 (0.99-1.16) 0.10 
  Model 2c Ref 0.98 (0.82-1.18) 1.11 (0.94-1.33) 0.20 1.05 (0.97-1.14) 0.23 
PFHxS       
  Median (IQR), ng/mL 0.8 (0.6-1.0) 1.5 (1.3-1.6) 3.0 (2.3-4.5)    
  no. cases/person-yearsa 337/1592 299/1324 344/1553    
  Model 1b Ref 1.08 (0.90-1.28) 1.13 (0.97-1.35) 0.10 1.05 (0.99-1.12) 0.09 
  Model 2c Ref 1.02 (0.86-1.23) 1.11 (0.94-1.31) 0.24 1.05 (0.98-1.12) 0.15 
a Averaged no. cases and person-years from 10 imputations. b Model 1 was adjusted for age at baseline, race/ethnicity, and study site. 
b Model 2 was additionally adjusted for education, parity, BMI at baseline, physical activity, smoking status, and prior hormone use at baseline.  




a) Exposure to n-PFOA and incidence of natural menopause by racial groups 
 
b) Exposure to PFNA and incidence of natural menopause by racial groups 
 
Figure III. 1 Adjusted hazard ratios (HR) (95% confidence intervals, 95% CI) for incident natural menopause with per doubling 
increase in serum concentrations of n-PFOA and PFNA. Models were adjusted for age at baseline, study site, education, parity, BMI 
at baseline, physical activity, smoking status, and prior hormone use at baseline. P values for the interaction terms with race/ethnicity 


































Figure III. 2 Adjusted survival curves for natural menopause by participant clusters. The model 
was adjusted for age at baseline, race/ethnicity, study site, education, parity, BMI at baseline, 
physical activity, smoking status, and prior hormone use at baseline. The hazards ratio for low-
medium, medium-high, and high groups were 1.30 (95% CI: 0.97-1.74), 1.31 (95% CI: 0.94-
1.83), and 1.63 (95% CI: 1.08-2.45), respectively, compared to the low group. The predicted 
median age at natural menopause for women with low overall PFAS concentration profile was 
52.8 years, and 51.8 years, 52.0 years and 50.8 years for those with low-medium, medium-high, 




Supplemental Table III. 1 Baseline participant characteristics overall and by K-means clusters. 












or n (%) 
Median (IQR) 
or n (%) 
Median (IQR) 
or n (%) 
Median (IQR) 
or n (%) 
Median (IQR) 
or n (%) 
Age, years 48.9 (47.0-50.8) 49.1 (47.0-50.7) 49.2 (47.2-51.1) 48.6 (46.9-50.4) 48.4 (46.9-50.8) 0.04 
Race/ethnicity           <.0001 
    White 577 (51.5%) 60 (42.0%) 199 (48.1%) 226 (55.7%) 92 (58.6%)   
     Black 235 (21.0%) 30 (21.0%) 63 (15.2%) 88 (21.7%) 54 (34.4%)   
     Chinese 142 (12.7%) 36 (25.1%) 73 (17.6%) 33 (8.1%) 0 (0.0%)   
     Japanese 166 (14.8%) 17 (11.9%) 79 (19.1%) 59 (14.5%) 11 (7.0%)   
Study site           <.0001 
    Southeast MI 202 (18.0%) 17 (11.9%) 67 (16.2%) 70 (17.2%) 48 (30.6%)   
    Boston, MA 182 (16.3%) 23 (16.1%) 62 (14.9%) 78 (19.2%) 19 (12.1%)   
    Oakland, CA      242 (21.6%) 51 (35.7%) 115 (27.8%) 61 (15.0%) 15 (9.6%)   
    Los Angeles, CA 299 (26.7%) 34 (23.8%) 115 (27.8%) 122 (30.1%) 28 (17.8%)   
    Pittsburgh, PA 195 (23.4%) 18 (12.6%) 55 (13.3%) 75 (18.5%) 47 (29.9%)   
Educational attainment           0.002 
    ≤High school 197 (17.7%) 28 (19.6%) 73 (17.7%) 61 (15.1%) 35 (22.4%)   
    Some college 350 (31.4%) 43 (30.0%) 110 (26.8%) 144 (35.6%) 53 (34.0%)   
    College 271 (24.3%) 48 (33.6%) 109 (26.5%) 86 (21.3%) 28 (18.0%)   
    Post-college 296 (26.6%) 24 (16.8%) 119 (29.0%) 113 (28.0%) 40 (25.6%)   
Parity           0.02 
    Nulliparous 215 (19.2%) 16 (11.2%) 76 (18.4%) 92 (22.7%) 31 (19.8%)   
    Parous 905 (80.8%) 127 (88.8%) 338 (81.6%) 314 (77.3%) 126 (80.2%)   
Prior hormone use 248 (22.1%) 33 (23.1%) 87 (21.0%) 83 (20.4%) 45 (28.7%)   
Smoking status           0.001 
    Never smoker 720 (64.4%) 99 (69.7%) 291 (70.3%) 246 (60.7%) 84 (53.5%)   
    Former smoker 291 (26.0%) 34 (23.9%) 96 (23.2%) 109 (26.9%) 52 (33.1%)   
    Current smoker 107 (9.6%) 9 (6.3%) 27 (6.5%) 50 (12.4%) 21 (13.4%)   
Physical activity score 7.9 (6.6-9.0) 7.5 (6.3-8.8) 7.9 (6.5-9.1) 7.9 (6.8-9.0) 7.7 (6.6-8.6) 0.11 








Supplemental Table III. 2 Covariates included in the imputation model for FMP age. 
Covariates related to timing of menopause 
Race/ethnicity 
Study site 




Day of menstrual cycle corresponding to blood draw 
Age 
History of oral contraceptive use 
History of exogenous hormone use other than oral contraceptives 
Number of live births 
Diabetes 
Cardiovascular disease diagnosis 
Smoking status 
Alcohol consumption 
Body mass index 










Supplemental Table III. 3 Median (inter-quartile range, IQR) serum concentrations of n-PFOS, Sm-PFOS, PFHxS, PFDoA, PFDeA, 


























































Sm-PFOS 99.9% 7.2 
(4.6-
10.8) 
100% 7.6  
(5.2-
11.6) 




























PFUA 30.0% <LOD 
(<LOD
-0.2) 










PFDoA 4.0% <LOD 2.6% <LOD 8.5% <LOD 0.7% <LOD 5.4% <LOD NA 


















































Sb-PFOA 18.2% <LOD 21.3% <LOD 17.4% <LOD 12.7% <LOD 13.3% <LOD NA 
NA, not available. 




Supplemental Table III. 4 Hazard ratio (HR) (95% confidence interval, 95% CI) of n-PFOS, Sm-PFOS, n-PFOA, PFNA, and PFHxS 
serum concentrations on incidence of natural menopause with surgical menopause excluded instead of censored (n=1051). 
PFAS 
Tertile of PFAS concentrations 
P value 
 for trend 
Per doubling increase 
HR (95%CI) 






n-PFOS       
  Median (Range), ng/mL 10.4 (8.1-12.2) 16.9 (15.6-18.7) 28.3 (24.2-37.8)    
  no. cases/person-years 183/1741 192/1719 203/1832    
  Model 1a Ref 1.08 (0.88-1.32) 1.15 (0.93-1.41) 0.19 1.05 (0.95-1.16) 0.34 
  Model 2b Ref 1.15 (0.93-1.42) 1.22 (0.98-1.51) 0.07 1.10 (0.99-1.22) 0.07 
Sm-PFOS       
  Median (Range), ng/mL 3.8 (2.9-4.6) 7.2 (6.2-8.1) 13.1 (10.9-17.2)    
  no. cases/person-years 195/1704 194/1782 189/1807    
  Model 1 (Unadjusted)a Ref 1.03 (0.84-1.26) 1.05 (0.85-1.31) 0.63 1.03 (0.94-1.12) 0.52 
  Model 2 (Adjusted)b Ref 1.11 (0.90-1.37) 1.18 (0.95-1.48) 0.14 1.07 (0.97-1.17) 0.16 
n-PFOA       
  Median (Range), ng/mL 2.3 (1.8-2.8) 4.0 (3.5-4.5) 6.6 (5.6-8.6)    
  no. cases/person-years 183/1686 195/1804 200/1802    
  Model 1 (Unadjusted)a Ref 1.14 (0.92-1.41) 1.24 (0.99-1.55) 0.06 1.04 (0.93-1.16) 0.50 
  Model 2 (Adjusted)b Ref 1.12 (0.90-1.39) 1.26 (1.01-1.58) 0.04 1.08 (0.97-1.21) 0.16 
PFNA       
  Median (Range), ng/mL 0.3 (0.3-0.4) 0.5 (0.5-0.6) 0.9 (0.7-1.0)    
  no. cases/person-years 168/1778 181/1572 229/1942    
  Model 1 (Unadjusted)a Ref 1.14 (0.92-1.41) 1.16 (0.94-1.42) 0.18 1.10 (0.99-1.22) 0.06 
  Model 2 (Adjusted)b Ref 1.14 (0.91-1.42) 1.14 (0.92-1.41) 0.25 1.09 (0.98-1.21) 0.11 
PFHxS       
  Median (Range), ng/mL 0.8 (0.6-1.0) 1.5 (1.3-1.6) 3.0 (2.3-4.5)    
  no. cases/person-years 203/1820 168/1610 207/1862    
  Model 1 (Unadjusted)a Ref 0.92 (0.74-1.13) 1.10 (0.90-1.35) 0.36 1.03 (0.95-1.11) 0.48 
  Model 2 (Adjusted)b Ref 1.06 (0.85-1.31) 1.06 (0.86-1.31) 0.59 1.01 (0.94-1.10) 0.74 









Supplemental Table III. 5 Hazard ratio (HR) (95% confidence interval, 95% CI) of n-PFOS, Sm-PFOS, n-PFOA, PFNA, and PFHxS 
serum concentrations on incidence of natural menopause after excluding women who reached natural menopause in 6 months since 
baseline (n=1091). 
PFAS 
Tertile of PFAS concentrations 
P value 
 for trend 
Per doubling increase 
HR (95%CI) 






n-PFOS       
  Median (Range), ng/mL 10.4 (8.1-12.2) 16.9 (15.6-18.7) 28.3 (24.2-37.8)    
  no. cases/person-years 170/1857 185/1880 194/1878    
  Model 1a Ref 1.08 (0.88-1.33) 1.23 (0.99-1.52) 0.06 107 (0.96-1.18) 0.24 
  Model 2b Ref 1.10 (0.89-1.37) 1.30 (1.04-1.62) 0.02 1.11 (0.99-1.24) 0.06 
Sm-PFOS       
  Median (Range), ng/mL 3.8 (2.9-4.6) 7.2 (6.2-8.1) 13.1 (10.9-17.2)    
  no. cases/person-years 183/1839 185/1920 181/1856    
  Model 1 (Unadjusted)a Ref 1.05 (0.85-1.29) 1.14 (0.91-1.42) 0.26 1.04 (0.95-1.14) 0.35 
  Model 2 (Adjusted)b Ref 1.11 (0.89-1.38) 1.28 (1.02-1.61) 0.03 1.08 (0.99-1.19) 0.10 
n-PFOA       
  Median (Range), ng/mL 2.3 (1.8-2.8) 4.0 (3.5-4.5) 6.6 (5.6-8.6)    
  no. cases/person-years 173/1815 184/1933 192/1868    
  Model 1 (Unadjusted)a Ref 1.13 (0.90-1.41) 1.29 (1.03-1.62) 0.03 1.06 (0.95-1.19) 0.30 
  Model 2 (Adjusted)b Ref 1.11 (0.88-1.39) 1.31 (1.04-1.66) 0.02 1.10 (0.98-1.24) 0.10 
PFNA       
  Median (Range), ng/mL 0.3 (0.3-0.4) 0.5 (0.5-0.6) 0.9 (0.7-1.0)    
  no. cases/person-years 163/1928 167/1675 219/2012    
  Model 1 (Unadjusted)a Ref 1.13 (0.90-1.40) 1.20 (0.97-1.48) 0.09 1.12 (1.01-1.24) 0.03 
  Model 2 (Adjusted)b Ref 1.13 (0.90-1.41) 1.18 (0.95-1.47) 0.14 1.10 (0.99-1.23) 0.08 
PFHxS       
  Median (Range), ng/mL 0.8 (0.6-1.0) 1.5 (1.3-1.6) 3.0 (2.3-4.5)    
  no. cases/person-years 193/1954 158/1725 198/1936    
  Model 1 (Unadjusted)a Ref 0.90 (0.73-1.12) 1.15 (0.93-1.41) 0.21 1.05 (0.97-1.13) 0.25 
  Model 2 (Adjusted)b Ref 1.02 (0.82-1.27) 1.09 (0.88-1.35) 0.44 1.02 (0.94-1.11) 0.56 









Supplemental Table III. 6 Hazard ratio (HR) (95% confidence interval, 95% CI) of natural 











  no. cases/person-years 68/765 220/2010 209/2122 81/727 












a Model 1 was adjusted for age at baseline, race/ethnicity, and study site. 
b Model 2 was additionally adjusted for education, parity, BMI at baseline, physical activity, 






Supplemental Figure III. 1 The study designs of the Study of Women’s Health Across the 













Supplemental Figure III. 3 Adjusted survival curves of natural menopause by tertiles of n-
PFOS serum concentrations. The model was adjusted for age at baseline, race/ethnicity, study 
site, education, parity, BMI at baseline, physical activity, smoking status, and prior hormone use 
at baseline. The hazards ratio of tertile 2 and tertile 3 was 1.06 (0.86-1.31) and 1.26 (1.02-1.57), 
compared to tertile 1 (ptrend=0.03). The predicted median age at natural menopause was for 





Supplemental Figure III. 4 Adjusted survival curves of natural menopause by tertiles of Sm-
PFOS serum concentrations. The model was adjusted for age at baseline, race/ethnicity, study 
site, education, parity, BMI at baseline, physical activity, smoking status, and prior hormone use 
at baseline. The hazards ratio of tertile 2 and tertile 3 was 1.11 (0.90-1.37) and 1.27 (1.01-1.59), 
compared to tertile 1 (ptrend=0.03). The predicted median age at natural menopause for tertile 1 





Supplemental Figure III. 5 Adjusted survival curves of natural menopause by tertiles of n-
PFOA serum concentrations. The model was adjusted for age at baseline, race/ethnicity, study 
site, education, parity, BMI at baseline, physical activity, smoking status, and prior hormone use 
at baseline. The hazards ratio of tertile 2 and tertile 3 was 1.12 (0.90-1.40) and 1.31 (1.04-1.65), 
compared to tertile 1 (ptrend=0.01). The predicted median age at natural menopause for tertile 1 





Supplemental Figure III. 6 Adjusted survival curves of natural menopause by tertiles of PFNA 
serum concentrations. The model was adjusted for age at baseline, race/ethnicity, study site, 
education, parity, BMI at baseline, physical activity, smoking status, and prior hormone use at 
baseline. The hazards ratio of tertile 2 and tertile 3 was 1.18 (0.95-1.47) and 1.20 (0.97-1.49), 
compared to tertile 1 (ptrend=0.10). The predicted median age at natural menopause for tertile 1 





Supplemental Figure III. 7 Adjusted survival curves of natural menopause by tertiles of PFHxS 
serum concentrations. The model was adjusted for age at baseline, race/ethnicity, study site, 
education, parity, BMI at baseline, physical activity, smoking status, and prior hormone use at 
baseline. The hazards ratio of tertile 2 and tertile 3 was 1.05 (0.84-1.30) and 1.11 (0.90-1.37), 
compared to tertile 1 (ptrend=0.33). The predicted median age at natural menopause for tertile 1 
















































Supplemental Figure III. 8 Adjusted hazard ratio (HR) (95% confidence interval, 95% CI) of natural menopause incidence with per 
doubling increase in serum concentrations of n-PFOS, Sm-PFOS and PFHxS. Models were adjusted for age at baseline, study site, 
education, parity, BMI at baseline, physical activity, smoking status, and prior hormone use at baseline. P values for the interaction 




















Supplemental Figure III. 9 Cluster means of the 5 standardized log-transformed serum PFAS concentrations using k-means 
clustering. Y-axis (cluster means) represents the mean standardized z-scores of log2-transformed PFAS concentrations. Cluster 1 
(n=143): “low” overall PFAS exposure pattern; clusters 2 (n=414): “moderate low” overall PFAS exopsure pattern; cluster 3 (n=406): 





Chapter IV. The Mediating Role of Follicle-Stimulating Hormone on the Relationships 






Exposure to perfluoroalkyl substances (PFAS) has been associated with earlier natural 
menopause, possibly through depletion of ovarian reserve and disturbance of hormone 
homeostasis. We aimed to investigate and quantify the degree to which follicle-stimulating 
hormone (FSH) could mediate the associations between PFAS exposure and natural menopause 
among 1120 premenopausal women aged 45-56 years in 1999-2000 from the Study of Women’s 
Health Across the Nation (SWAN). Serum concentrations of linear- and branched-chain 
perfluorooctane sulfonic acid (n-PFOS and Sm-PFOS), linear-chain perfluorooctanoic acid (n-
PFOA), and perfluorononanoic acid (PFNA) were measured in 1999-2000 and included in the 
analyses because their detection rates were larger than 70%. Accelerated failure time models 
were utilized to evaluate time to incident natural menopause. 578 women reached natural 
menopause, with a median survival time of 6.5 (95% CI: 6.1, 6.8) years. The proportion of the 
effect mediated through FSH was 8.5% (95% CI: -11.7%, 24.0%) for n-PFOS, 13.2% (95% CI: 
0.0%, 24.5%) for Sm-PFOS, 26.9% (95% CI: 15.6%, 38.4%) for n-PFOA, and 21.7% (6.8%, 
37.0%) for PFNA. No significant associations were observed for perfluorohexane sulfonic acid 
(PFHxS). PFAS are associated with an earlier age at natural menopause. The effect of PFAS on 
natural menopause may be partially explained by variation in FSH concentrations.  
 
Keywords: perfluoroalkyl substances, endocrine-disrupting chemicals, natural menopause, 






Menopause is ascertained after 12 months of amenorrhea and represents the depletion of 
ovarian reserve and the near complete cessation of estrogen secretion. Earlier age at the final 
menstrual period (FMP) has been associated with an increased risk of overall mortality (Jacobsen 
et al., 2003; Mondul et al., 2005; Ossewaarde et al., 2005), cardiovascular disease (Atsma et al., 
2006; Hu et al., 1999) and cardiovascular death (de Kleijn et al., 2002; Mondul et al., 2005; van 
der Schouw et al., 1996), low bone mineral density (Parazzini et al., 1996) and osteoporosis 
(Kritz-Silverstein and Barrett-Connor, 1993), and other chronic conditions (Shuster et al., 2010). 
Evidence also supports its clinical importance in quality of life (i.e. vasomotor symptoms, sleep 
disturbance, and depressive symptoms) (Bromberger et al., 2010; Dennerstein et al., 2000; 
Divakaran et al., 2001; Maki et al., 2010; Woods and Mitchell, 2010). Women with higher 
serum concentrations of perfluoroalkyl substances (PFAS) had an earlier onset of natural 
menopause (Ning Ding et al., 2019).  
PFAS are anthropogenic chemicals that have been widely used in consumer and 
industrial products such as non-stick cookware (Teflon) (Bradley et al., 2007; Ewan Sinclair et 
al., 2007); food packaging materials (Begley et al., 2005; Schaider et al., 2017; Trier et al., 
2011); stain- and water-resistant coating for clothing, furniture, and carpets (Scotchgard and 
Gore-Tex) (Hill et al., 2017; Lee et al., 2017); and aqueous fire-fighting foam (Butenhoff et al., 
2006; Kantiani et al., 2010; Kissa, 2011; Trudel et al., 2008). A recent study found that drinking 
water supplies for at least 6 million U.S. residents exceed the U.S. Environmental Protection 
Agency’s lifetime health advisory of 70 parts per trillion for two commonly detected compounds, 




combined (Hu et al., 2016). Once consumed, these chemicals can build up in the human body 
and persist for years (Ding et al., 2019).   
These compounds, especially PFOA and PFOS, have been identified as plausible 
endocrine disrupting chemicals with the potential to accelerate ovarian aging (Jensen and 
Leffers, 2008; Kar et al., 2017). Animal studies have reported effects on female reproduction 
including altered ovarian function, histopathologic changes in the reproductive tract and ovarian 
cell steroidogenesis (Chaparro-Ortega et al., 2018; Dixon et al., 2012; Zhao et al., 2012), likely 
through the activation of various transcriptional factors such as peroxisome proliferator-activated 
receptors (PPARs) (Andersen et al., 2008; White et al., 2011). Several hormones in the 
hypothalamic-pituitary-ovarian axis are markers of ovarian aging, including follicle-stimulating 
hormone (FSH) (Strauss and Barbieri, 2013). FSH levels increase progressively as the final 
menstrual period is approached (Randolph et al., 2004,  2011; Sowers et al., 2008), and thus is 
considered a biomarker of reproductive aging from active reproduction, through the stages of the 
menopausal transition (MT) to menopause (Harlow et al., 2012; Soules et al., 2001). Our recent 
finding based on data from the Study of Women’s Health Across the Nation (SWAN) has 
revealed that higher serum concentrations of PFAS were associated with increased levels of FSH 
in midlife women during the menopausal transition (Sung Kyun Park).  
Understanding the mediation mechanisms between PFAS exposure and natural 
menopause can provide evidence of associations, identify risk factors for ovarian aging, and 
inform precision health studies that seek to target specific biological pathways for interventions. 
However, it remains unknown whether and to what extent the association between PFAS and 
natural menopause is mediated by FSH. The goal of the present study was to examine and 




natural menopause incidence using data from the SWAN during 1999 and 2017. Specifically, we 
used a causal mediation approach to decompose natural direct effect (NDE) and natural indirect 
effect (NIE) in the survival setting (VanderWeele, 2011).  
2. Methods 
Study population 
 Data for this study are from the participants of SWAN, a multi-site, multi-ethnic, 
longitudinal cohort of community-based group of midlife women, designed to characterize 
physiological and psychosocial changes that occur during the menopausal transition and 
observed their effects on subsequent risk factors for chronic disease (Sowers et al., 2000). 
Between 1996 and 1997, 3320 women were enrolled in the cohort study. Eligibility criteria for 
entry into the longitudinal cohort included age 42-52 years, an intact uterus and at least one 
ovary, at least one menstrual period and no use of hormone medications within the three months 
before screening, , the ability to speak English or other designated languages including Spanish, 
Cantonese or Japanese, and self-identification as a member of one of the five eligible 
racial/ethnic groups. Each study site recruited White women and women with one of the pre-
specified race/ethnicities. Black women were enrolled in Pittsburgh, Boston, Chicago and 
Detroit, Japanese women in Los Angeles, Chinese women in Oakland, and Hispanic women in 
Newark. Data and specimens were collected in annual follow-up visits from 1996/97 through 
2016/17. The institutional review board at each participating site approved the study protocol.  
The SWAN Multi-Pollutant Study was initiated to examine the associations of multiple 
environmental pollutants including PFAS, polychlorinated biphenyls, organochlorine pesticides, 




among midlife women (Park et al., 2019). We used repository samples available from the third 
follow-up visit (Visit 3 in 1999-2000, the MPS baseline) for environmental exposure assessment. 
The MPS included only the four study sites: Boston, Oakland, Los Angeles, and Pittsburgh. 
Therefore, only White, Black, Chinese and Japanese women were included in the sample. Of 
1400 participants with serum samples available at baseline, we excluded 232 women who had 
already reached natural menopause and 48 women who had had a hysterectomy and/or 
oophorectomy prior to Visit 3, resulting in a final sample size of 1120 premenopausal women 
eligible for this study. 
PFAS measurement 
Serum PFAS concentrations were assessed at the Division of Laboratory Sciences, 
National Center for Environmental Health, Centers for Disease Control and Prevention. Serum 
samples were analyzed using an online solid phase extraction-high performance liquid 
chromatography-isotope dilution-tandem mass spectrometry (online SPE-HPLC-MS/MS) 
method (Kato et al., 2011). The analytic methods and quality control procedures have been 
described in detail (Ding et al., 2019). We measured 9 PFAS chemicals, including 
perfluorohexane sulfonic acid (PFHxS), linear-chain PFOS (n-PFOS), sum of branched-chain 
PFOS (Sm-PFOS), linear-chain PFOA (n-PFOA), sum of branched-chain PFOA (Sb-PFOA), 
perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDeA), perfluoroundecanoic acid 
(PFUA), and perfluorododecanoic acid (PFDoA). The limit of detection (LOD) was 0.1 ng/mL 
for all analytes. Measurements below the LODs were assigned LOD/√2. The coefficient of 
variation (CV) was 6-12% for quality controls. PFHxS, n-PFOS, Sm-PFOS, n-PFOA and PFNA 





Collection of biological specimens was scheduled for each participant before 10:00 A.M. 
on day 2-5 of a spontaneous menstrual cycle occurring within 60 days of recruitment at the 
baseline visit and annually thereafter. If a follicular phase sample could not be obtained, a 
random fasting sample was taken within 90 days of the anniversary of the baseline visit. Serum 
FSH measurements were conducted with a two-site chemiluminometric immunoassay using an 
ACS-180 automated analyzer (Bayer Diagnostics Corp., Norwood, MA). The LOD was 1.1 
mIU/mL. FSH was detected in all serum samples at the MPS baseline. The inter-and intra-assay 
CV were 12% and 6%, respectively. We used serum concentrations of FSH at Visit 3 (the MPS 
baseline) in 1999-2000 because there is currently no well-established method to handle multiple, 
correlated, time-varying mediators in the context of censored survival outcomes. 
Natural menopause incidence  
The ascertainment of natural menopause was based on self-reported bleeding patterns 
during the annual follow-up visits. Natural menopause was defined as 12 months of amenorrhea 
since the last menstrual period not because of hysterectomy, bilateral oophorectomy, or hormone 
therapy (HT). If a woman missed at least three consecutive visits prior to the first post-
menopause visit, the FMP date was set to missing. Of the 1120 premenopausal women, 578 had 
an observed date at the natural FMP during the follow-up visits through 2016/17, and 542 were 
censored for one of the following reasons: hysterectomy and/or oophorectomy before having ≥12 
months of amenorrhea (n=69); unknown FMP date because of HT use (n=451); or end of data 





Data on study site, race/ethnicity, and level of education and parity (the number of live 
births) were collected at the SWAN enrollment interview. Race/ethnicity was classified into self-
identified Black, Chinese, Japanese, or White. We categorized educational attainment as high 
school or less, some college, or college degree or higher. Information on prior hormone use was 
also collected at baseline. Other covariates were obtained at Visit 3. Age was calculated based on 
date of birth and date of visit and centered at 50 years. Weight and height were measured using a 
stadiometer and calibrated scales, respectively. Body mass index (BMI) was calculated as weight 
(kg)/height2 (m2) at baseline. Self-reported smoking status was classified as never smokers, 
former smokers only, or current smokers based on seven smoking questions adapted from the 
American Thoracic Society standard questions (Ferris, 1978). Physical activity was assessed 
using an adaptation of the Kaiser Physical Activity Survey (Sternfeld et al., 1999), which 
consists of 38 questions with primarily Likert-scale responses about physical activity in various 
domains, including sports/exercise, household/caregiving, and daily routine (defined as walking 
or biking for transportation and hours of television watching, which are reverse-coded). Domain-
specific indices were derived by averaging the ordinal responses to questions in each domain, 
resulting in values from 1 to 5. Thus, total physical activity score ranged from 3 to 15 with 15 
indicating the highest level of activity. 
Statistical analyses 
Univariate statistics were calculated for baseline participant characteristics and PFAS 
serum concentrations by racial/ethnic groups. Chi-square or Fisher’s exact statistics were 
computed for categorical variables; and analysis of variance (ANOVA) or Kruskal-Wallis tests 
were used for continuous variables. We censored a participant’s data if she reported initiating HT 




oophorectomy, or at the last menstrual period at the end of data collection if it occurred before 12 
months of amenorrhea, or because of ending data collection.  
The primary analytic objective was to estimate the extent to which FSH mediated 
associations between PFAS exposure and natural menopause incidence, while adjusting for 
baseline confounders (age, race/ethnicity, study site, education, parity, BMI, physical activity, 
smoking status, and prior hormone use) of the PFAS-natural menopause and FSH-natural 
menopause associations. Time to natural menopause was modeled using accelerated failure time 
(AFT) models with a Weibull distribution. AFT models were chosen because they outperformed 
Cox proportional hazards regression models in causal mediation analysis setting with non-rare 
outcomes (>10%) (Gelfand et al., 2016; VanderWeele, 2011). The Weibull distribution was 
selected by comparing Akaike information criterion (AIC) values.  
The outcome AFT model initially took the following general form:  
log(𝑇) = 𝜃0 + 𝜃1𝑃𝐹𝐴𝑆 + 𝜃2𝐹𝑆𝐻 + 𝜃3𝑃𝐹𝐴𝑆 × 𝐹𝑆𝐻 + 𝜃4𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 + 𝜎𝜀,  
where PFAS corresponds to log-transformed (base 2) serum PFAS concentrations, FSH is log-
transformed serum FSH concentrations at Visit 3, 𝑃𝐹𝐴𝑆 × 𝐹𝑆𝐻 is the interaction between PFAS 
and FSH, 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 are baseline confounders, 𝜎 describes the Weibull distribution scale and 
shape parameters, and 𝜀 symbolizes the errors which is independently and identically distributed. 
After evaluation of the interaction term, there was no significant exposure-mediator interaction, 
thus the model was reduced to  
log(𝑇) = 𝜃0 + 𝜃1𝑃𝐹𝐴𝑆 + 𝜃2𝐹𝑆𝐻 + 𝜃3𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 + 𝜎𝜀.                        (1) 




increase in PFAS concentrations. If exp (𝜃1) equals to 1, then there is null association between 
PFAS and natural menopause; if exp (𝜃1) < 1, PFAS exposure is associated with earlier time to 
natural menopause; and if exp (𝜃1) > 1, PFAS exposure is associated with postponed onset of 
natural menopause. We then fit a linear regression model for the mediator, FSH,  
𝐸(𝐹𝑆𝐻|𝑃𝐹𝐴𝑆, 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠) = 𝛽0 + 𝛽1𝑃𝐹𝐴𝑆 + 𝛽2𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 + 𝜀.              (2) 
Within the causal framework, we investigated the natural direct effect (NDE) and natural 
indirect effect (NIE) with survival data, as illustrated in Figure 1. Considering the mean time to 
natural menopause (T), the NDE refers to differences in the mean event time in association with 
a defined change in PFAS exposure (A) from the exposed level (a) to the reference level (a*), 
while holding the mediator level (M) for each participant that it would have been with A set at 
the reference value a*  if levels of confounders had otherwise remained unchanged. The NIE 
represents difference in mean time to natural menopause if A was held at a and if M for each 
participant changed to the levels that would have seen if that subject had been assigned to a*. So 
then the total effects are decomposed into NDE and NIE:  
𝐸(𝑇𝑎)/𝐸(𝑇𝑎∗) = [𝐸(𝑇𝑎𝑀𝑎∗)/𝐸(𝑇𝑎∗𝑀𝑎∗)] × [𝐸(𝑇𝑎𝑀𝑎)/𝐸(𝑇𝑎𝑀𝑎∗)] (VanderWeele, 2011). 
If model (1) holds for the outcome and model (2) holds for the mediator, these models 
yield the NDE and NIE of PFAS exposure on natural menopause as follows:  
NDE = exp (𝜃1); 
and, 





for changes in PFAS exposure from 𝑎 to 𝑎∗ on a counterfactual setting. The statistical 
significance was determined using 95% confidence intervals (95% CIs) that were calculated 
using bootstrap method with 1000 re-samplings. 
Assumptions and sensitivity analyses 
The mediation analysis described above assumes that the measured covariates control for 
confounding of: (1) the exposure-outcome association; (2) the mediator-outcome association; (3) 
the exposure-mediator relationship; and (4) that none of the mediator-outcome confounders are 
influenced by the exposure. For assumptions (1)-(4), which cannot be assessed directly, 
sensitivity analyses were conducted to estimate the potential bias in NDE and NIE estimates due 
to unmeasured confounding (Ding and Vanderweele, 2016; Vanderweele, 2010; VanderWeele, 
2013). Assuming a binary unknown confounder (e.g. having healthy lifestyle; exposure to other 
endocrine-disrupting chemicals), we used the bias formula to correct for unmeasured 
confounding (VanderWeele, 2013),  
𝐵𝑖𝑎𝑠(𝑁𝐷𝐸) =
1 + (𝛾 − 1)𝜋𝑎
1 + (𝛾 − 1)𝜋𝑎∗
 𝑎𝑛𝑑 𝐵𝑖𝑎𝑠(𝑁𝐼𝐸) =
1 + (𝛾 − 1)𝜋𝑎∗
1 + (𝛾 − 1)𝜋𝑎
, 
where 𝛾 is the effect of the hypothesized unadjusted confounder, U, on natural menopause; 𝜋𝑎 is 
the prevalence of U among women with the 75th percentile of PFAS concentrations given the 
baseline covariates; 𝜋𝑎∗ is the prevalence of U among women with the 25
th percentile of PFAS 
concentrations given the baseline covariates.  
We conducted sensitivity analyses by testing interaction terms in the regression models. 
In this case, the controlled direct effect (CDE), NDE and NIE are defined as follows: 





NDE = exp [𝜃1 + 𝜃3(𝛽0 + 𝛽1𝑎
∗ + 𝛽2𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠 + 𝜃2𝜎
2)(𝑎 − 𝑎∗) + 0.5𝜃3
2𝜎2(𝑎2 − 𝑎∗2)]; 
and, 
NIE = exp[(𝜃2𝛽1 + 𝜃3𝛽1𝑎)(𝑎 − 𝑎
∗)],  
where PFAS exposure levels changed from 𝑎 to 𝑎∗ (per doubling increase in serum PFAS 
concentrations) in a counterfactual setting. Without an interaction term between PFAS and 
FSH, CDE should equal NDE. 
To ensure the temporality between the exposure and mediator, we conducted further 
analyses using FSH levels measured at SWAN Visit 4 in 2000-2001. We excluded 101 women 
who reached their FMP or were censored by Visit 4 and an additional 53 women with missing 
values of FSH levels, after which 966 women available for the sensitivity analyses. All the 
analyses were performed using SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina). 
3. Results 
The analytic sample consists of 1120 premenopausal women with median age of 48.9 
(interquartile range, IQR: 47.0, 50.8) years at baseline. Baseline characteristics are displayed in 
Table III.1. A total of 577 (51.5%) were White, 235 (21.0%) were Black, 142 (12.7%) were 
Chinese, and 166 (14.8%) were Japanese women. More than half had received college or post-
college education and had never smoked. Most women had given birth to at least one child and 
22.1% had a history of prior hormone use. The median physical activity score was 7.9 (IQR: 6.6, 
9.0), indicating moderate physical activity. The median BMI was 26.1 (IQR: 22.7, 31.5) kg/m2.  
Adjusted percent changes in serum FSH concentrations per doubling increase in serum 




associated significantly with serum FSH concentrations. Participants had a 9.4% (95% CI:1.5%, 
18.0%) increment in baseline FSH concentrations per doubling increase in serum concentrations 
of Sm-PFOS. Additionally, women had FSH concentrations increased by 15.0% (95% CI: 4.9%, 
26.0%) per doubling increase in n-PFOA concentrations. No association was found for n-PFOS 
(percent change=4.1%, 95% CI: -4.8%, 13.7%), PFNA (percent change=4.9%, 95% CI: -3.6%, 
14.0%), and PFHxS (percent change=3.7%, 95% CI: -2.9%, 10.6%).  
Population median time to natural menopause was 6.5 (95% CI: 6.1, 6.8) years. As 
expected, women with higher FSH concentrations at Visit 3 tended to have earlier onset of 
natural menopause. After adjusting for age, race/ethnicity, study site, educational attainment, 
BMI, parity, physical activity score, smoking status and prior hormone use, women had 17% 
(95% CI: 12%, 22%) earlier time to natural menopause per doubling increase in serum FSH 
concentrations  
Table III.3 shows the results of causal mediation analysis decomposing total effects into 
NDE and NIE. For the total effects, the adjusted relative survival of natural menopause was 0.82 
(95% CI: 0.69, 0.96) per doubling increase in serum n-PFOS concentrations, 0.84 (95% CI: 0.69, 
1.00) for Sm-PFOS, 0.79 (95% CI: 0.66, 0.93) for n-PFOA, 0.84 (95% CI: 0.71, 0.97) for PFNA, 
and 0.90 (95% CI: 0.76, 1.05) for PFHxS. When FSH was included as a mediator, 26.9% (95% 
CI: 15.6%, 38.4%) of the total effects of n-PFOA on natural menopause was attributable to 
indirect effects through FSH. 21.7% (95% CI: 6.8%, 37.0%) and 13.2% (95% CI: 0.0%, 24.5%) 
of the total effects of PFNA and Sm-PFOS was attributable to indirect effects, respectively. No 
causal mediation effects were observed for n-PFOS (percent mediated=8.5%, 95% CI: -11.7%, 




Details of the assumption testing results are provided in the Supplemental Tables IV.1-
IV.4. Assuming that an unmeasured confounder (e.g. healthy lifestyle) decreases the risk of 
earlier natural menopause, and that it is more prevalent among women with lower n-PFOA or 
Sm-PFOS concentrations, the observed NDE seems to be overestimated and the NIE seems to be 
underestimated. For example, if there is an unmeasured confounder with a relative survival of 
1.2 on natural menopause and a larger prevalence in women with higher n-PFOA concentrations 
(10% vs. 25% in the 75th and 25th percentiles of n-PFOA concentrations), the estimated NDE 
would have a relative survival of 0.96 and the estimated NIE would have a relative survival of 
0.94 (Supplemental Tables IV.1-IV.2). Therefore, the estimated percent of mediation would be 
59% larger than the observed 26.9%. The sensitivity analyses also confirmed that there was no 
interaction between PFAS exposure and FSH (Supplemental Table IV.5). The mediating role of 
FSH on the associations between n-PFOA and natural menopause remained when using FSH at 
SWAN Visit 4 instead of FSH at Visit 3 as the mediator (percent mediated=36.4%, 95% CI: 
1.0%, 54.8%), as shown in Supplemental Table IV.6.  
If the unknown confounder (e.g. other endocrine-disrupting chemicals) increases the risk 
of earlier natural menopause, and it is more prevalent among women with higher n-PFOA or Sm-
PFOS concentrations, the NDE would be overestimated, then the NIE would be underestimated. 
In these scenarios, the degree of mediation of exposure to n-PFOA and Sm-PFOS by FSH would 
be underestimated without adjustment. Otherwise, the observed natural direct effect 
underestimates the true direct effect, whereas the observed natural indirect effect overestimates 
the true indirect effect.  
4. Discussion 




and Sm-PFOS on shortening time to incident natural menopause is partially explained through 
increasing serum concentrations of FSH. Although PFAS exposure has been linked to earlier 
menopause and higher FSH concentrations, the potential mediating role of FSH in the 
association between PFAS and menopause has not been previously examined. This study is the 
first, to our knowledge, that supports a potential mechanistic pathway for the associations 
between PFAS exposure and reproductive outcomes in human populations using a causal 
mediation approach.  
As proposed by Baron and Kenny in 1986, mediation requires strong relationships (1) 
between the exposure and the mediating variable, and (2) between the mediating variable and the 
outcome of interest (Baron and Kenny, 1986). Previous studies have documented associations 
between PFAS exposure and circulating levels of FSH in the human body (43,56). Exposure to 
PFOS and PFHxS has been associated with increased serum concentrations of FSH in patients 
with premature ovarian insufficiency (Zhang et al., 2018). This longitudinal study using SWAN 
data also detected positive relationships between n-PFOA exposure and increases in FSH 
concentrations among midlife women (Sung Kyun Park). Experimental studies have confirmed 
the endocrine-disrupting role of PFAS, possibly through an activation of peroxisome 
proliferator-activated receptors (PPARs) (White et al., 2011). 
The second criterion, an association between FSH and natural menopause, is well 
established. FSH is a glycoprotein hormone that is critical for ovarian folliculogenesis. FSH acts 
through FSH receptors (FSHR) located on the membrane of granulosa cells to facilitate antral 
follicle development and, in combination with luteinizing hormone, stimulate preovulatory 
follicle growth and form a corpus luteum after ovulation (Hillier, 2001; McGee et al., 2015). 




changes accelerate approximately 2 years before the FMP; and FSH concentrations stabilize 
approximately 2 years after the FMP (Randolph et al., 2011). FSH is also a candidate biomarker 
assay to estimate ovarian reserve as a reflection of decreased negative feedback from a 
diminishing cohort of follicles, with elevated FSH levels commonly used to confirm the onset of 
menopause (Roudebush et al., 2008).  
In the present study, exposure to PFAS was related to shorter time to natural menopause 
in midlife women. In experiments in vitro and in in vivo animal models, inverse associations 
were reported for PFAS exposure with diminished ovarian reserve (i.e. the number of ovarian 
follicles and oocytes) (Bellingham et al., 2009; Chen et al., 2017; Domínguez et al., 2016; Du et 
al., 2019; Feng et al., 2015,  2017; Hallberg et al., 2019; López-Arellano et al., 2019) and 
reduced steroidogenic enzyme activities (Chaparro-Ortega et al., 2018; Shi et al., 2009; Wang et 
al., 2018). We found that FSH was a statistically significant mediator for the associations of 
exposure to n-PFOA and Sm-PFOS with natural menopause incidence, with the proportion 
mediated by FSH of 26.8% and 23.8%, respectively. Other possible mechanisms for the effect of 
PFAS on menopause timing include interruption of gap junction intercellular communication 
between oocytes and granulosa cells (Domínguez et al., 2016; López-Arellano et al., 2019), 
oxidative stress (Wielsøe et al., 2015), and/or distribution of thyroid hormone homeostasis 
(Chang et al., 2008; Lau et al., 2003; Thibodeaux et al., 2003). 
This study has several strengths. First, the prospective design minimized the possibility of 
reverse causation. Second, standard annual follow-up visits instead of one-time questionnaire 
provided reliable estimates of date of FMP. Furthermore, the availability of serum concentrations 
of FSH at Visit 3 (the MPS baseline) allowed assessment of the mediating role of FSH on the 




There are limitations that should be acknowledged. First, the age range for the cohort was 
restricted to 45-56 years at the MPS baseline. This left-truncation resulted in an overestimation 
of median age at FMP (Cain et al., 2011). Women who experienced menopause before baseline, 
especially those with premature menopause (before age 40) or early menopause (before age 45) 
were not included in the MPS cohort, which could bias our effect estimates towards the null. 
Second, more than 40% of the cohort was censored at the initiation of HT before the participant 
was classified as post-menopausal. Although we considered many confounding variables in the 
analyses, residual or unmeasured confounding might still bias our effect estimates. Given the 
expected direction of residual confounding (i.e. unmeasured confounders like healthy lifestyle 
would likely decrease the risk of earlier natural menopause, while other endocrine-disrupting 
chemicals may shorten the time to natural menopause), our sensitivity analyses suggest that the 
observed indirect effects may have underestimated the true mediated effect while the observed 
direct effects were overestimated. Finally, the indirect effects through changing FSH 
concentrations assessed at Visit 3 alone ignore the mediating process and therefore underestimate 
the proportion mediated (Vansteelandt et al., 2019).  
In conclusion, this study is the first to investigate and quantify the degree to which FSH 
is an explanatory factor for the shortened time to natural menopause in midlife women with 
higher exposure to PFAS. Although mediation analysis still does not concretely establish a 
causal pathway, our findings provide evidence that PFAS exposure may accelerate ovarian aging 
through endocrinologic mechanisms associated with changing serum concentrations of FSH. 
Any potential mechanism underlying the relationships between PFAS exposure and natural 
menopause is likely to involve an interplay of hormones, beyond the action of single hormone 
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Table IV. 1 Baseline characteristics among 1120 premenopausal women in the Study of 
Women’s Health Across the Nation. 
Baseline characteristic 
Total (n=1120) 
Median (IQR) or n (%) 
Age at baseline, years 48.9 (47.0-50.8) 
Race/ethnicity  
   White 577 (51.5%) 
    Black 235 (21.0%) 
    Chinese 142 (12.7%) 
    Japanese 166 (14.8%) 
Study site  
    Southeast MI 202 (18.0%) 
    Boston, MA 182 (16.3%) 
    Oakland, CA      242 (21.6%) 
    Los Angeles, CA 299 (26.7%) 
    Pittsburgh, PA 195 (23.4%) 
Educational attainment  
    ≤High school 197 (17.7%) 
    Some college 350 (31.4%) 
    College 271 (24.3%) 
    Post-college 296 (26.6%) 
Parity  
    Nulliparous 215 (19.2%) 
    Parous 905 (80.8%) 
Prior hormone use  248 (22.1%) 
Smoking status  
    Never smoker 720 (64.4%) 
    Former smoker 291 (26.0%) 
    Current smoker 107 (9.6%) 
Physical activity score 7.9 (6.6-9.0) 
Body mass index, kg/m2 26.1 (22.7-31.5) 




Table IV. 2 Adjusteda percent changes (95% confidence interval, 95% CI) in serum 
concentrations of follicle-stimulating hormone (FSH) per doubling increase in serum PFAS 
concentrations. 
 FSH, mIU/mL 
 Percent change  95% CI 
n-PFOS 4.1%  -4.8%, 13.7% 
Sm-PFOS 9.4%  1.5%, 18.0% 
n-PFOA 15.0%  4.9%, 26.0% 
PFNA 4.9%  -3.6%, 14.0% 
PFHxS 3.7%  -2.9%, 10.6% 
a Models were adjusted for baseline covariates including age, race/ethnicity, study site, 
education, body mass index, parity, physical activity, smoking status, and prior hormone use. 
Abbreviations: n-PFOS, linear-chain perfluorooctane sulfonic acid; Sm-PFOS, branched-chain 
perfluorooctane sulfonic acid; n-PFOA, linear-chain perfluorooctanoic acid; PFNA, 






Table IV. 3 Natural direct effects of PFAS exposure on natural menopause, natural indirect effects of PFAS exposure on natural 
menopause through altering follicle-stimulating hormone (FSH) levels, total effects of PFAS exposure on natural menopause and 
percent mediated.a,b,c 




95% CI Relative 
survivald 
95% CI Relative 
survivald 
95% CI Percent 95% CI 
n-PFOS  0.84  0.71, 0.97 0.98  0.94, 1.02 0.82  0.69, 0.96 8.5%  -11.7%, 24.0% 
Sm-PFOS 0.86  0.72, 1.02 0.97  0.94, 1.00 0.84  0.69, 1.00 13.2%  0.0%, 24.5% 
n-PFOA 0.85  0.72, 0.98 0.93  0.89, 0.97 0.79  0.66, 0.93 26.9%  15.6%, 38.4% 
PFNA 0.88  0.74, 1.01 0.96  0.92, 0.99 0.84  0.71, 0.97 21.7%  6.8%, 37.0% 
PFHxS 0.92  0.79, 1.07 0.98  0.94, 1.01 0.90  0.76, 1.05 18.3%  -13.0%, 40.8% 
a Causal Mediation analysis was based on (1) AFT for the outcome model with time to natural menopause as the dependent variable 
and both exposure (PFAS) and mediator (FSH) as independent variables with adjustment for confounders; (2) linear regression for the 
mediator model with FSH as the dependent variable and PFAS as independent variable with adjustment for confounders. 
b Models were adjusted for age at baseline, race/ethnicity, study site, education, BMI at baseline, parity, physical activity, smoking 
status and prior hormone use at baseline. 
c Serum concentrations of PFAS were log-transformed with base 2. The effects of PFAS exposure were interpreted in relative survival 
and related 95% CI with a doubling increase in PFAS concentrations. 
d Relative survival less than 1 means that PFAS exposure is associated with earlier onset of natural menopause. 
Abbreviations: n-PFOS, linear-chain perfluorooctane sulfonic acid; Sm-PFOS, branched-chain perfluorooctane sulfonic acid; n-






Figure IV. 1 Conceptual model for mediation analysis in the context of the present study.C 
represents baseline confounders, including age at baseline, race/ethnicity, study site, education, 
BMI at baseline, parity at baseline, physical activity without work at baseline, smoking status at 
baseline, prior oral contraceptive use at baseline; A is serum concentrations of PFAS at baseline; 
M is follicle-stimulating hormone at baseline; T represents time to natural menopause. 





Supplemental Table IV. 1 Natural direct effects of PFAS exposure on natural menopause, natural indirect effects of PFAS exposure 
on natural menopause through altering follicle-stimulating hormone (FSH) levels, total effects of PFAS exposure on natural 
menopause, and percent mediated. a,b,c,d  






Total effect Percent mediated 
 Relative 
survivale 
95% CI Relative 
survivale 
95% CI Relative 
survivale 









0.95  0.88, 1.02 0.95  0.88, 1.02 0.98  0.97, 1.00 0.93  0.86, 1.00 24.4%  6.0%, 
39.0% 
n-PFOA 0.93  0.85, 1.03 0.92  0.84, 1.01 0.97  0.95, 0.99 0.90  0.82, 0.98 23.9%  10.0%, 
36.6% 
PFNA 0.92  0.85, 1.00 0.93  0.85, 1.02 0.99  0.98, 1.01 0.92  0.84, 1.02 4.5% -16.2%, 
23.4% 
PFHxS 0.98  0.92, 1.04 0.98  0.92, 1.04 0.99  0.98, 1.01 0.97  0.91, 1.03 23.1%  -42.5%, 
49.2% 
a Causal Mediation analysis was based on (1) AFT for the outcome model with time to natural menopause as the dependent variable 
and both exposure (PFAS) and mediator (FSH) as independent variables with adjustment for confounders; (2) linear regression for the 
mediator model with FSH as the dependent variable and PFAS as independent variable with adjustment for confounders. 
b Models were adjusted for age at baseline, race/ethnicity, study site, education, BMI at baseline, parity, physical activity, smoking 
status and prior hormone use at baseline. 
c Interaction terms between PFAS exposure and serum FSH levels were considered in the analyses. Controlled direct effects were 
computed when keeping FSH at its geometric mean level (23.8 mIU/mL). 
d Serum concentrations of PFAS were log-transformed with base 2. The effects of PFAS exposure were interpreted in relative survival 
and related 95% CI with a doubling increase in PFAS concentrations. 
e Relative survival less than 1 means that PFAS exposure is associated with earlier onset of natural menopause. 
Abbreviations: n-PFOS, linear-chain perfluorooctane sulfonic acid; Sm-PFOS, branched-chain perfluorooctane sulfonic acid; n-
PFOA, linear-chain perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid.; 95% confidence 




Supplemental Table IV. 2 Natural direct effects of PFAS exposure on natural menopause, natural indirect effects of PFAS exposure 
on natural menopause through altering follicle-stimulating hormone (FSH) levels, total effects of PFAS exposure on natural 
menopause and percent mediated (N=966). a,b,c,d  




95% CI Relative 
survivale 
95% CI Relative 
survivale 
95% CI Percent 95% CI 
n-PFOS 0.96  0.89, 1.03 0.99  0.98, 1.01 0.96  0.88-1.02 10.9%  -53.8%, 36.9% 
Sm-PFOS 0.98  0.91, 1.04 0.99  0.97, 1.00 0.97  0.90-1.03 35.1%  -11.8%, 55.7% 
n-PFOA 0.97  0.90, 1.05 0.98  0.97, 1.00 0.96  0.88-1.03 36.4%  1.0%, 54.8% 
PFNA 0.94  0.88, 1.00 1.00  0.98, 1.02 0.94  0.88-1.01 0%  -35.2%, 19.6% 
PFHxS 0.99  0.94, 1.04 1.01  0.99, 1.02 1.00  0.94-1.05 -118.1%  -201.2%, 43.8% 
a Causal Mediation analysis was based on (1) AFT for the outcome model with time to natural menopause as the dependent variable 
and both exposure (PFAS) and mediator (FSH) as independent variables with adjustment for confounders; (2) linear regression for the 
mediator model with FSH as the dependent variable and PFAS as independent variable with adjustment for confounders. 
b Models were adjusted for age at baseline, race/ethnicity, study site, education, BMI at baseline, parity, physical activity, smoking 
status and prior hormone use at baseline. 
c Serum concentrations of FSH measured at SWAN V04 were used in the analyses.  
d Serum concentrations of PFAS were log-transformed with base 2. The effects of PFAS exposure were interpreted in relative survival 
and related 95% CI with a doubling increase in PFAS concentrations. 
e Relative survival less than 1 means that PFAS exposure is associated with earlier onset of natural menopause. 
Abbreviations: n-PFOS, linear-chain perfluorooctane sulfonic acid; Sm-PFOS, branched-chain perfluorooctane sulfonic acid; n-
PFOA, linear-chain perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFHxS, perfluorohexane sulfonic acid.; 95% confidence 








Supplemental Table IV. 3 Bias-corrected natural direct effect of n-PFOA exposure on natural 
menopause incidence for varying prevalence of unmeasured confounder (U) among women with 
the 25th and 75th percentiles of n-PFOA serum concentrations, with relative survival of U on 
natural menopause=0.8 or 1.2. 
Relative survival=0.8 






 1% 10% 25% 50% 75% 90% 99% 
1% 0.93 0.95 0.97 1.03 1.09 1.13 1.16 
10% 0.91 0.93 0.96 1.01 1.07 1.11 1.14 
25% 0.88 0.90 0.93 0.98 1.04 1.08 1.10 
50% 0.84 0.85 0.88 0.93 0.98 1.02 1.04 
75% 0.79 0.81 0.83 0.88 0.93 0.96 0.99 
90% 0.76 0.78 0.80 0.85 0.90 0.93 0.95 
99% 0.75 0.76 0.78 0.83 0.88 0.91 0.93 
Relative survival=1.2 






 1% 10% 25% 50% 75% 90% 99% 
1% 0.93 0.91 0.89 0.85 0.81 0.79 0.78 
10% 0.95 0.93 0.90 0.86 0.82 0.80 0.79 
25% 0.97 0.96 0.93 0.89 0.85 0.83 0.81 
50% 1.02 1.00 0.97 0.93 0.89 0.87 0.85 
75% 1.07 1.05 1.02 0.97 0.93 0.91 0.89 
90% 1.09 1.08 1.04 1.00 0.95 0.93 0.92 
99% 1.11 1.09 1.06 1.01 0.97 0.94 0.93 
a The 25th and 75th percentiles of serum n-PFOA concentrations were 2.8 ng/mL and 5.7 ng/mL. 
The interquartile change was approximately a doubling increase in n-PFOA serum 
concentrations, so it was used in the sensitivity analyses.   
b Percent mediated =
𝑁𝐷𝐸 × (𝑁𝐼𝐸 − 1)
(𝑁𝐷𝐸 × 𝑁𝐼𝐸 − 1)⁄ × 100%. 





Supplemental Table IV. 4 Bias-corrected natural indirect effect of n-PFOA exposure on natural 
menopause incidence for varying prevalence of unmeasured confounder (U) among women with 
the 25th and 75th percentiles of n-PFOA serum concentrations, with relative survival of U on 
natural menopause=0.8 or 1.2. 
Relative survival=0.8 






 1% 10% 25% 50% 75% 90% 99% 
1% 0.97 0.95 0.92 0.87 0.83 0.80 0.78 
10% 0.99 0.97 0.94 0.89 0.84 0.81 0.79 
25% 1.02 1.00 0.97 0.92 0.87 0.84 0.82 
50% 1.07 1.06 1.02 0.97 0.92 0.88 0.86 
75% 1.14 1.12 1.08 1.03 0.97 0.94 0.91 
90% 1.18 1.16 1.12 1.06 1.00 0.97 0.95 
99% 1.21 1.18 1.15 1.09 1.03 0.99 0.97 
Relative survival=1.2  






 1% 10% 25% 50% 75% 90% 99% 
1% 0.97 0.99 1.02 1.06 1.11 1.14 1.16 
10% 0.95 0.97 1.00 1.05 1.09 1.12 1.14 
25% 0.92 0.94 0.97 1.02 1.06 1.09 1.11 
50% 0.88 0.90 0.92 0.97 1.01 1.04 1.06 
75% 0.84 0.86 0.88 0.93 0.97 0.99 1.01 
90% 0.82 0.84 0.86 0.90 0.94 0.97 0.98 
99% 0.81 0.82 0.85 0.89 0.93 0.95 0.97 
a The 25th and 75th percentiles of serum n-PFOA concentrations were 2.8 ng/mL and 5.7 ng/mL. 
The interquartile change was approximately a doubling increase in n-PFOA serum 
concentrations, so it was used in the sensitivity analyses.   
b Percent mediated =
𝑁𝐷𝐸 × (𝑁𝐼𝐸 − 1)
(𝑁𝐷𝐸 × 𝑁𝐼𝐸 − 1)⁄ × 100%. 






Supplemental Table IV. 5 Bias-corrected natural direct effect of Sm-PFOS exposure on natural 
menopause incidence for varying prevalence of unmeasured confounder (U) among women with 
the 25th and 75th percentiles of Sm-PFOS serum concentrations, with relative survival of U on 
natural menopause=0.8 or 1.2. 
Relative survival=0.8 






 1% 10% 25% 50% 75% 90% 99% 
1% 0.94 0.96 0.99 1.04 1.10 1.14 1.17 
10% 0.92 0.94 0.97 1.02 1.08 1.12 1.15 
25% 0.89 0.91 0.94 0.99 1.05 1.09 1.11 
50% 0.85 0.86 0.89 0.94 0.99 1.03 1.05 
75% 0.80 0.81 0.84 0.89 0.94 0.97 1.00 
90% 0.77 0.79 0.81 0.86 0.91 0.94 0.96 
99% 0.75 0.77 0.79 0.84 0.89 0.92 0.94 
Relative survival=1.2 






 1% 10% 25% 50% 75% 90% 99% 
1% 0.94 0.92 0.90 0.86 0.82 0.80 0.79 
10% 0.96 0.94 0.91 0.87 0.83 0.81 0.80 
25% 0.98 0.97 0.94 0.90 0.86 0.84 0.82 
50% 1.03 1.01 0.98  0.94 0.90 0.88 0.86 
75% 1.08 1.06 1.03 0.98 0.94 0.92 0.90 
90% 1.11 1.09 1.06 1.01 0.96 0.94 0.92 
99% 1.12 1.10 1.07 1.02 0.98 0.95 0.94 
a The 25th and 75th percentiles of serum Sm-PFOS concentrations were 4.6 ng/mL and 10.8 
ng/mL. The interquartile change was approximately a doubling increase in Sm-PFOS serum 
concentrations, so it was used in the sensitivity analyses.   
b Percent mediated =
𝑁𝐷𝐸 × (𝑁𝐼𝐸 − 1)
(𝑁𝐷𝐸 × 𝑁𝐼𝐸 − 1)⁄ × 100%. 
Abbreviations: NDE, natural direct effect; NIE, natural indirect effect; Sm-PFOS, branched-





Supplemental Table IV. 6 Bias-corrected natural indirect effect of Sm-PFOS exposure on 
natural menopause incidence for varying prevalence of unmeasured confounder (U) among 
women with the 25th and 75th percentiles of Sm-PFOS serum concentrations, with relative 
survival of U on natural menopause=0.8 or 1.2. 
Relative survival=0.8 






 1% 10% 25% 50% 75% 90% 99% 
1% 0.98 0.96 0.93 0.88 0.83 0.80 0.79 
10% 1.00 0.98 0.95 0.90 0.85 0.82 0.80 
25% 1.03 1.01 0.98 0.93 0.88 0.84 0.83 
50% 1.09 1.07 1.03 0.98 0.92 0.89 0.87 
75% 1.15 1.13 1.09 1.04 0.98 0.94 0.92 
90% 1.19 1.17 1.13 1.07 1.01 0.98 0.96 
99% 1.22 1.20 1.16 1.10 1.04 1.00 0.98 
Relative survival=1.2  






 1% 10% 25% 50% 75% 90% 99% 
1% 0.98 1.00 1.03 1.08 1.12 1.15 1.17 
10% 0.96 0.98 1.01 1.06 1.10 1.13 1.15 
25% 0.94 0.95 0.98 1.03 1.07 1.10 1.12 
50% 0.89 0.91 0.93 0.98 1.02 1.05 1.07 
75% 0.85 0.87 0.89 0.94 0.98 1.01 1.02 
90% 0.83 0.85 0.87 0.91 0.95 0.98 0.99 
99% 0.82 0.83 0.86 0.90 0.94 0.96 0.98 
a The 25th and 75th percentiles of serum Sm-PFOS concentrations were 4.6 ng/mL and 10.8 
ng/mL. The interquartile change was approximately a doubling increase in Sm-PFOS serum 
concentrations, so it was used in the sensitivity analyses.   
b Percent mediated =
𝑁𝐷𝐸 × (𝑁𝐼𝐸 − 1)
(𝑁𝐷𝐸 × 𝑁𝐼𝐸 − 1)⁄ × 100%. 
Abbreviations: NDE, natural direct effect; NIE, natural indirect effect; Sm-PFOS, branched-








Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are ubiquitous environmental 
toxicants that are widely used in consumer products and industry, such as non-stick cookware 
(Teflon) (Bradley et al., 2007); food packaging materials (Schaider et al., 2017); cosmetics 
(Danish EPA, 2018) and personal care products (Boronow et al., 2019); and fire-fighting foam 
(Kissa, 2011). PFAS have received unprecedented attention recently due to nationwide drinking 
water contamination that impacts up to 110 million residents in the United States (EWG et al., 
2019). Due to the widespread use of PFAS and their persistence in the environment, several 
PFAS such as perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), 
perfluorohexane sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA) are detectable in 
>98% of serum samples of the U.S. general population (ATSDR, 2018). Upon exposure, PFAS 
have the potential to impact the process of reproductive aging in women. However, few human 
studies have examined associations between these compounds and the timing of natural 
menopause. This dissertation fills a critical research gap in the current literature by advancing 
our understanding of potential reproductive and endocrinological mechanisms by which PFAS 
may impact ovarian aging during the menopausal transition.  
1. Summary of findings 
Aim 1 
To improve our understanding of exposure to per- and polyfluoroalkyl substances 
(PFAS) in midlife women, we describe longitudinal changes in PFAS serum concentrations 
during the menopausal transition and evaluated whether time trends differed by participant 
characteristics. This chapter was based on four repeated measurements of blood serum samples 




Black and Chinese) 45-56 years of age at baseline from three study sites (i.e. Boston, MA; 
southeast MI, and Oakland, CA) in the United States. We measured 11 PFAS compounds, 
including linear-and branched-chain isomers of perfluorooctanoic acid (n-PFOA and Sb-PFOA, 
respectively), linear- and branched-chain isomers of perfluorooctane sulfonic acid (n-PFOS and 
Sm-PFOS, respectively), 2-(N-ethyl-perfluorooctane sulfonamide) acetate (EtFOSAA), 2-(N-
methyl-perfluorooctane sulfonamide) acetate (MeFOSAA), perfluorohexane sulfonic acid 
(PFHxS), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDeA), 
perfluoroundecanoic acid (PFUA), and perfluorododecanoic acid (PFDoA). 
Serum concentrations of n-PFOA, n-PFOS and Sm-PFOS decreased significantly 
(P=0.001 for n-PFOA; P<.0001 for n-PFOS and Sm-PFOS) from 1999 to 2011. Detection rates 
of PFOS precursor compounds EtFOSAA and MeFOSAA also decreased. In contrast, serum 
PFHxS concentrations remained unchanged (P=0.05). An alternative compound, PFNA serum 
concentrations increased significantly (P<.0001). Detection rates of other replacement 
compounds, including PFDeA and PFUA doubled.  
After adjusting for age at baseline, study site, body mass index at baseline, parity and 
menstruation status, temporal trends of PFAS exposures were not uniform across racial/ethnic 
groups (P=0.001 for n-PFOA, P=0.0007 for n-PFOS, P=0.03 for Sm-PFOS, P=0.008 for 
PFHxS). Compared to other racial/ethnic groups, Chinese women showed a much slower decline 
in serum concentrations of n-PFOA, n-PFOS and Sm-PFOS, and little difference in PFHxS 
concentrations over time. Although serum concentrations of PFNA did not change significantly 
by race/ethnicity (P=0.13), Chinese women had consistently higher concentrations compared to 
others (P=0.03 at baseline for racial/ethnic differences). Menstrual bleeding was negatively 




menstruation status. Nulliparity was positively correlated with serum PFAS at the MPS baseline 
while the differences between nulliparity and parity narrowed over time.   
This chapter updates the existing knowledge on human exposure to PFAS. It provides 
valuable data on midlife women’s exposure to PFAS as they transitioned through menopause in 
the 1990s and first decade of the 2000s and temporal trends of PFAS serum concentrations, 
which have rarely been reported before. This chapter also provides new evidence on the 
contribution of race/ethnicity, menstruation and parity status to the longitudinal changes of PFAS 
serum concentrations. The main strengths of this analysis include: 
• We examined 11 PFAS in the population of multiethnic midlife women. 
• The repeated measurements during 1999 and 2011 also allow for an examination 
of longitudinal intra-individual changes in PFAS serum concentrations. 
• The wide geographical and racial/ethnic coverage of the SWAN participants 
enabled us to compare differences in biomarkers levels across multiple groups 
and increased the generalizability of our findings. 
Aim 2 
In this chapter, we examined whether exposure to PFAS was associated with incident 
natural menopause. While the association between PFAS and natural menopause have been 
reported previously (Dhingra et al., 2016; Knox et al., 2011; Taylor et al., 2014), the results of 
those studies have been inconsistent. These studies also raised concerns about reverse causation 
in that it is unclear whether PFAS exposure contributed to earlier menopause, or cessation of 





We, therefore, utilized a prospective cohort of 1,120 multiethnic women (including 
White, Black, Chinese and Japanese) who were premenopausal at baseline from the Study of 
Women’s Health Across the Nation with approximately annual clinic visits during 1999 and 
2017. Concentrations of PFHxS, linear-chain PFOS (n-PFOS), branched-chain PFOS (Sm-
PFOS), linear-chain PFOA (n-PFOA), and PFNA were measured in blood serum samples 
collected at baseline (1999-2000). We evaluated the associations between baseline serum 
concentrations of PFAS and incidence of natural menopause and assessed whether the 
relationships differed by racial/ethnic groups. We next identified subgroups exposed to different 
overall patterns of PFAS using k-means clustering method and evaluated the combined effects of 
PFAS mixtures on natural menopause.  
In this 17-year prospective cohort of 1,120 women with 5,466 person-years of 
observations in annual follow-up visits, we found that higher baseline serum concentrations of n-
PFOS, Sm-PFOS, and n-PFOA were significantly associated with earlier onset of natural 
menopause. After adjusting for age at baseline, race/ethnicity, study site, education, parity, 
baseline body mass index, time-varying physical activity, time-varying smoking status and prior 
hormone use at baseline, women with the highest tertile of baseline serum concentrations had a 
hazards ratio of natural menopause of 1.26 (95% CI: 1.02-1.57) for n-PFOS (Ptrend=0.03), 1.27 
(95% CI: 1.01-1.59) for Sm-PFOS (Ptrend=0.03), and 1.31 (95% CI: 1.04-1.65) for n-PFOA 
(Ptrend=0.01). When examining interactions between PFAS exposure and race/ethnicity, 
significant associations with incident natural menopause were observed for PFNA and n-PFOA 
in White women but not in other racial/ethnic groups.  
In the mixture analysis, we identified four overall exposure patterns of PFAS, i.e., “low”, 




exposure had significantly earlier natural menopause (HR=1.66, 95% CI: 1.17-2.36), compared 
to those with low overall exposure profiles. High overall PFAS exposure patterns might lead to 
1.8 years earlier median time to natural menopause.  
As age at the final menstrual period reflects a woman’s overall health, it has become 
clinically more important to investigate the role of potential endocrine-disrupting chemicals and 
timing of natural menopause. This chapter updates the existing knowledge on the endocrine-
disrupting roles of PFAS. It is the first prospective cohort, to our knowledge, to evaluate the 
associations of exposure to various PFAS with the occurrence of natural menopause in 
multiethnic midlife women. Additionally, no previous research of which we are aware has 
explored the mixture effects of PFAS on timing of ovarian aging.  
This chapter includes direct measurements of PFAS exposure prior to menopause, 
prospectively determination of date of the final menstrual period, and a large cohort of 
community-based midlife women from four racial/ethnic groups followed for up to 17 years. The 
main advantages of this chapter include: 
• The prospective design minimized the possibility of reverse causation which 
cannot be ruled out in the previous studies as women appear to have higher PFAS 
concentrations after menopause. 
• Standard approximately annual follow-up visits instead of one-time recall 
provided more reliable estimates of the date of the final menstrual period.  
• The wide geographical and racial/ethnic coverage of the SWAN participants 
enabled us to compare differences in biomarkers levels across multiple groups 





Our previous studies have shown that PFAS exposure was associated with earlier onset of 
natural menopause (Ning Ding et al., 2019). In a separate analysis, higher serum concentrations 
of PFAS were associated with increased levels of follicle-stimulating hormone (FSH) in midlife 
women during the menopausal transition . In this chapter, we conducted causal mediation 
analysis of the relationships between PFAS exposure and incident natural menopause by altering 
FSH levels. We utilized the same prospective cohort of 1,120 multiethnic women (including 
White, Black, Chinese and Japanese) who were premenopausal at baseline from the Study of 
Women’s Health Across the Nation. Concentrations of PFHxS, linear-chain PFOS (n-PFOS), 
branched-chain PFOS (Sm-PFOS), linear-chain PFOA (n-PFOA), and PFNA were measured in 
blood serum samples collected at baseline (1999-2000). Serum concentrations of FSH were also 
assessed at baseline. Time to natural menopause was modeled using accelerated failure time 
(AFT) models with a Weibull distribution. AFT models were chosen because they outperformed 
Cox proportional hazards regression models in causal mediation analysis with non-rare outcomes 
(Gelfand et al., 2016; VanderWeele, 2011). Baseline covariates included age, race/ethnicity, 
study site, educational attainment, BMI, parity, physical activity score, smoking status and prior 
hormone use. 
With FSH as being the mediator, 26.8% (95% CI: 10.3%, 39.3%) of the total effects of n-
PFOA on natural menopause is attributable to indirect effects through the mediator, and 23.8% 
(95% CI: 3.8%, 38.3%) of the total effects of Sm-PFOS is attributable to indirect effects. No 
causal mediation effects were observed for n-PFOS (percent mediated=8.1%, 95% CI: -15.8%, 
22.6%), PFNA (percent mediated=8.9%, 95% CI: -8.5%, 22.0%), and PFHxS (percent 




test the assumptions of no unmeasured confounding. Assuming an unknown confounder, either 
protective against earlier menopause (e.g. healthy lifestyle) or other hazardous endocrine-
disrupting chemicals, it is possible that the observed percent of mediation are underestimated.  
Use of mediation analysis in environmental epidemiology is surprisingly limited although 
many studies in environmental epidemiology measure markers of intermediate biological 
changes (e.g. hormone levels) in addition to examining exposure and health outcomes. This 
chapter updates existing knowledge regarding the endocrine-disrupting roles of PFAS. It is the 
first study, to our knowledge, to evaluate the mediating role of hormones on the associations 
between PFAS exposure and reproductive outcomes, specifically age at menopause.  
2. Public health implications 
Biomonitoring studies at the population level are important to alert researchers about 
geographical or time trends and provide a picture of the amount of PFAS actually accumulated in 
the blood for a specific period of time. In particular, time trends in population-level 
biomonitoring data provide evidence of whether policy change are effective and can contribute 
to lowering population-wide exposure levels. For example, the phase-out of leaded gasoline in 
1970s has contributed to a tremendous reduction in blood lead levels in the U.S. general 
population. Similarly, the voluntary phase-outs of PFOA and PFOS by industries and regulatory 
bodies since 2000 in the United States (USEPA, 2002; 3M, 2000), have resulted in population-
wide reductions in exposure to legacy compounds, which was confirmed in this dissertation. 
However, serum concentrations of PFHxS remained unchanged and PFNA exposure increased, 
suggesting that emerging compounds need to be restricted in industrial applications and 




PFAS are widespread drinking water contaminants because they are mobile in 
groundwater, as well as persistent and bioaccumulative in the environment (Post et al. 2017). 
There are currently no federal drinking water standards in the U.S. despite widespread drinking 
water contamination and ubiquitous population-wide exposure. Instead, the U.S. EPA released a 
non-enforceable lifetime health advisory for PFOA and PFOS at 70 parts per trillion (ppt), 
separately or combined, in 2016  (U.S. EPA 2016). Without an enforceable standard, public 
water systems are not required to routinely test for PFOA and PFOS or to treat water exceeding 
the health standards. In the absence of federal standards, seven U.S. states have adopted or 
proposed their own health-based drinking water guideline levels (ITRC 2017), ranging from 13 
to 1000 ppt. Several states have established guideline levels below EPA’s health advisory, 
suggesting that EPA’s approach may not be sufficiently protective.  
In addition, there are no health reference guidelines for other compounds. In 2019, the 
Michigan Department of Environment, Great Lakes, and Energy (EGLE) has proposed 
Maximum Contaminant Levels (MCLs) for seven types of PFAS including PFNA at 6 ppt, 
PFOA at 8 ppt, PFHxA at 400000 ppt, PFOS at 16 ppt, PFHxS at 51 ppt, PFBS at 420 ppt, and 
GenX at 370 ppt (EGLE 2019). Discrepancies in PFAS drinking water guidelines between the 
U.S. EPA and the states that adopted stricter guidelines suggest the remaining scientific 
uncertainty and assumptions that underlie these decisions. More research on risk assessment for 
PFAS in different exposure scenarios through drinking water consumption is urgently needed to 
set PFAS drinking water guidelines.  
Most previous studies were limited to one race/ethnic group and conducted within high-
exposed communities (e.g. the C8 Health Project conducted in residents from the Mid-Ohio 




dissertation fills research gaps on race/ethnic disparities and provides data from midlife women 
that have been understudied. Midlife women could be identified as susceptible populations for 
public health interventions, because serum PFAS concentrations may reaccumulate years after 
pregnancy and cessation of menstrual bleeding. This dissertation also recommends that future 
toxicokinetic studies account for menstruation and parity as important routes of elimination. 
With the aging population in the U.S., the number of individuals aged 65 years and older 
is projected to more than double in the upcoming decades, rising from 40.2 million in 2010 to an 
estimated 88.5 million by 2050 (Richardson et al., 2014). Women will comprise the majority of 
the aging population, as nearly half of them are in the age range during which women typically 
experience perimenopause, the menopausal transition, or have entered the postmenopausal phase 
of their lives (Ortman et al., 2014). Few studies have collected data on midlife women and 
focused on menopausal transition and reproductive outcomes in women’s later life. The SWAN 
study design and its longitudinal nature allowed for the study of long-term reproductive effects 
from endocrine-disrupting chemicals (EDCs) and their mixtures. 
Age at the final menstrual period may be marker for not only reproductive aging but also 
for general health and somatic aging. Menopause could be the first step of a causal pathway that, 
because of hormonal changes, results in organ dysfunction. Many undesirable side effects result 
from the menopausal transition and reproductive senescence. Common symptoms during this 
period include vasomotor hot flushes, sweating, vaginal dryness, vaginal atrophy, dyspareunia, 
urinary incontinence, irritability, depression, and insomnia. More serious side effects can result 
from a prolonged estrogen deficiency and premature menopause, including a significant loss of 
bone mineral density and an increased risk of serious cardiovascular diseases, such as 




important public health concern because with advancing life expectancy a full one-third of 
women’s lives are spent postmenopause. 
Using the SWAN data, this dissertation suggests that exposure to PFAS may lead to 
earlier onset of menopause in midlife women, a risk factor for chronic disease and mortality. 
Women who had high overall concentration profiles of PFAS exposure reached their natural 
menopause 2.0 years earlier compared to those in the low group. It has been reported that various 
factors such as educational attainment, occupation, use of oral contraceptives, age at menarche, 
obesity, smoking, and alcohol consumption (Gold et al., 2013; Morris et al. 2012). Among these 
factors, smoking has been identified as one of the most significant cause of accelerating the onset 
of natural menopause. In our sample, current smokers tended to reach their natural menopause 
1.1 years earlier compared to women who have never smoked before. Thus, similar to cigarette 
smoking, PFAS may also be an important risk factor for earlier onset of menopause.  
PFAS compounds are found in the blood of most people and are all potentially 
modifiable. Given the endocrine-disrupting role of these chemicals, it is important to set up early 
control of PFAS exposure in women, especially those living in a city with a PFAS-contaminated 
public water supply. The medical community should be aware of potential risk posed by PFAS 
and other EDCs to maintenance of reproductive function. Health practitioners should also be 
prepared for questions about these chemicals because it is a topic of concern to patients who may 
present with these endocrine-disrupting chemicals. In addition, altering consumer product 
behaviors is one way for individuals to lower their personal exposure to these harmful chemicals. 
Consumer products known to contain PFAS based on product testing include dental floss, non-
stick cookware, food packaging materials, sofa and furniture treated with PFAS prior to sale, ski 




2012; Guo et al., 2009). From a precautionary point of view, it makes sense to avoid the use of 
PFAS-containing consumer products.  
Furthermore, our findings suggest that PFAS exposure may accelerate ovarian aging 
through endocrinologic mechanisms related to variations in FSH levels. It revealed an underlying 
mechanism of how PFAS exposure disrupted ovarian function and led to earlier onset of natural 
menopause. The estimation of the mediating role of FSH could inform future precision health 
studies that seek to target specific biological pathways for interventions. Overall, this dissertation 
contributed in providing implications for policy makers and health professionals to help them 
with the improvement of public’s health, especially among women in their later life stage. 
3. Future directions 
In combination with this dissertation’s research findings and study limitations, several 
additional research questions and improvements for future studies are proposed as follows: 
(1) Measurement of emerging PFAS compounds: The phase out of PFOA and PFOS has led 
to an increasing usage of alternative compounds (Ateia et al., 2019). For example, GenX 
chemicals are used to make high-performance fluoropolymers and non-stick coatings without the 
use of PFOA; and PFBS is a replacement chemical for PFOS (USEPA, 2018). However, there is 
inadequate evidence of general toxicity as well as ovarian toxicity of such alternative 
compounds. Future studies should fill these gaps with regard to sources and pathway of exposure 
and toxic effects of emerging PFAS on reproductive outcomes and their related chronic 
conditions. 
(2) Expanded measurements of biomarkers: In regard to Aim 3, FSH could partially explain 




other possible mechanisms include oxidative stress (Wielsøe et al., 2015) and/or distribution of 
thyroid hormone homeostasis (Chang et al., 2008; Lau et al., 2003; Thibodeaux et al., 2003). It 
would be informative to measure thyroid hormone levels and biomarkers of oxidative stress (e.g. 
Gamma-glutamyl transferase). By doing so, we can better capture the pathways that might lead 
to earlier onset of natural menopause and understand the biological mechanisms through which 
PFAS alter reproductive function 
 (3) Analysis of EDC mixtures: Previous studies have linked phthalates, polychlorinated 
biphenyls (PCBs), polybrominated diphenyl esters (PBDEs), and other EDCs to impaired 
ovarian function (Craig and Ziv-Gal, 2018; Grindler et al., 2015; Harley et al., 2019). It is 
increasingly recognized that environmental endocrine disruption is most often not due to the 
effect of a single compound, but rather due to co-exposure to mixtures of chemicals at low 
concentrations (Alyea and Watson, 2009; Braun et al., 2016; Wang et al., 2018,  2019). Thus, 
future research should examine the effects of exposure to a mixture of persistent and non-
persistent EDCs on ovarian health. 
 (4) Linking natural menopause to health conditions: This dissertation estimates the 
associations between PFAS exposure and incident natural menopause. The toxicity of PFAS on 
ovarian function is not fully understood. Future studies should explore the associations of PFAS 
exposure with vasomotor symptoms (e.g. hot flashes, night sweats), duration of menopausal 
transition, and hormone trajectories. The physiology of reproductive aging likely represents an 
interplay between multiple central and peripheral physiologic systems. Overall, a major follow-
up question that arises from this dissertation is “what is the health consequences to midlife 
women?” An important next step is to link data on environmental exposures, age at natural 




decline). By doing so, we can better inform policy makers and health practitioners about 
population-level burden of environmental exposures and costs to society.  
4. Overall conclusion 
In conclusion, this dissertation fills a critical research gap in the current literature on 
endocrine disruption and reports evidence that exposure to PFAS is associated with earlier onset 
of natural menopause, possibly though altering FSH levels and depleting the ovarian reserve. By 
analyzing the temporal variations of PFAS serum concentrations and their determinants, this 
dissertation also identifies midlife women as potential susceptible subpopulations. Recent 
biomonitoring data, health effects data, and additional information to be solicited from the public 
will inform the development of public health strategies and safety regulation for a broader class 
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